WO2021090941A1 - 免疫チェックポイント阻害剤の薬理作用の評価方法、算出方法、評価装置、算出装置、評価プログラム、算出プログラム、記録媒体、評価システムおよび端末装置 - Google Patents
免疫チェックポイント阻害剤の薬理作用の評価方法、算出方法、評価装置、算出装置、評価プログラム、算出プログラム、記録媒体、評価システムおよび端末装置 Download PDFInfo
- Publication number
- WO2021090941A1 WO2021090941A1 PCT/JP2020/041614 JP2020041614W WO2021090941A1 WO 2021090941 A1 WO2021090941 A1 WO 2021090941A1 JP 2020041614 W JP2020041614 W JP 2020041614W WO 2021090941 A1 WO2021090941 A1 WO 2021090941A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ala
- arg
- phe
- met
- trp
- Prior art date
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
Definitions
- the present invention relates to an evaluation method, a calculation method, an evaluation device, a calculation device, an evaluation program, a calculation program, a recording medium, an evaluation system, and a terminal device for the pharmacological action of an immune checkpoint inhibitor.
- Immune checkpoint inhibitor treatment is a method of treating cancer by releasing the immunosuppressive state caused by cancer and normalizing the immune function of the living body.
- Malignant melanoma, non-small cell lung cancer, small cell lung cancer, malignant Efficacy in various cancer types such as pleural spleen, renal cell carcinoma, Hodgkin lymphoma, merkel cell carcinoma, urinary tract epithelial carcinoma, head and neck cancer, esophageal carcinoma, gastric cancer, hepatocellular carcinoma, breast cancer and bladder cancer There is.
- treatment results have been accumulated, such as reports of cured cases of advanced / recurrent cancers that are difficult to cure with conventional treatment methods, and surgical therapy, which is a conventional treatment method, It is becoming more widespread as a fourth treatment in addition to radiation therapy and chemotherapy.
- amino acids are universal nutrients used as substrates and energy sources for biological components such as proteins and nucleic acids, and are essential for the regulation of cancer cell proliferation and immune cell function.
- Required for immune response to cancers such as cysteine, glutamine, phenylalanine, tryptophan and arginine due to increased amino acid utilization in energy metabolism due to cancer cell proliferation, protein catabolism occurring in systemic organs and abnormal amino acid metabolism mediated by various immunomodulatory cells It is thought that a competitive state of amino acids is brought about, and as a result, it leads to immune avoidance of cancer (Non-Patent Document 1).
- Non-Patent Document 5 a method for evaluating the function of MDSC related to the life prognosis of critically ill patients by analyzing arginine in blood has been presented. More recently, IDO-mediated tryptophan metabolites quinolinic acid and a combination of tryptophan and kynurenine have been reported as indicators for predicting the prognosis of immune checkpoint inhibitor treatment (Non-Patent Document 6). It has been reported in malignant melanoma and renal cell carcinoma that activation of such tryptophan metabolic pathway can be a prognostic index for immune checkpoint inhibitor treatment, and it is possible that a common immunosuppressive mechanism is working in various cancer types. Sex is suggested (Non-Patent Document 7).
- Patent Document 1 relating to a method for evaluating the therapeutic effect of cancer immunotherapy using an amino acid concentration has been published.
- a treatment method suitable for each patient can be selected more accurately. It can be done, which in turn leads to improved outcomes of immune checkpoint inhibitor treatment.
- a treatment method suitable for each patient can be selected more accurately. It can be done, which in turn leads to improved outcomes of immune checkpoint inhibitor treatment.
- Non-Patent Document 1-4 does not discuss the possibility of evaluating local changes in immune cell function using metabolites in blood. Further, Non-Patent Document 5 does not relate to evaluation of a local immune response due to cancer. Further, in Non-Patent Document 6, sufficient discrimination accuracy is not obtained. Further, Patent Document 1 does not show that the prognosis of immune checkpoint inhibitor treatment can be predicted.
- the present invention has been made in view of the above problems, and is an evaluation method and a calculation method capable of providing highly reliable information that can be used as a reference for understanding individual differences in the pharmacological action of immune checkpoint inhibitors.
- the evaluation method according to the present invention comprises 21 kinds of amino acids (Glu, Arg, Orn, Cit, His, Val, Phe, Tyr, Met) in the blood to be evaluated. , Pro, Asn, Leu, Lys, Thr, Ile, Gln, Ala, Ser, a-ABA, Trp and Gly) and 15 amino acid-related metabolites (AnthA, hAnthA, hIAA, hKyn, hTrp, IAA, ILA, Calculated using the concentration value of at least one metabolite of Kyn, KynA, NFKyn, NP, PA, QA, Serot and XA), or an expression containing the variable to which the concentration value is substituted and the concentration value. It is characterized by including an evaluation step of evaluating the pharmacological action of the immune checkpoint inhibitor in the evaluation target by using the value of the above formula.
- immune checkpoint inhibitors include PD-1 inhibitors (such as nivolumab or pembrolizumab), PD-L1 inhibitors (such as atezolizumab or duvalmab) and CTLA-4 inhibitors (such as ipilimumab).
- PD-1 inhibitors such as nivolumab or pembrolizumab
- PD-L1 inhibitors such as atezolizumab or duvalmab
- CTLA-4 inhibitors such as ipilimumab.
- the pharmacological action includes a pharmacological action (main action) and a general pharmacological action (side effect).
- the blood was collected from the evaluation target before or after the treatment with the immune checkpoint inhibitor was started.
- the evaluation step is characterized in that the effect of the treatment on the evaluation target is evaluated.
- first the start of treatment includes, for example, before the first narrowly defined treatment in the broadly defined treatment over a certain period of time is performed.
- after the start of treatment means, for example, after the first narrow-sense treatment in the broad-sense treatment over a certain period of time and before the final narrow-sense treatment is performed (for example,). (For example, “during treatment”, which is generally referred to), or after the final narrow-sense treatment in a broad-sense treatment for a certain period of time (for example, "after treatment”, which is generally referred to), etc. included.
- the blood was collected from the evaluation target before the treatment with the immune checkpoint inhibitor was started, and the evaluation step was performed. It is characterized in that the risk of occurrence of side effects due to the treatment in the evaluation target is evaluated.
- the evaluation method according to the present invention is characterized in that, in the evaluation method, the evaluation step is executed in the control unit of the information processing device including the control unit.
- the concentration value of at least one of the 21 types of amino acids and the 15 types of amino acid-related metabolites in the blood to be evaluated and the variable to which the concentration value is substituted is characterized by including a calculation step of calculating the value of the formula using a formula for evaluating the pharmacological action of the immune checkpoint inhibitor including.
- the blood is collected from the evaluation target before or after the treatment with the immune checkpoint inhibitor is started.
- the formula is for evaluating the effect of the treatment.
- the blood was collected from the evaluation target before the treatment with the immune checkpoint inhibitor was started, and the above formula was used. It is characterized in that it is for evaluating the risk of occurrence of side effects due to treatment.
- the calculation method according to the present invention is characterized in that, in the calculation method, the calculation step is executed in the control unit of the information processing device including the control unit.
- the evaluation device is an evaluation device including a control unit, and the control unit is at least one of the 21 types of amino acids and the 15 types of amino acid-related metabolites in the blood to be evaluated.
- the evaluation device is communicably connected to the terminal device that provides the concentration data related to the concentration value or the value of the above formula in the evaluation device via a network, and the control unit is connected to the terminal.
- the evaluation means further includes a data receiving means for receiving the concentration data transmitted from the device or the value of the formula, and a result transmitting means for transmitting the evaluation result obtained by the evaluation means to the terminal device. Is characterized by using the density value included in the density data received by the data receiving means or the value of the formula.
- the calculation device is a calculation device including a control unit, and the control unit is at least one of the 21 types of amino acids and the 15 types of amino acid-related metabolites in the blood to be evaluated. It is characterized by providing a calculation means for calculating the value of the formula using a formula for evaluating the concentration value of one metabolite and the pharmacological action of the immune checkpoint inhibitor including the variable to which the concentration value is substituted. And.
- the evaluation program according to the present invention is an evaluation program to be executed in an information processing apparatus provided with a control unit, and the 21 kinds of amino acids in the blood to be evaluated and the said to be executed in the control unit.
- concentration value of at least one metabolite of 15 kinds of amino acid-related metabolites, or the formula including the variable to which the concentration value is substituted and the value of the formula calculated using the concentration value It is characterized by including an evaluation step for evaluating the pharmacological action of the immune checkpoint inhibitor in the evaluation target.
- the calculation program according to the present invention is a calculation program to be executed in an information processing apparatus provided with a control unit, and the 21 kinds of amino acids in the blood to be evaluated and the above-mentioned amino acids to be executed in the control unit.
- the above formula is used. It is characterized by including a calculation step for calculating a value.
- the recording medium according to the present invention is a computer-readable recording medium on which the evaluation program or the calculation program is recorded.
- the recording medium according to the present invention is a non-temporary computer-readable recording medium, and includes a programmed instruction for causing an information processing apparatus to execute the evaluation method or the calculation method. It is characterized by.
- the evaluation system is an evaluation system configured by connecting an evaluation device including a control unit and a terminal device including a control unit so as to be communicable via a network, and the control of the terminal device.
- the part includes concentration data regarding the concentration values of the 21 types of amino acids and at least one of the 15 types of amino acid-related metabolites in the blood to be evaluated, or variables to which the concentration values are assigned.
- a data transmission means for transmitting the formula and the value of the formula calculated using the concentration value to the evaluation device, and a result of receiving the evaluation result regarding the pharmacological action of the immune checkpoint inhibitor transmitted from the evaluation device.
- the control unit of the evaluation device includes the receiving means, the data receiving means for receiving the density data transmitted from the terminal device or the value of the formula, and the density data received by the data receiving means.
- An evaluation means for evaluating the pharmacological action of the immune checkpoint inhibitor in the evaluation target using the concentration value contained in the above or the value of the above formula, and the evaluation result obtained by the evaluation means are evaluated by the terminal. It is characterized by comprising a result transmitting means for transmitting to an apparatus.
- the terminal device is a terminal device provided with a control unit, and the control unit includes a result acquisition means for acquiring an evaluation result regarding the pharmacological action of the immune checkpoint inhibitor, and the evaluation result is , The concentration value of at least one of the 21 kinds of amino acids and the 15 kinds of amino acid-related metabolites in the blood to be evaluated, or the formula including the variable to which the concentration value is substituted and the concentration value. It is a result of evaluating the pharmacological action of the immune checkpoint inhibitor in the evaluation target using the value of the above formula calculated using.
- the terminal device is communicably connected to the evaluation device for evaluating the pharmacological action of the immune checkpoint inhibitor in the terminal device via a network, and the control unit relates to the concentration value.
- the data transmission means for transmitting the concentration data or the value of the formula to the evaluation device is provided, and the result acquisition means receives the evaluation result transmitted from the evaluation device.
- FIG. 1 is a principle configuration diagram showing the basic principle of the first embodiment.
- FIG. 2 is a principle configuration diagram showing the basic principle of the second embodiment.
- FIG. 3 is a diagram showing an example of the overall configuration of this system.
- FIG. 4 is a diagram showing another example of the overall configuration of this system.
- FIG. 5 is a block diagram showing an example of the configuration of the evaluation device 100 of this system.
- FIG. 6 is a diagram showing an example of information stored in the density data file 106a.
- FIG. 7 is a diagram showing an example of information stored in the index state information file 106b.
- FIG. 8 is a diagram showing an example of information stored in the designated index state information file 106c.
- FIG. 9 is a diagram showing an example of information stored in the formula file 106d1.
- FIG. 1 is a principle configuration diagram showing the basic principle of the first embodiment.
- FIG. 2 is a principle configuration diagram showing the basic principle of the second embodiment.
- FIG. 3 is a diagram showing an example of
- FIG. 10 is a diagram showing an example of information stored in the evaluation result file 106e.
- FIG. 11 is a block diagram showing the configuration of the evaluation unit 102d.
- FIG. 12 is a block diagram showing an example of the configuration of the client device 200 of this system.
- FIG. 13 is a block diagram showing an example of the configuration of the database device 400 of this system.
- FIG. 14 is a diagram showing concentration values of each amino acid and each amino acid-related metabolite.
- FIG. 15 is a diagram showing analysis results obtained by multivariate analysis using a univariate Cox hazard model.
- FIG. 16 is a diagram showing analysis results obtained by multivariate analysis using a univariate Cox hazard model.
- FIG. 15 is a diagram showing analysis results obtained by multivariate analysis using a univariate Cox hazard model.
- FIG. 17 is a diagram showing the distribution of C-Index for a two-variable discriminant, a three-variable discriminant, a four-variable discriminant, a five-variable discriminant, and a six-variable discriminant.
- FIG. 18 is a diagram showing the frequency of appearance of amino acid variables in the discriminant.
- FIG. 19 is a diagram showing the frequency of appearance of amino acid variables and amino acid-related metabolite variables in the discriminant.
- FIG. 20 is a diagram showing the frequency of appearance of amino acid variables in the discriminant.
- FIG. 21 is a diagram showing the frequency of appearance of amino acid variables and amino acid-related metabolite variables in the discriminant.
- FIG. 22 is a diagram showing the discriminant performance of the discriminant created with the goal of minimizing AIC (Akaike's Information Criterion) by the stepwise method.
- FIG. 23 is a diagram showing analysis results obtained by multivariate analysis using a univariate logistic regression model.
- FIG. 24 is a diagram showing the distribution of AOC_AUC for a two-variable discriminant, a three-variable discriminant, a four-variable discriminant, a five-variable discriminant, and a six-variable discriminant.
- FIG. 25 is a diagram showing the frequency of appearance of amino acid variables in the discriminant.
- FIG. 26 is a diagram showing the frequency of appearance of amino acid variables and amino acid-related metabolite variables in the discriminant.
- FIG. 27 is a diagram showing analysis results obtained by multivariate analysis using a univariate Cox hazard model.
- FIG. 28 is a diagram showing the analysis results obtained by the univariate correlation analysis.
- first embodiment an embodiment of the evaluation method according to the present invention
- second embodiment an embodiment of the evaluation device, evaluation method, evaluation program, recording medium, evaluation system, and terminal device according to the present invention
- second embodiment an embodiment of the evaluation device, evaluation method, evaluation program, recording medium, evaluation system, and terminal device according to the present invention
- FIG. 1 is a principle configuration diagram showing the basic principle of the first embodiment.
- the 21 amino acids in blood including plasma, serum, etc.
- an evaluation target having cancer for example, an individual such as an animal or a human
- concentration data regarding the concentration value of at least one of the 15 kinds of amino acid-related metabolites is acquired (step S11).
- can be the target of treatment means, for example, that there is a possibility of selecting treatment or that treatment is scheduled.
- step S11 concentration data derived from blood collected before the treatment of cancer (for example, treatment by surgical therapy, chemotherapy, radiotherapy, cancer immunotherapy, etc.) is started from the evaluation target (treatment start).
- concentration data derived from the blood collected after the start of the treatment concentration data after the start of the treatment
- concentration data after the start of the treatment includes, for example, before the first narrow-sense treatment in the broad-sense treatment over a certain period of time is performed.
- after the start of treatment means, for example, after the first narrow-sense treatment in the broad-sense treatment over a certain period of time and before the final narrow-sense treatment is performed (for example, generally referred to as “after””. This includes (eg, “during treatment”), or after the final, narrowly defined treatment of a broader treatment over a period of time (eg, commonly referred to as “after treatment”).
- the concentration data measured by a company or the like that measures the concentration value may be acquired.
- the concentration data may be obtained from the blood collected from the evaluation target by measuring the concentration value by, for example, the following measuring methods such as (A), (B) or (C).
- the unit of the concentration value may be, for example, a molar concentration, a weight concentration, or an enzyme activity, and may be obtained by adding, subtracting, multiplying, or dividing an arbitrary constant to these concentrations.
- A Plasma is separated from blood by centrifuging the collected blood sample. All plasma samples are cryopreserved at -80 ° C until the concentration value is measured.
- acetonitrile is added to perform derivatization treatment, and if necessary, impurities such as phospholipids are removed by solid layer extraction or the like, and a labeling reagent (3-aminopyridyl-N-hydroxysuccinimidimi) is removed.
- a labeling reagent (3-aminopyridyl-N-hydroxysuccinimidimi) is removed.
- LC / MS liquid chromatography-mass spectrometry
- Plasma samples are cryopreserved at -80 ° C until the concentration value is measured.
- sulfosalicylic acid is added to perform deproteinization treatment, and then the concentration value is analyzed by an amino acid analyzer based on the post-column derivatization method using a ninhydrin reagent.
- C The collected blood sample is subjected to blood cell separation using a membrane, MEMS (Micro Electro Mechanical Systems) technology or the principle of centrifugation, and plasma or serum is separated from the blood.
- Plasma or serum samples for which concentration values are not measured immediately after acquisition are cryopreserved at ⁇ 80 ° C. until concentration values are measured.
- a molecule that reacts with or binds to a target blood substance such as an enzyme or an aptamer is used, and the concentration value is analyzed by quantifying a substance that increases or decreases due to substrate recognition or a spectroscopic value.
- step S12 the pharmacological action of the immune checkpoint inhibitor in the evaluation target is evaluated (predicted) using the concentration value included in the concentration data acquired in step S11 (step S12).
- data such as missing values and outliers may be removed from the concentration data acquired in step S11.
- "evaluating the pharmacological action of the immune checkpoint inhibitor in the evaluation target” means, for example, evaluating the pharmacological action of the immune checkpoint inhibitor appearing in the evaluation target.
- the evaluation may be performed using the calculated ratio or difference value.
- step S12 the effect (prognosis of treatment) of the treatment with the immune checkpoint inhibitor in the evaluation target is evaluated by using the concentration value included in the concentration data before the start of the treatment and / or the concentration data after the start of the treatment. You may. Further, in step S12, the concentration value included in the concentration data before the start of treatment may be used to evaluate the risk of side effects caused by treatment with the immune checkpoint inhibitor in the evaluation target.
- the concentration data of the evaluation target is acquired in step S11, and in step S12, the immunity check in the evaluation target is performed using the concentration value included in the concentration data of the evaluation target acquired in step S11.
- Evaluate the pharmacological action of point inhibitors (in short, obtain information for evaluating the pharmacological action of immune checkpoint inhibitors in the evaluation target). This makes it possible to provide highly reliable information that can be used as a reference for understanding individual differences in the pharmacological action of immune checkpoint inhibitors.
- the evaluation result obtained in this embodiment can be utilized as reference information when deciding the treatment method.
- the evaluation result obtained in this embodiment can be utilized for determining the continuation of treatment of the immune checkpoint inhibitor, or further. It can be used as reference information when deciding on a treatment method.
- the concentration value of at least one of the 21 types of amino acids and 15 types of amino acid-related metabolites determines the pharmacological action of the immune checkpoint inhibitor in the evaluation target. It may be determined that it is reflected, and further, the concentration value (the above-mentioned ratio or difference value may be used) is converted by, for example, the method described below, and the converted value is an immune check in the evaluation target. It may be determined that it reflects the pharmacological action of the point inhibitor. In other words, the concentration value or the converted value itself may be treated as an evaluation result regarding the pharmacological action of the immune checkpoint inhibitor in the evaluation target.
- the possible range of concentration values is a predetermined range (for example, 0.0 to 1.0, 0.0 to 10.0, 0.0 to 100.0, or -10.0 to -10.0.
- a predetermined range for example, 0.0 to 1.0, 0.0 to 10.0, 0.0 to 100.0, or -10.0 to -10.0.
- any value can be added, subtracted, multiplied, or divided with respect to the density value, or the density value can be converted into a predetermined conversion method (for example, exponential conversion, logarithmic conversion, etc.).
- the density value is converted by converting by angle conversion, square root conversion, probit conversion, inverse number conversion, Box-Cox conversion, or power conversion), or by combining these calculations with the density value. You may.
- a value of an exponential function with the concentration value as an index and the base of the Napier number (specifically, the probability p that the prognosis of treatment with an immune checkpoint inhibitor is poor or the risk of side effects due to the treatment is high is defined.
- the value of p / (1-p) when the natural logarithm ln (p / (1-p)) at that time is equal to the concentration value) may be further calculated, or the value of the calculated exponential function. May be further calculated by dividing 1 by the sum of the values (specifically, the value of the probability p). Further, the concentration value may be converted so that the converted value under a specific condition becomes a specific value.
- the concentration value may be converted so that the converted value when the specificity is 80% is 5.0 and the converted value when the specificity is 95% is 8.0. Further, for each amino acid and each amino acid-related metabolite, the concentration distribution may be normally distributed and then deviated so as to have an average of 50 and a standard deviation of 10. In addition, these conversions may be performed by gender or age.
- the concentration value in the present specification may be the concentration value itself or the value after converting the concentration value.
- position information regarding the position of a predetermined mark on a predetermined indicator that is visually displayed on a display device such as a monitor or a physical medium such as paper can be obtained.
- the concentration value of at least one metabolite of may be the above-mentioned ratio or difference value) or, when the concentration value is converted, is generated using the converted value, and the generated position information is the immunity in the evaluation target. It may be determined that it reflects the pharmacological action of the checkpoint inhibitor.
- the predetermined measuring rod is for evaluating the pharmacological action of the immune checkpoint inhibitor in the evaluation target.
- the predetermined mark corresponds to the concentration value or the converted value, and is, for example, a circle mark or a star mark.
- the concentration value (may be the above-mentioned ratio or difference value) of at least one of the 21 kinds of amino acids and the 15 kinds of amino acid-related metabolites is a predetermined value (average value ⁇ 1SD, 2SD, Immune checkpoint inhibitors in the evaluation target when they are lower than 3SD, N quantile, N percentile, or cut-off value with clinical significance) or below a predetermined value, or above or above a predetermined value or higher than a predetermined value.
- concentration deviation value is less than the average value -2SD (concentration deviation value ⁇ 30) or when the concentration deviation value is higher than the average value + 2SD (concentration deviation value> 70), the immune checkpoint in the evaluation target
- concentration deviation value is less than the average value -2SD (concentration deviation value ⁇ 30) or when the concentration deviation value is higher than the average value + 2SD (concentration deviation value> 70)
- concentration deviation value is higher than the average value + 2SD (concentration deviation value> 70
- the concentration value (may be the above-mentioned ratio or difference value) and the concentration value (the above-mentioned ratio or difference value) of at least one of the 21 types of amino acids and the 15 types of amino acid-related metabolites.
- the pharmacological action of the immune checkpoint inhibitor in the evaluation target may be determined by calculating the value of the formula using a formula containing a variable to which (may be) is substituted.
- the calculated value of the formula reflects the pharmacological action of the immune checkpoint inhibitor in the evaluation target, and further, the value of the formula is converted and converted by, for example, the method described below. It may be determined that the later value reflects the pharmacological action of the immune checkpoint inhibitor in the evaluation subject. In other words, the value of the formula or the converted value itself may be treated as an evaluation result regarding the pharmacological action of the immune checkpoint inhibitor in the evaluation target.
- the possible range of values in the equation is a predetermined range (eg 0.0 to 1.0, 0.0 to 10.0, 0.0 to 100.0, or -10.0.
- the value of p / (1-p) when the natural logarithm ln (p / (1-p)) at the time of definition is equal to the value of the equation) may be further calculated, or the calculated exponential function may be calculated.
- a value obtained by dividing the value of 1 by the sum of the value (specifically, the value of the probability p) may be further calculated.
- the value of the expression may be converted so that the converted value under a specific condition becomes a specific value.
- the value of the equation may be converted so that the converted value when the specificity is 80% is 5.0 and the converted value when the specificity is 95% is 8.0.
- the values of the equation may be converted into deviation values so that the average is 50 and the standard deviation is 10. In addition, these conversions may be performed by gender or age.
- the value of the expression in the present specification may be the value of the expression itself or the value after converting the value of the expression.
- the position information regarding the position of a predetermined mark on a predetermined measuring rod that is visibly displayed on a display device such as a monitor or a physical medium such as paper is converted into the value of the formula or the value of the formula when the value of the formula is converted. It may be generated using the later values, and it may be determined that the generated position information reflects the pharmacological action of the immune checkpoint inhibitor in the evaluation target.
- the predetermined measuring rod is for evaluating the pharmacological action of the immune checkpoint inhibitor in the evaluation target, and is, for example, a measuring rod with a scale, which is "the value of the formula or the value after conversion".
- the predetermined mark corresponds to the value of the expression or the value after conversion, and is, for example, a circle mark or a star mark.
- the pharmacological action of the immune checkpoint inhibitor in the evaluation target may be qualitatively evaluated.
- the concentration value may be the above-mentioned ratio or difference value
- the concentration value may be the above-mentioned ratio or difference value
- the concentration value may be the above-mentioned ratio or difference value of at least one of the 21 kinds of amino acids and the 15 kinds of amino acid-related metabolites and a preset one or a value.
- Multiple thresholds or “concentration value (may be the above-mentioned ratio or difference value) of at least one of the 21 kinds of amino acids and the above 15 kinds of amino acid-related metabolites, the concentration value (the above-mentioned ratio).
- the evaluation target is the prognosis of treatment with an immune checkpoint inhibitor or the occurrence of side effects due to the treatment. It may be classified into any one of a plurality of categories defined with at least risk in mind. It should be noted that the plurality of categories include categories for assigning subjects with a poor prognosis of the treatment or a high risk of side effects due to the treatment, and categories for having a good prognosis of the treatment or risk of side effects due to the treatment.
- the plurality of categories include a category for assigning a subject having a poor prognosis of the treatment or a high risk of developing side effects due to the treatment, and a category for having a good prognosis of the treatment or side effects caused by the treatment. Category may be included to belong to subjects with low risk of occurrence.
- the concentration value (which may be the above-mentioned ratio or difference value) or the value of the formula is converted by a predetermined method, and the evaluation target is classified into any one of a plurality of categories using the converted value. You may.
- the format of the formula used for evaluation is not particularly limited, but may be, for example, the formula shown below.
- Linear models such as multiple regression equations based on the least square method, linear discrimination equations, principal component analysis, canonical discrimination analysis
- Generalized linear models such as logistic regression and Cox regression based on the most probable method
- Generalized linear mixed model considering variable effects such as individual differences and facility differences-Formulas created by cluster analysis such as K-means method and hierarchical cluster analysis-MCMC (Markov chain Monte Carlo method), Bayesian network, Expressions created based on Bayesian statistics such as the hierarchical Bayes method
- Expressions created by classification such as support vector machines and decision trees
- Expressions created by methods that do not belong to the above categories such as partial equations ⁇ Sum of expressions of different formats Expression as shown by
- the formula used for evaluation is described in, for example, the method described in International Publication No. 2004/052191, which is an international application by the applicant, or International Publication No. 2006/098192, which is an international application by the applicant. It may be created by the method. If the formulas are obtained by these methods, the pharmacological action of the immune checkpoint inhibitor is evaluated by using the formulas regardless of the unit of the concentration value of amino acids or amino acid-related metabolites in the concentration data as input data. Can be suitably used for
- a coefficient and a constant term are added to each variable, and the coefficient and the constant term may be preferably a real number, more preferably.
- Is a value that belongs to the range of the 99% confidence interval of the coefficient and the constant term obtained for performing the various classifications from the data, and more preferably, it is obtained for performing the various classifications from the data. Any value that belongs to the range of the 95% confidence interval of the coefficient and constant terms may be used.
- the value of each coefficient and its confidence interval may be obtained by multiplying it by a real number
- the value of the constant term and its confidence interval may be obtained by adding, subtracting, multiplying or dividing an arbitrary real constant.
- the numerator of the fractional expression is represented by the sum of variables A, B, C, ... And / or the denominator of the fractional expression is the sum of variables a, b, c, ... It is represented by.
- the fractional formula also includes the sum of the fractional formulas ⁇ , ⁇ , ⁇ , ... With such a configuration (for example, ⁇ + ⁇ ).
- the fractional expression also includes a divided fractional expression.
- the variables used for the numerator and denominator may have appropriate coefficients. Also, the variables used for the numerator and denominator may be duplicated. In addition, an appropriate coefficient may be added to each minute formula. Further, the coefficient value of each variable and the value of the constant term may be real numbers.
- the fractional expression includes the variable of the molecule and the variable of the denominator exchanged.
- values related to other biological information may be further used.
- the formulas used in the evaluation are values related to other biological conditions. It may further include one or more variables to which (eg, the values listed below) are assigned.
- Blood test values for tumor markers albumin, total protein, triglyceride (neutral fat), HbA1c, LDL cholesterol, HDL cholesterol, amylase, total bilirubin, uric acid, etc. 3.
- Immune-related test values such as blood cytokines, number of immunocompetent cells, intracellular cytokines responsible for immunocompetence, and delayed hyperreactivity (DTH). Value obtained from image information such as ultrasonic echo, upper / lower endoscope, X-ray, CT, MRI, etc. 5.
- Biological indicators such as age, height, weight, BMI, blood pressure, gender, smoking information, diet information, drinking information, exercise information, stress information, sleep information, family history information, disease history information (diabetes, pancreatitis, etc.) Value 6. Values obtained from multi-layer omics analysis information, information on oncogene mutations, information on microsatellite instability, information on cancer-derived antigens and antibodies, or information on molecular expression such as PD-1 and PD-L1.
- FIG. 2 is a principle configuration diagram showing the basic principle of the second embodiment.
- the description overlapping with the above-described first embodiment may be omitted.
- a case where the value of the formula or the value after conversion thereof is used when evaluating the pharmacological action of the immune checkpoint inhibitor is described as an example, but for example, the concentration value, the ratio of the concentration values, or Differences in concentration values or values after conversion thereof (for example, concentration deviation values) may be used.
- the control unit is at least one of the 21 amino acids and the 15 amino acid-related metabolites in the blood of an evaluation target (eg, an individual such as an animal or human) that can be treated with an immune checkpoint inhibitor.
- the value of the formula is calculated using the concentration value included in the concentration data acquired in advance regarding the concentration value of the metabolite and the formula stored in advance in the storage unit including the variable to which the concentration value is assigned. Therefore, the pharmacological action of the immune checkpoint inhibitor in the evaluation target is evaluated (step S21).
- the control unit may, for example, determine the ratio of the concentration value before the start of the treatment to the concentration value after the start of the treatment.
- the pharmacological action of the immune checkpoint inhibitor in the evaluation target may be evaluated by calculating the difference and substituting the calculated ratio or the value of the difference into a variable to calculate the value of the equation. This makes it possible to provide highly reliable information that can be used as a reference for understanding individual differences in the pharmacological action of immune checkpoint inhibitors.
- step S21 may be one created based on the formula creation process (steps 1 to 4) described below.
- the outline of the expression creation process will be described.
- the process described here is just an example, and the method of creating an expression is not limited to this.
- the index status information includes concentration data (for example, concentration data before the start of treatment for amino acids and amino acid-related metabolites, concentration data after the start of treatment for amino acids and amino acid-related metabolites, or treatment of amino acids and amino acid-related metabolites.
- Concentration data on the amount of change before and after the start of treatment, etc.) and index data on the prognosis of treatment with an immune checkpoint inhibitor or the risk of side effects due to the treatment eg, binary data on poor / good prognosis
- binary data on the presence or absence of side effects, etc. binary data on the presence or absence of side effects, etc.
- a plurality of different formula creation methods are performed from the index state information.
- a plurality of candidate formulas may be created in combination with those related to multivariate analysis such as trees. Specifically, it is multivariate data composed of concentration data and index data obtained by analyzing blood obtained before and / or after the start of treatment from a large number of patients who can be treated with immune checkpoint inhibitors.
- a plurality of groups of candidate expressions may be created in parallel using a plurality of different algorithms.
- discriminant analysis and logistic regression analysis may be performed simultaneously using different algorithms to create two different candidate expressions.
- the candidate formula may be created by converting the index state information using the candidate formula created by performing the principal component analysis and performing discriminant analysis on the converted index state information. As a result, the optimum formula for evaluation can be finally created.
- the candidate formula created using the principal component analysis is a linear formula that includes each variable that maximizes the variance of all concentration data.
- the candidate formula created using discriminant analysis is a high-order formula (including exponent and logarithm) that includes each variable that minimizes the ratio of the sum of the variances within each group to the variance of all concentration data. is there.
- the candidate expression created using the support vector machine is a high-order expression (including a kernel function) including each variable that maximizes the boundary between groups.
- the candidate formula created by using the multiple regression analysis is a higher-order formula including each variable that minimizes the sum of the distances from all the concentration data.
- the candidate formula created by using Cox regression analysis is a linear model including a logarithmic hazard ratio, and is a linear formula including each variable and its coefficient that maximizes the likelihood of the model.
- the candidate expression created by using logistic regression analysis is a linear model representing the logarithmic odds of the probability, and is a linear expression including each variable that maximizes the likelihood of the probability.
- k-means method k neighborhoods of each density data are searched, the group to which the neighborhood points belong is defined as the group to which the data belongs, and the group to which the input density data belongs. This is a method of selecting a variable that best matches the group defined as.
- the cluster analysis is a method of clustering (grouping) the points at the closest distance among all the concentration data.
- the decision tree is a method of assigning an order to variables and discriminating a group of concentration data from possible patterns of variables having a higher order.
- the control unit verifies (mutually verifies) the candidate formula created in step 1 based on a predetermined verification method (step 2).
- the verification of the candidate formula is performed for each candidate formula created in step 1.
- step 2 based on at least one of the bootstrap method, holdout method, N-fold method, leave one-out method, etc., the discrimination rate, sensitivity, specificity, and information criterion of the candidate formula (Akaike's information) At least one of quantification criteria (AIC), Bayesian information criterion (BIC)), ROC_AUC (area under the curve of the receiver characteristic curve), C-index (Concordance index), and the like may be verified.
- AIC quantification criteria
- BIC Bayesian information criterion
- ROC_AUC area under the curve of the receiver characteristic curve
- C-index Conscordance index
- the discrimination rate is an evaluation method according to the present embodiment, in which an evaluation target whose true state is negative (for example, an evaluation target having a good treatment prognosis or an evaluation target having no side effects) is correctly evaluated as negative. It is the ratio that the evaluation target whose true state is positive (for example, the evaluation target having a poor treatment prognosis or the occurrence of side effects) is correctly evaluated as positive. Further, the sensitivity is a ratio in which the evaluation target whose true state is positive is correctly evaluated as positive in the evaluation method according to the present embodiment. The specificity is the ratio at which the evaluation target whose true state is negative is correctly evaluated as negative in the evaluation method according to the present embodiment.
- the Akaike Information Criterion is a standard that indicates how well the observed data matches the statistical model in the case of regression analysis, etc., and is "-2 x (maximum log likelihood of the statistical model) +2.
- the model with the smallest value defined by " ⁇ (number of free parameters of statistical model)” is judged to be the best.
- the Bayesian Information Criterion is a model selection criterion derived based on the concept of Bayesian statistics, and is "-2 x (maximum log-likelihood of statistical model) + (number of free parameters of statistical model).
- the model with the smallest value defined by "x ln (sample size)" (model with few parameters) is judged to be the best.
- C-index is an index that indicates the accuracy of prognosis prediction proposed by Harrell et al.
- C-index is an index that indicates the accuracy of prognosis prediction proposed by Harrell et al.
- the predictability is an average of the discrimination rate, sensitivity, and specificity obtained by repeating the verification of the candidate formula.
- Robustness is a variance of discrimination rate, sensitivity, and specificity obtained by repeating the verification of candidate expressions.
- the control unit selects the variable of the candidate expression based on the predetermined variable selection method, and selects the combination of the concentration data included in the index state information used when creating the candidate expression. (Step 3).
- the variable may be selected for each candidate expression created in step 1. This makes it possible to appropriately select the variables of the candidate expression.
- step 1 is executed again using the index state information including the concentration data selected in step 3.
- a variable of the candidate expression may be selected based on at least one of the stepwise method, the best path method, the neighborhood search method, and the genetic algorithm from the verification result in step 2.
- the best path method is a method of selecting variables by sequentially reducing the variables included in the candidate expression one by one and optimizing the evaluation index given by the candidate expression.
- the control unit repeatedly executes the above-mentioned steps 1, 2 and 3 and, based on the verification results accumulated by this, is a candidate to be used in the evaluation from among a plurality of candidate formulas.
- the formula used for the evaluation is created (step 4).
- the candidate formula for example, there are a case where the optimum one is selected from the candidate formulas created by the same formula creation method and a case where the optimum one is selected from all the candidate formulas.
- the processes related to the creation of the candidate expression, the verification of the candidate expression, and the selection of the variable of the candidate expression are systematized (systematized) in a series of flows.
- an optimal formula can be created for evaluating the pharmacological action of immune checkpoint inhibitors.
- the concentration values of the 21 types of amino acids and at least one of the 15 types of amino acid-related metabolites are used for multivariate statistical analysis to obtain an optimal and robust set of variables.
- a variable selection method and cross-validation are combined for selection to extract an expression with high evaluation performance.
- FIG. 3 is a diagram showing an example of the overall configuration of this system.
- FIG. 4 is a diagram showing another example of the overall configuration of this system.
- this system includes an evaluation device 100 for evaluating the pharmacological action of an immune checkpoint inhibitor in an individual to be evaluated, the 21 types of amino acids in blood, and the 15 types of amino acid-related metabolites.
- a client device 200 (corresponding to the terminal device of the present invention) that provides individual concentration data regarding the concentration value of at least one of the metabolites is communicably connected via the network 300.
- the client device 200 that provides the data used for the evaluation and the client device 200 that provides the evaluation result may be different.
- this system is a database device that stores index state information used when creating an expression in the evaluation device 100, an expression used in the evaluation, and the like, in addition to the evaluation device 100 and the client device 200.
- the 400 may be connected and configured so as to be communicable via the network 300.
- FIG. 5 is a block diagram showing an example of the configuration of the evaluation device 100 of the present system, and conceptually shows only the portion of the configuration related to the present invention.
- the evaluation device 100 uses a control unit 102 such as a CPU (Central Processing Unit) that collectively controls the evaluation device, a communication device such as a router, and a wired or wireless communication line such as a dedicated line. It is composed of a communication interface unit 104 that is communicably connected to the network 300, a storage unit 106 that stores various databases, tables, files, and the like, and an input / output interface unit 108 that is connected to the input device 112 and the output device 114. Each of these parts is communicably connected via an arbitrary communication path.
- the evaluation device 100 may be configured in the same housing as various analyzers (for example, amino acid and amino acid-related metabolite analyzers).
- the concentration value of at least one of the 21 kinds of amino acids and the 15 kinds of amino acid-related metabolites in blood is calculated (measured), and the calculated value is output (printing, monitor display, etc.).
- a small analyzer having a configuration may be further provided with an evaluation unit 102d described later, and the result obtained by the evaluation unit 102d may be output using the configuration. ..
- the communication interface unit 104 mediates communication between the evaluation device 100 and the network 300 (or a communication device such as a router). That is, the communication interface unit 104 has a function of communicating data with another terminal via a communication line.
- the input / output interface unit 108 is connected to the input device 112 and the output device 114.
- the output device 114 in addition to a monitor (including a home television), a speaker or a printer can be used (in the following, the output device 114 may be described as the monitor 114).
- the input device 112 can use a monitor that realizes a pointing device function in cooperation with the mouse.
- the storage unit 106 is a storage means, and for example, a memory device such as a RAM (Random Access Memory) or a ROM (Read Only Memory), a fixed disk device such as a hard disk, a flexible disk, an optical disk, or the like can be used.
- a computer program for giving instructions to the CPU and performing various processes in cooperation with the OS (Operating System) is recorded in the storage unit 106.
- the storage unit 106 stores the density data file 106a, the index state information file 106b, the designated index state information file 106c, the formula-related information database 106d, and the evaluation result file 106e.
- the concentration data file 106a contains concentration data relating to the concentration values of the 21 amino acids and at least one of the 15 amino acid-related metabolites in the blood (for example, the concentration data before the start of treatment and the concentration data after the start of treatment). Store one or both of the concentration data of.
- FIG. 6 is a diagram showing an example of information stored in the density data file 106a. As shown in FIG. 6, the information stored in the concentration data file 106a is configured by correlating the individual number for uniquely identifying the individual (sample) to be evaluated and the concentration data.
- the density data is treated as a numerical value, that is, a continuous scale, but the density data may be a nominal scale or an ordinal scale. In the case of a nominal scale or an ordinal scale, analysis may be performed by giving an arbitrary numerical value to each state.
- the concentration data may be combined with values related to other biological information (see above).
- the index state information file 106b stores the index state information used when creating the expression.
- FIG. 7 is a diagram showing an example of information stored in the index state information file 106b.
- the information stored in the index status information file 106b includes an individual number, index data regarding the prognosis of treatment with an immune checkpoint inhibitor or the risk of side effects due to the treatment, and concentration data. It is configured to be related to each other.
- the index data and the concentration data are treated as numerical values (that is, continuous scales), but the index data and the concentration data may be a nominal scale or an ordinal scale. In the case of a nominal scale or an ordinal scale, analysis may be performed by giving an arbitrary numerical value to each state.
- the designated index status information file 106c stores the index status information designated by the designated unit 102b, which will be described later.
- FIG. 8 is a diagram showing an example of information stored in the designated index state information file 106c. As shown in FIG. 8, the information stored in the designated index state information file 106c is configured by correlating the individual number, the designated index data, and the designated concentration data with each other.
- the formula-related information database 106d is composed of a formula file 106d1 that stores the formula created by the formula creation unit 102c described later.
- the expression file 106d1 stores the expression used at the time of evaluation.
- FIG. 9 is a diagram showing an example of information stored in the formula file 106d1.
- the information stored in the expression file 106d1 includes the rank, the expression (in FIG. 9, Fp (His, %), Fp (His, hKyn, Kyn), Fk (His, hKyn,). (Kyn, ...), Etc.), the threshold value corresponding to each formula creation method, and the verification result of each formula (for example, the value of each formula) are associated with each other.
- the evaluation result file 106e stores the evaluation results obtained by the evaluation unit 102d, which will be described later.
- FIG. 10 is a diagram showing an example of information stored in the evaluation result file 106e.
- the information stored in the evaluation result file 106e includes an individual number for uniquely identifying the individual (sample) to be evaluated, concentration data of the individual acquired in advance, and the pharmacological action of the immune checkpoint inhibitor (treatment prognosis).
- the evaluation result regarding the evaluation result (for example, the value of the formula calculated by the calculation unit 102d1 described later, the value after the value of the formula is converted by the conversion unit 102d2 described later, the position information generated by the generation unit 102d3 described later, Alternatively, the classification results obtained by the classification unit 102d4, which will be described later, and the like) are associated with each other.
- control unit 102 has an internal memory for storing a control program such as an OS, a program that defines various processing procedures, required data, and the like, and various information processing is performed based on these programs. To execute. As shown in the drawing, the control unit 102 is roughly divided into an acquisition unit 102a, a designation unit 102b, an expression creation unit 102c, an evaluation unit 102d, a result output unit 102e, and a transmission unit 102f.
- the control unit 102 removes data with missing values, removes data with many outliers, and data with missing values with respect to the index status information transmitted from the database device 400 and the density data transmitted from the client device 200. It also performs data processing such as removal of variables with many.
- the acquisition unit 102a acquires information (specifically, concentration data, index state information, formula, etc.). For example, the acquisition unit 102a receives information (specifically, concentration data, index state information, formula, etc.) transmitted from the client device 200 or the database device 400 via the network 300 or the like to obtain information. Acquisition may be performed. The acquisition unit 102a may receive data used for evaluation transmitted from a client device 200 different from the client device 200 to which the evaluation result is transmitted. Further, for example, when the evaluation device 100 includes a mechanism (including hardware and software) for reading out the information recorded on the recording medium, the acquisition unit 102a may use the information (specifically, the information) recorded on the recording medium. Specifically, the information may be acquired by reading out the concentration data, the index state information, the formula, etc.) via the mechanism. The designation unit 102b designates the index data and the concentration data to be targeted when creating the formula.
- the formula creation unit 102c creates a formula based on the index state information acquired by the acquisition unit 102a and the index state information designated by the designation unit 102b.
- the formula creation unit 102c may create the formula by selecting a desired formula from the storage unit 106. Further, the formula creation unit 102c may create a formula by selecting and downloading a desired formula from another computer device (for example, a database device 400) in which the formula is stored in advance.
- the evaluation unit 102d is a concentration included in a formula obtained in advance (for example, a formula created by the formula creation unit 102c or a formula acquired by the acquisition unit 102a) and the concentration data of the individual acquired by the acquisition unit 102a. By calculating the value of the formula using the value, the pharmacological action of the immune checkpoint inhibitor in the individual is evaluated.
- the evaluation unit 102d is a concentration value of at least one of the 21 kinds of amino acids and 15 kinds of amino acid-related metabolites, a ratio of concentration values, a difference in concentration values, or a value after conversion thereof (for example,). The concentration deviation value) may be used to evaluate the pharmacological action of the immune checkpoint inhibitor in an individual.
- FIG. 11 is a block diagram showing the configuration of the evaluation unit 102d, and conceptually shows only the portion of the configuration related to the present invention.
- the evaluation unit 102d further includes a calculation unit 102d1, a conversion unit 102d2, a generation unit 102d3, and a classification unit 102d4.
- the calculation unit 102d1 is assigned a concentration value (which may be the above-mentioned ratio or difference value) of at least one of the 21 types of amino acids and the 15 types of amino acid-related metabolites, and a variable to which the concentration value is assigned. Calculate the value of the equation using an equation that includes at least.
- the evaluation unit 102d may store the value of the formula calculated by the calculation unit 102d1 as an evaluation result in a predetermined storage area of the evaluation result file 106e.
- the conversion unit 102d2 converts the value of the formula calculated by the calculation unit 102d1 by, for example, the conversion method described above.
- the evaluation unit 102d may store the value after conversion by the conversion unit 102d2 as an evaluation result in a predetermined storage area of the evaluation result file 106e. Further, the conversion unit 102d2 may convert the concentration value included in the concentration data or the ratio or difference of the concentration value by, for example, the conversion method described above.
- the generation unit 102d3 uses the value of the formula calculated by the calculation unit 102d1 or the conversion unit 102d2 to obtain position information regarding the position of a predetermined mark on a predetermined object that is visibly displayed on a display device such as a monitor or a physical medium such as paper. It is generated using the value after conversion in (concentration value, ratio of concentration value, difference of concentration value, or these converted values).
- the evaluation unit 102d may store the position information generated by the generation unit 102d3 as an evaluation result in a predetermined storage area of the evaluation result file 106e.
- the classification unit 102d4 uses the value of the formula calculated by the calculation unit 102d1 or the value after conversion by the conversion unit 102d2 (the concentration value, the ratio of the concentration values, the difference between the concentration values, or the value after conversion thereof). Individuals are classified into one of a plurality of categories defined with at least the prognosis of treatment with an immune checkpoint inhibitor or the risk of developing side effects due to the treatment.
- the result output unit 102e outputs the processing results (including the evaluation results obtained by the evaluation unit 102d) of each processing unit of the control unit 102 to the output device 114.
- the transmission unit 102f transmits the evaluation result to the client device 200 that is the source of the individual density data, and transmits the formula and the evaluation result created by the evaluation device 100 to the database device 400.
- the transmission unit 102f may transmit the evaluation result to a client device 200 different from the client device 200 that transmits the data used for the evaluation.
- FIG. 12 is a block diagram showing an example of the configuration of the client device 200 of the present system, and conceptually shows only the portion of the configuration related to the present invention.
- the client device 200 is composed of a control unit 210, a ROM 220, an HD (Hard Disk) 230, a RAM 240, an input device 250, an output device 260, an input / output IF270, and a communication IF280, and each of these units is via an arbitrary communication path. Is connected so that it can communicate with each other.
- the client device 200 is an information processing device (for example, a known personal computer, a workstation, a home-use game device, an Internet TV, a PDA) to which peripheral devices such as a printer, a monitor, and an image scanner are connected as needed. It may be based on a terminal, a mobile terminal, a mobile communication terminal, an information processing terminal such as a PDA (Personal Digital Assist), or the like).
- the input device 250 is a keyboard, mouse, microphone, or the like.
- the monitor 261 described later also realizes the pointing device function in cooperation with the mouse.
- the output device 260 is an output means for outputting information received via the communication IF 280, and includes a monitor (including a home television) 261 and a printer 262. In addition, the output device 260 may be provided with a speaker or the like.
- the input / output IF270 is connected to the input device 250 and the output device 260.
- the communication IF280 connects the client device 200 and the network 300 (or a communication device such as a router) in a communicable manner.
- the client device 200 is connected to the network 300 via a communication device such as a modem, a TA (Terminal Adapter), a router, and a telephone line, or via a dedicated line.
- a communication device such as a modem, a TA (Terminal Adapter), a router, and a telephone line, or via a dedicated line.
- the client device 200 can access the evaluation device 100 according to a predetermined communication rule.
- the control unit 210 includes a receiving unit 211 and a transmitting unit 212.
- the receiving unit 211 receives various information such as the evaluation result transmitted from the evaluation device 100 via the communication IF 280.
- the transmission unit 212 transmits various information such as individual concentration data to the evaluation device 100 via the communication IF 280.
- the control unit 210 may be realized by a CPU and a program that interprets and executes all or any part of the processing performed by the control unit by the CPU and the CPU.
- a computer program for giving instructions to the CPU in cooperation with the OS and performing various processes is recorded in the ROM 220 or HD 230.
- the computer program is executed by being loaded into the RAM 240, and constitutes the control unit 210 in cooperation with the CPU.
- the computer program may be recorded in an application program server connected to the client device 200 via an arbitrary network, and the client device 200 may download all or a part thereof as needed. ..
- all or any part of the processing performed by the control unit 210 may be realized by hardware such as wired logic.
- control unit 210 includes an evaluation unit 210a (calculation unit 210a1, conversion unit 210a2, generation unit 210a3, and classification unit 210a4) having the same function as that of the evaluation unit 102d provided in the evaluation device 100. ) May be provided.
- the evaluation unit 210a uses the conversion unit 210a2 to obtain the value of the equation according to the information included in the evaluation result transmitted from the evaluation device 100.
- the concentration value, the ratio of the concentration values, or the difference between the concentration values may be converted, or the value of the formula or the converted value (concentration value, the ratio of the concentration values or the difference between the concentration values, or after the conversion thereof is performed by the generation unit 210a3).
- the position information corresponding to (may be the value of) is generated, or the value of the formula or the value after conversion (concentration value, the ratio of the concentration values or the difference between the concentration values, or the value after conversion thereof may be used by the classification unit 210a4). May be used to classify an individual into any one of a plurality of categories.
- the network 300 has a function of connecting the evaluation device 100, the client device 200, and the database device 400 so as to be able to communicate with each other.
- the Internet for example, the Internet, an intranet, a LAN (Local Area Network) (including both wired and wireless) and the like.
- the network 300 includes VAN (Value-Added Network), personal computer communication network, public switched telephone network (including both analog / digital), dedicated line network (including both analog / digital), and CATV ().
- IMT International Mobile Telecommunication
- GSM Global System for Mobile Communications
- PDCill including methods, etc.
- wireless calling networks local wireless networks such as Bluetooth (registered trademark), PHS networks, satellite communication networks (CS (Communication Satellite), BS (Roadcasting Satellite), or ISDB (Integrated Services Digital Broadcast). ) Etc.) and the like.
- FIG. 13 is a block diagram showing an example of the configuration of the database device 400 of the present system, and conceptually shows only the portion of the configuration related to the present invention.
- the database device 400 has a function of storing index state information used when creating an expression in the evaluation device 100 or the database device, an expression created in the evaluation device 100, an evaluation result in the evaluation device 100, and the like.
- the database device 400 uses a control unit 402 such as a CPU that collectively controls the database device, a communication device such as a router, and a wired or wireless communication circuit such as a dedicated line.
- a communication interface unit 404 that connects the device to the network 300 so that it can communicate, a storage unit 406 that stores various databases, tables, files (for example, files for Web pages), and an input / output device 412 and an output device 414 that are connected to each other. It is composed of an output interface unit 408, and each of these units is connected so as to be communicable via an arbitrary communication path.
- the storage unit 406 is a storage means, and for example, a memory device such as a RAM / ROM, a fixed disk device such as a hard disk, a flexible disk, an optical disk, or the like can be used.
- the storage unit 406 stores various programs and the like used for various processes.
- the communication interface unit 404 mediates communication between the database device 400 and the network 300 (or a communication device such as a router). That is, the communication interface unit 404 has a function of communicating data with another terminal via a communication line.
- the input / output interface unit 408 is connected to the input device 412 and the output device 414.
- the output device 414 a speaker or a printer can be used in addition to a monitor (including a home television).
- the input device 412 in addition to a keyboard, a mouse, and a microphone, a monitor that realizes a pointing device function in cooperation with the mouse can be used.
- the control unit 402 has an internal memory for storing a control program such as an OS, a program that defines various processing procedures, and required data, and executes various information processing based on these programs. As shown in the drawing, the control unit 402 is roughly classified into a transmission unit 402a and a reception unit 402b.
- the transmission unit 402a transmits various information such as index state information and formulas to the evaluation device 100.
- the receiving unit 402b receives various information such as an expression and an evaluation result transmitted from the evaluation device 100.
- the evaluation device 100 executes from the reception of the concentration data to the calculation of the value of the formula, the classification into the individual categories, and the transmission of the evaluation result, and the client device 200 receives the evaluation result.
- the client device 200 is provided with the evaluation unit 210a, it is sufficient for the evaluation device 100 to calculate the value of the expression.
- the conversion of the value of the expression and the position information The evaluation device 100 and the client device 200 may appropriately share and execute the generation of the data and the classification of the individual into categories.
- the evaluation unit 210a converts the value of the expression by the conversion unit 210a2, or the value of the expression or the value after conversion by the generation unit 210a3.
- the position information corresponding to the above may be generated, or the individual may be classified into any one of a plurality of categories by using the value of the formula or the value after conversion in the classification unit 210a4.
- the evaluation unit 210a When the client device 200 receives the converted value from the evaluation device 100, the evaluation unit 210a generates position information corresponding to the converted value by the generation unit 210a3, or the classification unit 210a4 converts the value.
- the later values may be used to classify the individual into any one of a plurality of categories.
- the evaluation unit 210a uses the value of the formula or the converted value in the classification unit 210a4. Individuals may be classified into any one of a plurality of categories.
- all or a part of the processes described as being automatically performed can be manually performed, or the processes described as being manually performed. It is also possible to automatically perform all or part of the above by a known method.
- processing procedure, control procedure, specific name, information including parameters such as registration data and search conditions of each processing, screen examples, and database configuration shown in the above documents and drawings are not specified unless otherwise specified. Can be changed arbitrarily.
- each component shown in the figure is a functional concept and does not necessarily have to be physically configured as shown in the figure.
- each processing function performed by the control unit 102 even if all or any part thereof is realized by the CPU and a program interpreted and executed by the CPU. It may be realized as hardware by wired logic.
- the program is recorded on a non-temporary computer-readable recording medium including a programmed instruction for causing the information processing apparatus to execute the evaluation method or calculation method according to the present invention, and is evaluated as necessary. It is read mechanically by the device 100. That is, a computer program for giving instructions to the CPU in cooperation with the OS and performing various processes is recorded in a storage unit 106 or the like such as a ROM or an HDD (Hard Disk Drive). This computer program is executed by being loaded into RAM, and cooperates with a CPU to form a control unit.
- this computer program may be stored in the application program server connected to the evaluation device 100 via an arbitrary network, and all or a part thereof can be downloaded as needed.
- the evaluation program or calculation program according to the present invention may be stored in a non-temporary computer-readable recording medium, or may be configured as a program product.
- the "recording medium” includes a memory card, a USB (Universal Serial Bus) memory, an SD (Secure Digital) card, a flexible disk, a magneto-optical disk, a ROM, an EPROM (Erasable Programmable Read Only Memory), and an EPROM (Epil).
- a “program” is a data processing method described in any language or description method, regardless of the format such as source code or binary code.
- the "program” is not necessarily limited to a single program, but is distributed as a plurality of modules or libraries, or cooperates with a separate program represented by the OS to achieve its function. Including things. It should be noted that well-known configurations and procedures can be used for the specific configuration and reading procedure for reading the recording medium in each device shown in the embodiment, the installation procedure after reading, and the like.
- Various databases and the like stored in the storage unit 106 are memory devices such as RAM and ROM, fixed disk devices such as hard disks, flexible disks, and storage means such as optical disks, and are used for various processes and website provision. Stores programs, tables, databases, files for web pages, etc.
- the evaluation device 100 may be configured as an information processing device such as a known personal computer or workstation, or may be configured as the information processing device to which an arbitrary peripheral device is connected. Further, the evaluation device 100 may be realized by mounting software (including a program or data) that realizes the evaluation method or calculation method of the present invention on the information processing device.
- the specific form of the distribution / integration of the device is not limited to the one shown in the drawing, and all or a part thereof may be functionally or physically in an arbitrary unit according to various additions or functional loads. It can be distributed and integrated. That is, the above-described embodiments may be arbitrarily combined and implemented, or the embodiments may be selectively implemented.
- Blood was collected from the peripheral vein before the start of treatment and 6 weeks after the start of treatment, the blood sample was cooled immediately after blood collection, and plasma was separated from the blood sample.
- concentration values of free amino acids and amino acid-related metabolites in plasma were measured using an LC-MS analyzer or an LC-MS / MS analyzer according to the measurement method (A) described in the above-described embodiment.
- the degree of cancer progression, histological type, clinical laboratory test values, etc. were collected from the patients.
- the treatment prognosis (overall survival) for each patient was followed for up to 2 years (mean follow-up 272 days) from the start of treatment.
- FIG. 14 shows changes in blood concentrations of the 21 types of amino acids and the 15 types of amino acid-related metabolites before and after the start of treatment.
- FIG. 14 shows the average value (pre) of the concentration value of each amino acid and each amino acid-related metabolite before the start of treatment and the average value (post) of the concentration value 6 weeks after the start of treatment.
- hKyn, Kyn and QA were significantly increased 6 weeks after the start of treatment as compared with before the start of treatment (p ⁇ 0.05).
- FIG. 15 shows hazard ratios, P-values and C-Index in univariate COX hazard analysis of each amino acid and each amino acid-related metabolite and overall survival.
- FIG. 16 shows hazard ratios, P-values and C-indexes in univariate COX hazard analysis of each amino acid and each amino acid-related metabolite and treatment prognosis (overall survival).
- the blood concentration of the 10 amino acids and the 5 amino acid-related metabolites that had a significant correlation with the treatment prognosis 6 weeks after the start of treatment can be an index for predicting the treatment prognosis of the immune checkpoint inhibitor. It has been found.
- Multivariate analysis of the effects of amino acid and amino acid-related metabolite concentration values in plasma on overall survival using a Cox proportional hazard model was performed, and a discriminant was created to predict the treatment prognosis of immune checkpoint inhibitors.
- variable selection in multivariate analysis using the Cox proportional hazard model when only amino acids are used as explanatory variables, the above 21 types of amino acids are targeted regardless of the presence or absence of significant differences, and combinations of amino acids and amino acid-related metabolites are used.
- the explanatory variable When used as an explanatory variable, the explanatory variable was selected based on P ⁇ 0.15 in the univariate analysis.
- a two-variable discriminant, a three-variable discriminant, a four-variable discriminant, a five-variable discriminant, and a six-variable discriminant were created.
- a discriminant of two variables up to the top 100 discriminants a discriminant of three variables up to the top 100 discriminants, a discriminant of four variables up to the top 100 discriminants, and the top 100 discriminants of discrimination performance.
- the combinations of variables are shown for the discriminants of the five variables up to and the discriminants of the six variables up to the top 100 in the discrimination performance.
- the combination of variables in the discriminant of the top 100 discriminants of the discriminant performance obtained from the amino acids before the start of treatment is described in the following [101. Formula of two variables obtained from amino acids before the start of treatment].
- the combination of variables in the discriminant of the top 100 discriminants of the discriminant performance obtained from the amino acids before the start of treatment is described in the following [102. Formula of three variables obtained from amino acids before the start of treatment].
- the combination of variables in the discriminant of the four variables up to the top 100 in the discrimination performance obtained from the amino acids before the start of treatment is described in the following [103. Formula of 4 variables obtained from amino acids before the start of treatment].
- the combination of variables in the discriminant of the top 100 discriminants of the top 100 discriminants obtained from amino acids and amino acid-related metabolites before the start of treatment is described in the following [106. Formula of two variables obtained from amino acids and amino acid-related metabolites before the start of treatment].
- the combination of variables in the discriminant of the top 100 discriminants of the top 100 discriminants obtained from amino acids and amino acid-related metabolites before the start of treatment is described in the following [107.
- Formula of three variables obtained from amino acids and amino acid-related metabolites before the start of treatment is described in the following [108.
- the combination of variables in the discriminant of the top 100 discriminants of the top 100 discriminants obtained from amino acids and amino acid-related metabolites before the start of treatment is described in the following [109.
- the combination of variables in the discriminant of the top 100 discriminants of the top 100 discriminants obtained from amino acids and amino acid-related metabolites before the start of treatment is described in the following [110.
- the combination of variables in the discriminant of the top 100 discriminants of the discriminant performance obtained from the amino acids 6 weeks after the start of treatment is described in the following [111. Formula of two variables obtained from amino acids after the start of treatment].
- the combination of variables in the discriminant of the three variables up to the top 100 in the discrimination performance obtained from the amino acids 6 weeks after the start of treatment is described in the following [112. Formula of three variables obtained from amino acids after the start of treatment].
- the combination of variables in the discriminant of the four variables up to the top 100 in the discrimination performance obtained from the amino acids 6 weeks after the start of treatment is described in the following [113. Formula of 4 variables obtained from amino acids after the start of treatment].
- the combination of variables in the discriminant of the top 100 discriminants of the top 100 discriminants obtained from amino acids and amino acid-related metabolites 6 weeks after the start of treatment is described in the following [116. Formula of two variables obtained from amino acids and amino acid-related metabolites after the start of treatment].
- the combination of variables in the discriminant of the top 100 discriminants of the top 100 discriminants obtained from amino acids and amino acid-related metabolites 6 weeks after the start of treatment is described in the following [117. Formula of three variables obtained from amino acids and amino acid-related metabolites after the start of treatment].
- the combination of variables in the discriminant of the four variables up to the top 100 in discrimination performance obtained from amino acids and amino acid-related metabolites 6 weeks after the start of treatment is described in the following [118.
- Formula of four variables obtained from amino acids and amino acid-related metabolites after the start of treatment The combination of variables in the discriminant of the top 100 discriminants of the top 100 discriminants obtained from amino acids and amino acid-related metabolites 6 weeks after the start of treatment is described in the following [119. Formula of 5 variables obtained from amino acids and amino acid-related metabolites after the start of treatment]. The combination of variables in the discriminant of the top 100 discriminants of the top 100 discriminants obtained from amino acids and amino acid-related metabolites 6 weeks after the start of treatment is described in the following [120. Formula of 5 variables obtained from amino acids and amino acid-related metabolites after the start of treatment].
- FIG. 17 shows the distribution of C-index representing the performance of the discriminant shown in [6 variable formulas obtained from amino acids and amino acid-related metabolites after the start of treatment].
- the horizontal axis is the number of variables to be combined, and the vertical axis is C-index.
- each distribution shown in (A) is a distribution of C-index corresponding to each discriminant obtained from the concentration value of amino acid
- each distribution shown in (B) is an amino acid and an amino acid-related metabolite. It is a distribution of C-index corresponding to each discriminant obtained from the concentration value.
- the distribution corresponding to the symbols A11, A21, A31, A41, A51, B11, B21, B31, B41, B51 is the distribution of C-index corresponding to the discriminant obtained from the concentration value before the start of treatment.
- the distribution corresponding to A12, A22, A32, A42, A52, B12, B22, B32, B42, B52 is the distribution of C-index corresponding to the discriminant obtained from the concentration value 6 weeks after the start of treatment.
- FIG. 18 shows [101. Formula of two variables obtained from amino acids before the start of treatment] to [105. The frequency of occurrence of variables in the discriminant shown in [6 variable formulas obtained from amino acids before the start of treatment] is shown.
- FIG. 19 shows [106. From [Two-variable equations obtained from amino acids and amino acid-related metabolites before the start of treatment] to [110. The frequency of occurrence of variables in the discriminant shown in [6 variable formulas obtained from amino acids and amino acid-related metabolites before the start of treatment] is shown.
- FIG. 20 shows [111. Formula of two variables obtained from amino acids after the start of treatment] to [115. The frequency of occurrence of variables in the discriminant shown in [6 variable formulas obtained from amino acids after the start of treatment] is shown.
- FIG. 21 shows [116. Two-variable equations obtained from amino acids and amino acid-related metabolites after the start of treatment] to [120. The frequency of occurrence of variables in the discriminant shown in [6 variable formulas obtained from amino acids and amino acid-related metabolites after the start of treatment] is shown.
- FIG. 22 is a diagram illustrating the discriminant performance of the discriminant created with the goal of minimizing the AIC (Akaike's Information Criterion) by the stepwise method among the above discriminants.
- a discriminant was created with four parameters consisting of Ser, Gly, Arg and QA.
- the C-index representing the performance of the created discriminant is 0.775, and when the upper quartile is the cutoff value, the P value of the log rank test is 3.97 ⁇ 10-13.
- the risk ratio was 15.79.
- the created discriminant was able to predict the prognosis of immune checkpoint inhibitor treatment with high accuracy.
- side effects related to treatment with immune checkpoint inhibitors were investigated for the lung cancer patients described in Example 1.
- Side effects related to treatment with immune checkpoint inhibitors include interstitial pneumonia (7 cases), pneumonia (10 cases), rash / pruritus (10 cases), enteritis / diarrhea (6 cases), fever (3 cases), Hyperthyroidism (2 cases), fatigue (2 cases), joint pain (1 case), taste disorder (1 case), AST and ALT abnormalities (1 case) were observed in a total of 22 cases, for a total of 43 cases.
- 5 cases of interstitial pneumonia (2 cases), pneumonia (2 cases), and enteritis (1 case) were observed as side effects of Grade 3 or higher due to CTCAE (Common Terminology Criteria for Adverse Events).
- FIG. 23 shows the ROC_AUC and P values in the univariate correlation analysis between each amino acid and the risk of side effects. Seven types of significantly changing amino acids, His, Ala, Arg, Pro, Tyr, Lys and Trp, were confirmed, and one type of hKyn was confirmed as a significantly changing amino acid-related metabolite. It was found that the seven types of amino acids and the one type of amino acid-related metabolites, which had a significant correlation with the risk of side effects, can be indicators for predicting the risk of side effects caused by immune checkpoint inhibitors.
- variable selection in multivariate analysis by logistic regression model when only amino acids are used as explanatory variables, the above 21 types are targeted regardless of the presence or absence of significant differences, and the combination of amino acids and amino acid-related metabolites is used as the explanatory variable.
- the explanatory variables were selected based on P ⁇ 0.20 in the univariate analysis.
- a two-variable discriminant, a three-variable discriminant, a four-variable discriminant, a five-variable discriminant, and a six-variable discriminant were created.
- a discriminant of two variables up to the top 100 discriminants a discriminant of three variables up to the top 100 discriminants, a discriminant of four variables up to the top 100 discriminants, and the top 100 discriminants of discrimination performance.
- the combinations of variables are shown for the discriminants of the five variables up to and the discriminants of the six variables up to the top 100 in the discrimination performance.
- the combination of variables in the discriminant of the top 100 discriminants of the discriminant performance obtained from the amino acids before the start of treatment is described in the following [201. Formula of two variables obtained from amino acids before the start of treatment].
- the combination of variables in the discriminant of the top 100 discriminants of the discriminant performance obtained from the amino acids before the start of treatment is described in the following [202. Formula of three variables obtained from amino acids before the start of treatment].
- the combination of variables in the discriminant of the four variables up to the top 100 in the discrimination performance obtained from the amino acids before the start of treatment is described in the following [203. Formula of 4 variables obtained from amino acids before the start of treatment].
- the combination of variables in the discriminant of the top 100 discriminants of the top 100 discriminants obtained from amino acids and amino acid-related metabolites before the start of treatment is described in the following [206. Formula of two variables obtained from amino acids and amino acid-related metabolites before the start of treatment].
- the combination of variables in the discriminant of the top 100 discriminants of the top 100 discriminants obtained from amino acids and amino acid-related metabolites before the start of treatment is described in the following [207. Formula of three variables obtained from amino acids and amino acid-related metabolites before the start of treatment].
- the combination of variables in the discriminant of the top 100 discriminants of the top 100 discriminants obtained from amino acids and amino acid-related metabolites before the start of treatment is described in the following [208.
- the combination of variables in the discriminant of the top 100 discriminants of the top 100 discriminants obtained from amino acids and amino acid-related metabolites before the start of treatment is described in the following [209.
- the combination of variables in the discriminant of the top 100 discriminants of the top 100 discriminants obtained from amino acids and amino acid-related metabolites before the start of treatment is described in the following [210.
- FIG. 24 shows the distribution of ROC_AUC representing the performance of the discriminant shown in [6 variable equations obtained from amino acids and amino acid-related metabolites before the start of treatment].
- the horizontal axis is the number of variables to be combined, and the vertical axis is ROC_AUC.
- the distributions corresponding to the symbols C11, C21, C31, C41, and C51 are the distributions of ROC_AUC corresponding to the discriminants obtained from the amino acid concentration values, and correspond to the symbols C12, C22, C32, C42, and C52.
- the distribution is the distribution of ROC_AUC corresponding to the discriminant obtained from the concentration values of amino acids and amino acid-related metabolites. It was shown that the discriminant created in this example can create a highly accurate discriminant for predicting side effects that occur after the start of treatment.
- FIG. 25 shows [201. Formula of two variables obtained from amino acids before the start of treatment] to [205. The frequency of occurrence of variables in the discriminant shown in [6 variable formulas obtained from amino acids before the start of treatment] is shown.
- FIG. 26 shows [206. From [Two-variable equations obtained from amino acids and amino acid-related metabolites before the start of treatment] to [210. The frequency of occurrence of variables in the discriminant shown in [6 variable formulas obtained from amino acids and amino acid-related metabolites before the start of treatment] is shown.
- the progression-free survival (PFS) and response rate which are indicators of the prognosis of treatment with immune checkpoint inhibitors, were also analyzed.
- Blood samples were obtained from patients with advanced / recurrent lung cancer scheduled to be treated with an immune checkpoint inhibitor, and 19 types of amino acids (Arg, Orn, Cit, His, Val, Ph, Tyr, Met, Pro, Trp, Asn, Analysis of Leu, Lys, Thr, Ile, Gln, Ala, Ser, and Gly) and eight amino acid-related metabolites (AnthA, hKyn, hTrp, Kyn, KynA, NP, QA, and XA) were performed.
- the anti-PD-1 antibody nivolumab or pembrolizumab was used as the antibody therapeutic agent.
- Blood was collected from the peripheral vein before the start of treatment, the blood sample was cooled immediately after blood collection, and plasma was separated from the blood sample.
- concentration values of free amino acids and amino acid-related metabolites in plasma were measured using an LC-MS analyzer or an LC-MS / MS analyzer according to the measurement method (A) described in the above-described embodiment.
- the degree of cancer progression, histological type, clinical laboratory test values, etc. were collected from the patients.
- treatment response rate and treatment prognosis for each patient were followed for up to 2 years (mean follow-up period 272 days) from the start of treatment.
- FIG. 27 shows hazard ratios, P-values and C-Index in univariate COX hazard analysis of each amino acid and each amino acid-related metabolite with PFS.
- Three types of amino acids that are significantly changed are Ala, Arg, and Lys, and four types of amino acid-related metabolites that are significantly (P ⁇ 0.05) changed are hKyn, AnthA, QA, and NP.
- Multivariate analysis of the effects of amino acid and amino acid-related metabolite concentration values in plasma on PFS was performed using a Cox proportional hazard model, and a linear discriminant was created to predict the therapeutic prognosis of immune checkpoint inhibitors. Deaths during the follow-up period were treated as events, and patients who could not be followed due to side effects such as treatment interruption or transfer were treated as censored.
- variable selection in multivariate analysis using the Cox proportional hazard model when only amino acids are used as explanatory variables, the 19 types of amino acids are targeted regardless of whether there is a significant difference, and the combination of amino acids and amino acid-related metabolites is used as the explanatory variable.
- the explanatory variables were selected based on P ⁇ 0.20 in the univariate analysis.
- a two-variable discriminant, a three-variable discriminant, a four-variable discriminant, a five-variable discriminant, and a six-variable discriminant were created.
- the combination of variables in the discriminant of the two variables up to the top 99 in the discrimination performance and the C-index value are described in the following [301.
- the combination of variables in the discriminant of the three variables up to the top 100 in the discriminant performance and the C-index value in the [2-variable formula obtained from amino acids before the start of treatment] using PFS as an evaluation index are shown in the following [302.
- the combination of variables in the discriminant of the four variables up to the top 100 in the discriminant performance and the C-index value are added to the [three-variable formula obtained from amino acids before the start of treatment using PFS as an evaluation index] in the following [303.
- the four-variable formula obtained from amino acids before the start of treatment using PFS as an evaluation index] the combination of variables in the discriminant of the five variables up to the top 100 in the discrimination performance, and the C-index value are described in the following [304.
- the 5-variable formula obtained from amino acids before the start of treatment using PFS as an evaluation index] the combination of variables in the discriminant of the 6 variables up to the top 100 discriminants, and the C-index value are described in the following [305.
- PFS is used as an evaluation index and is shown in the 6-variable formula obtained from amino acids before the start of treatment].
- these combinations were obtained from amino acids before the start of treatment using PFS as an evaluation index.
- PFS Using PFS as an evaluation index, the four-variable formula obtained from amino acids and amino acid-related metabolites before the start of treatment], the combination of variables in the five-variable discriminant of the top 100 discriminants, and the C-index value.
- PFS is used as an evaluation index and is shown in the formula of 6 variables obtained from amino acids and amino acid-related metabolites before the start of treatment]. These combinations were obtained from amino acids and amino acid-related metabolites before the start of treatment using PFS as an evaluation index.
- the treatment response rate with immune checkpoint inhibitors was analyzed.
- the best effect was determined according to the RECIST guideline Version 1.1 (EUROPEAN JOURNAL OF CANCER 45 (2009) 228-247), but there was no complete response case (CR).
- CR complete response case
- PR partial response
- SD stable
- PD progression
- the response rate was 30.2% when the PR judgment was successful.
- FIG. 28 shows odds ratios, P-values and ROC_AUC in univariate correlation analysis of each amino acid and each amino acid-related metabolite with therapeutic response rate. No variables showing a significant difference were found, but two types of amino acids, Ala and Arg, were confirmed as amino acids showing a significant tendency (P ⁇ 0.1), and AnthA and NP were confirmed as amino acid-related metabolites showing a significant tendency. Two types were confirmed (see the P-value shown in bold in FIG. 28).
- Multivariate analysis of the effects of concentration values of amino acids and amino acid-related metabolites in plasma on treatment response rate was performed using a logistic regression model, and a discriminant was created to predict the treatment response rate of immune checkpoint inhibitors.
- variable selection in multivariate analysis by logistic regression model when only amino acids are used as explanatory variables, the 19 types of amino acids are targeted regardless of the presence or absence of significant differences, and the combination of amino acids and amino acid-related metabolites is used as the explanatory variable.
- the explanatory variables were selected based on P ⁇ 0.30 in the univariate analysis.
- a two-variable discriminant, a three-variable discriminant, a four-variable discriminant, a five-variable discriminant, and a six-variable discriminant were created.
- the combination of variables in the discriminant of the two variables up to the top 87 in discrimination performance and the ROC_AUC value are described in the following [311.
- the combination of variables in the discriminant of the top 98 discriminants and the ROC_AUC value in the [2-variable formula obtained from amino acids before the start of treatment] with the response rate as an evaluation index are shown in the following [312.
- the combination of variables in the discriminant of the four variables up to the top 100 in the discriminant performance and the ROC_AUC value are added to the [3 variable formula obtained from amino acids before the start of treatment using the response rate as an evaluation index] in the following [313.
- the four-variable formula obtained from amino acids before the start of treatment using the response rate as an evaluation index] the combination of variables in the five-variable discriminant formula up to the top 100 discriminants, and the ROC_AUC value are shown in the following [314.
- the 5-variable formula obtained from amino acids before the start of treatment using the response rate as an evaluation index] the combination of variables in the 6-variable discriminant formula up to the top 100 discriminants, and the ROC_AUC value are shown in the following [315.
- the 6-variable formula obtained from amino acids before the start of treatment using the response rate as an evaluation index] is shown. These combinations were obtained from amino acids before the start of treatment using the response rate as an evaluation index.
- the combination of variables in the discriminant of the two variables up to the top 99 in the discrimination performance and the ROC_AUC value are described in the following [316.
- the two-variable formula obtained from amino acids and amino acid-related metabolites before the start of treatment using the response rate as an evaluation index] the combination of variables in the three-variable discriminant of the top 100 discriminants, and the ROC_AUC value are as follows.
- the combination of variables in the discriminant of the four variables up to the top 100 discriminants, and the ROC_AUC value are as follows. [318.
- the four-variable formula obtained from amino acids and amino acid-related metabolites before the start of treatment using the response rate as an evaluation index] are as follows. [319.
- the 5-variable formula obtained from amino acids and amino acid-related metabolites before the start of treatment using the response rate as an evaluation index] the combination of variables in the 6-variable discriminant of the top 100 discriminants, and the ROC_AUC value are as follows. [320.
- the 6-variable formula obtained from amino acids and amino acid-related metabolites before the start of treatment using the response rate as an evaluation index] is shown. These combinations were obtained from amino acids and amino acid-related metabolites before the start of treatment using the response rate as an evaluation index.
- the present invention can be widely implemented in many industrial fields, particularly in fields such as pharmaceuticals, foods, and medical treatments, and in particular, predicts the therapeutic prognosis of immune checkpoint inhibitors and causes side effects. It is extremely useful in the field of bioinformatics to discriminate.
- Evaluation device 100 Evaluation device 102 Control unit 102a Reception unit 102b Designation unit 102c Expression creation unit 102d Evaluation unit 102d1 Calculation unit 102d2 Conversion unit 102d3 Generation unit 102d4 Classification unit 102e Result output unit 102f Transmission unit 104 Communication interface unit 106 Storage unit 106a Concentration data file 106b Index status information file 106c Designated index status information file 106d Expression related information database 106d1 Expression file 106e Evaluation result file 108 Input / output interface unit 112 Input device 114 Output device 200 Client device (terminal device (information communication terminal device)) 300 network 400 database device
- Trp Kyn, 0.8; Val, Kyn, 0.788; Leu, hKyn, 0.788; Leu, NP, 0.788; AnthA, NP, 0.786; Val, NP, 0.786; Cit, NP, 0.784; Leu, Kyn, 0.784; Leu, AnthA, 0.784; Orn, Trp, 0.783; Orn, NP, 0.781; Val, hKyn, 0.781; Ile, Kyn, 0.781; Cit, QA, 0.779; AnthA, QA, 0.777; Leu, QA, 0.777; Thr, Kyn, 0.777; ABA, QA, 0.777; hKyn, XA, 0.777; Met, Kyn, 0.773; Arg, NP, 0.773; Thr, NP, 0.773; Val, QA, 0.771
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Primary Health Care (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Computational Biology (AREA)
- Data Mining & Analysis (AREA)
- Databases & Information Systems (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
(略称)(正式名称)
Ala Alanine
AnthA Anthranic Acid
Arg Arginine
Asn Asparagine
ABA α-Aminobutyric acid
Cit Citrulline
Gln Glutamine
Glu Glutamic acid
Gly Glycine
hAnthA 3-Hydroxy Anthranilic Acid
hIAA 5-Hydroxy Indol 3-Acetic Acid
His Histidine
hKyn hydroxy Kynurenine
hTrp 5-hydroxy Tryptophan
IAA Indol 3-Acetic Acid
ILA Indol 3-Lactic Acid
Ile Isoleucine
Kyn Kynurenine
KynA Kynurenic Acid
Leu Leucine
Lys Lysine
Met Methionine
NFKyn N-Formyl Kynurenine
NP Neopterin
Orn Ornithine
PA Picolinic Acid
Phe Phenylalanine
Pro Proline
QA Quinolinic Acid
Ser Serine
Serot Serotonine
Thr Threonine
Trp Tryptophan
Tyr Tyrosine
Val Valine
XA Xanthurenic Acid
[1-1.第1実施形態の概要]
ここでは、第1実施形態の概要について図1を参照して説明する。図1は第1実施形態の基本原理を示す原理構成図である。
(A)採取した血液サンプルを遠心することにより血液から血漿を分離する。全ての血漿サンプルは、濃度値の測定時まで-80℃で凍結保存する。濃度値測定時には、アセトニトリルを添加し除蛋白処理を行った後、必要に応じて固層抽出等によりリン脂質等の夾雑物を除去し、標識試薬(3-アミノピリジル-N-ヒドロキシスクシンイミジルカルバメート)を用いてプレカラム誘導体化を行い、そして、液体クロマトグラフィー質量分析法(LC/MS)により濃度値を分析する(国際公開第2003/069328号、国際公開第2005/116629号または非特許文献「Chromatography 2019,40,127-133」を参照)。
(B)採取した血液サンプルを遠心することにより血液から血漿を分離する。全ての血漿サンプルは、濃度値の測定時まで-80℃で凍結保存する。濃度値測定時には、スルホサリチル酸を添加し除蛋白処理を行った後、ニンヒドリン試薬を用いたポストカラム誘導体化法を原理としたアミノ酸分析計により濃度値を分析する。
(C)採取した血液サンプルを、膜やMEMS(Micro Electro Mechanical Systems)技術または遠心分離の原理を用いて血球分離を行い、血液から血漿または血清を分離する。血漿または血清取得後すぐに濃度値の測定を行わない血漿または血清サンプルは、濃度値の測定時まで-80℃で凍結保存する。濃度値測定時には、酵素やアプタマーなど、標的とする血中物質と反応または結合する分子等を用い、基質認識によって増減する物質や分光学的値を定量等することにより濃度値を分析する。
濃度値の取り得る範囲が所定範囲(例えば0.0から1.0までの範囲、0.0から10.0までの範囲、0.0から100.0までの範囲、又は-10.0から10.0までの範囲、など)に収まるようにするためなどに、例えば、濃度値に対して任意の値を加減乗除したり、濃度値を所定の変換手法(例えば、指数変換、対数変換、角変換、平方根変換、プロビット変換、逆数変換、Box-Cox変換、又はべき乗変換など)で変換したり、また、濃度値に対してこれらの計算を組み合わせて行ったりすることで、濃度値を変換してもよい。例えば、濃度値を指数としネイピア数を底とする指数関数の値(具体的には、免疫チェックポイント阻害剤による治療の予後が不良であるまたは当該治療による副作用の発生リスクが高い確率pを定義したときの自然対数ln(p/(1-p))が濃度値と等しいとした場合におけるp/(1-p)の値)をさらに算出してもよく、また、算出した指数関数の値を1と当該値との和で割った値(具体的には、確率pの値)をさらに算出してもよい。
また、特定の条件のときの変換後の値が特定の値となるように、濃度値を変換してもよい。例えば、特異度が80%のときの変換後の値が5.0となり且つ特異度が95%のときの変換後の値が8.0となるように濃度値を変換してもよい。
また、各アミノ酸および各アミノ酸関連代謝物ごとに、濃度分布を正規分布化した後、平均50、標準偏差10となるように偏差値化してもよい。
なお、これらの変換は、男女別や年齢別に行ってもよい。
なお、本明細書における濃度値は、濃度値そのものであってもよく、濃度値を変換した後の値であってもよい。
式の値の取り得る範囲が所定範囲(例えば0.0から1.0までの範囲、0.0から10.0までの範囲、0.0から100.0までの範囲、又は-10.0から10.0までの範囲、など)に収まるようにするためなどに、例えば、式の値に対して任意の値を加減乗除したり、式の値を所定の変換手法(例えば、指数変換、対数変換、角変換、平方根変換、プロビット変換、逆数変換、Box-Cox変換、又はべき乗変換など)で変換したり、また、式の値に対してこれらの計算を組み合わせて行ったりすることで、式の値を変換してもよい。例えば、式の値を指数としネイピア数を底とする指数関数の値(具体的には、免疫チェックポイント阻害剤による治療の予後が不良であるまたは当該治療による副作用の発生リスクが高い確率pを定義したときの自然対数ln(p/(1-p))が式の値と等しいとした場合におけるp/(1-p)の値)をさらに算出してもよく、また、算出した指数関数の値を1と当該値との和で割った値(具体的には、確率pの値)をさらに算出してもよい。
また、特定の条件のときの変換後の値が特定の値となるように、式の値を変換してもよい。例えば、特異度が80%のときの変換後の値が5.0となり且つ特異度が95%のときの変換後の値が8.0となるように式の値を変換してもよい。
また、式の値を、平均50、標準偏差10となるように偏差値化してもよい。
なお、これらの変換は、男女別や年齢別に行ってもよい。
なお、本明細書における式の値は、式の値そのものであってもよく、式の値を変換した後の値であってもよい。
・最小二乗法に基づく重回帰式、線形判別式、主成分分析、正準判別分析などの線形モデル
・最尤法に基づくロジスティック回帰、Cox回帰などの一般化線形モデル
・一般化線形モデルに加えて個体間差、施設間差などの変量効果を考慮した一般化線形混合モデル
・K-means法、階層的クラスター解析などクラスター解析で作成された式
・MCMC(マルコフ連鎖モンテカルロ法)、ベイジアンネットワーク、階層ベイズ法などベイズ統計に基づき作成された式
・サポートベクターマシンや決定木などクラス分類により作成された式
・分数式など上記のカテゴリに属さない手法により作成された式
・異なる形式の式の和で示されるような式
1.アミノ酸およびアミノ酸関連代謝物以外の他の血中の代謝物(糖類・脂質等)、タンパク質、ペプチド、ミネラル、ホルモン等の濃度値
2.腫瘍マーカー、アルブミン、総蛋白、トリグリセリド(中性脂肪)、HbA1c、LDLコレステロール、HDLコレステロール、アミラーゼ、総ビリルビン、尿酸等の血液検査値
3.血中サイトカイン、免疫担当細胞数、免疫担当細胞内サイトカイン、遅延型過分反応(DTH)等の免疫関連検査値
4.超音波エコー、上部・下部内視鏡、X線、CT、MRI等の画像情報から得られる値
5.年齢、身長、体重、BMI、血圧、性別、喫煙情報、食事情報、飲酒情報、運動情報、ストレス情報、睡眠情報、家族の既往歴情報、疾患歴情報(糖尿病、膵炎等)等の生体指標に関する値
6.多層オミックス解析情報、癌遺伝子変異に関する情報、マイクロサテライト不安定性に関する情報、癌由来抗原および抗体に関する情報、または、PD-1やPD-L1等の分子発現に関する情報から得られる値
[2-1.第2実施形態の概要]
ここでは、第2実施形態の概要について図2を参照して説明する。図2は第2実施形態の基本原理を示す原理構成図である。なお、本第2実施形態の説明では、上述した第1実施形態と重複する説明を省略する場合がある。特に、ここでは、免疫チェックポイント阻害剤の薬理作用を評価する際に、式の値又はその変換後の値を用いるケースを一例として記載しているが、例えば、濃度値、濃度値の比若しくは濃度値の差分又はこれらの変換後の値(例えば濃度偏差値など)を用いてもよい。
ここでは、第2実施形態にかかる評価システム(以下では本システムと記す場合がある。)の構成について、図3から図13を参照して説明する。なお、本システムはあくまでも一例であり、本発明はこれに限定されない。特に、ここでは、免疫チェックポイント阻害剤の薬理作用を評価する際に、式の値又はその変換後の値を用いるケースを一例として記載しているが、例えば、濃度値、濃度値の比若しくは濃度値の差分又はこれらの変換後の値(例えば濃度偏差値など)を用いてもよい。
例えば、クライアント装置200は、評価装置100から式の値を受信した場合には、評価部210aは、変換部210a2で式の値を変換したり、生成部210a3で式の値又は変換後の値に対応する位置情報を生成したり、分類部210a4で式の値又は変換後の値を用いて個体を複数の区分のうちのどれか1つに分類したりしてもよい。
また、クライアント装置200は、評価装置100から変換後の値を受信した場合には、評価部210aは、生成部210a3で変換後の値に対応する位置情報を生成したり、分類部210a4で変換後の値を用いて個体を複数の区分のうちのどれか1つに分類したりしてもよい。
また、クライアント装置200は、評価装置100から式の値又は変換後の値と位置情報とを受信した場合には、評価部210aは、分類部210a4で式の値又は変換後の値を用いて個体を複数の区分のうちのどれか1つに分類してもよい。
本発明にかかる評価装置、算出装置、評価方法、算出方法、評価プログラム、算出プログラム、記録媒体、評価システムおよび端末装置は、上述した第2実施形態以外にも、請求の範囲に記載した技術的思想の範囲内において種々の異なる実施形態にて実施されてよいものである。
102 制御部
102a 受信部
102b 指定部
102c 式作成部
102d 評価部
102d1 算出部
102d2 変換部
102d3 生成部
102d4 分類部
102e 結果出力部
102f 送信部
104 通信インターフェース部
106 記憶部
106a 濃度データファイル
106b 指標状態情報ファイル
106c 指定指標状態情報ファイル
106d 式関連情報データベース
106d1 式ファイル
106e 評価結果ファイル
108 入出力インターフェース部
112 入力装置
114 出力装置
200 クライアント装置(端末装置(情報通信端末装置))
300 ネットワーク
400 データベース装置
Arg,Met, 0.76; Arg,Phe, 0.753; Arg,Ile, 0.741; Arg,Lys, 0.737; Arg,Tyr, 0.73; Arg,Leu, 0.729; His,Phe, 0.729; Gly,Arg, 0.729; Arg,ABA, 0.727; Glu,Arg, 0.725; His,Met, 0.725; Arg,Val, 0.724; Thr,Arg, 0.72; Arg,Pro, 0.718; Gln,Arg, 0.711; His,ABA, 0.711; Asn,Arg, 0.706; His,Leu, 0.706; Arg,Trp, 0.703; Ser,Arg, 0.702; Phe,Trp, 0.701; Gly,His, 0.701; His,Arg, 0.699; His,Val, 0.698; Ala,Arg, 0.697; Cit,Arg, 0.697; Arg,Orn, 0.696; His,Tyr, 0.696; Gly,Cit, 0.695; His,Pro, 0.694; Asn,His, 0.693; Gly,Trp, 0.691; His,Orn, 0.691; Ser,His, 0.69; Ala,Phe, 0.689; Glu,His, 0.689; Gln,His, 0.688; Gly,Ala, 0.687; His,Cit, 0.687; Asn,Cit, 0.687; Ala,Cit, 0.686; Met,Trp, 0.683; His,Lys, 0.683; Glu,Cit, 0.68; His,Thr, 0.679; Tyr,Trp, 0.679; Ser,Cit, 0.678; Cit,Phe, 0.676; His,Ala, 0.674; His,Trp, 0.673; Ala,Met, 0.668; Ala,Orn, 0.667; Ala,Leu, 0.666; Ala,Ile, 0.665; Leu,Trp, 0.664; ABA,Trp, 0.662; Ser,Ala, 0.661; Thr,Cit, 0.661; Ala,Tyr, 0.661; Cit,Tyr, 0.661; Val,Phe, 0.66; Glu,Trp, 0.66; Glu,Ala, 0.658; Gly,Orn, 0.658; Ile,Trp, 0.657; Ser,Trp, 0.657; Ala,Pro, 0.655; Ala,Val, 0.654; Gly,Lys, 0.654; Ala,ABA, 0.654; Cit,Val, 0.654; Ala,Trp, 0.653; Gln,Ala, 0.65; Thr,Phe, 0.649; Gly,Thr, 0.649; Orn,Trp, 0.648; Thr,Ala, 0.647; Ala,Lys, 0.646; Gly,Val, 0.645; Cit,Lys, 0.645; Asn,Ala, 0.645; Lys,Phe, 0.643; Pro,Trp, 0.642; Lys,Trp, 0.641; Gln,Trp, 0.638; Thr,ABA, 0.638; Tyr,Phe, 0.637; Asn,Trp, 0.636; Thr,Ile, 0.636; Thr,Tyr, 0.633; Glu,Thr, 0.631; Thr,Orn, 0.63; Ser,Thr, 0.629; Thr,Val, 0.629; Thr,Pro, 0.629; Thr,Lys, 0.627; Asn,Thr, 0.626; Gln,Thr, 0.625; Thr,Met, 0.622; Thr,Leu, 0.621
Ala,Arg,Met, 0.784; His,Arg,Met, 0.781; Arg,Met,Trp, 0.777; Ala,Arg,Phe, 0.776; Arg,Met,Phe, 0.771; Glu,Arg,Met, 0.771; Arg,Val,Phe, 0.769; Arg,Val,Met, 0.768; Arg,ABA,Met, 0.764; Arg,Tyr,Met, 0.763; Gln,Arg,Met, 0.763; Arg,Met,Leu, 0.763; Thr,Arg,Met, 0.762; Arg,Met,Lys, 0.762; Ser,Arg,Phe, 0.762; Arg,Met,Orn, 0.76; Ala,Arg,Lys, 0.76; Arg,Phe,Trp, 0.759; Arg,Met,Ile, 0.759; Cit,Arg,Met, 0.759; Arg,Pro,Met, 0.756; Asn,Arg,Phe, 0.755; Arg,Orn,Phe, 0.755; Arg,Ile,Phe, 0.754; Arg,Pro,Phe, 0.754; Arg,Leu,Phe, 0.754; Gly,Arg,Phe, 0.754; Arg,Tyr,Phe, 0.753; Arg,Lys,Phe, 0.752; His,Arg,Phe, 0.752; Cit,Arg,Phe, 0.75; Glu,Arg,Ile, 0.748; Gly,Thr,Arg, 0.748; Arg,Pro,Ile, 0.746; Arg,Tyr,Lys, 0.745; Arg,Pro,Lys, 0.745; Arg,Val,Ile, 0.743; Arg,Tyr,Ile, 0.742; Gly,Arg,Ile, 0.742; Thr,Arg,Ile, 0.742; Cit,Arg,Ile, 0.742; Arg,Lys,Leu, 0.741; Arg,Orn,Leu, 0.741; His,Arg,Ile, 0.74; Asn,Arg,Ile, 0.74; Arg,ABA,Tyr, 0.74; Gly,Arg,Lys, 0.74; Arg,Ile,Trp, 0.739; Ala,Arg,Ile, 0.739; Gln,Arg,Ile, 0.739; Gly,Gln,Arg, 0.739; Arg,Leu,Trp, 0.738; Ala,Arg,Tyr, 0.738; His,Arg,Lys, 0.738; Gly,Arg,ABA, 0.738; Arg,Pro,ABA, 0.737; Ser,Arg,Leu, 0.737; Gly,Arg,Leu, 0.737; Glu,Arg,ABA, 0.737; Arg,ABA,Ile, 0.736; Arg,Pro,Leu, 0.736; Glu,Arg,Leu, 0.736; Gln,Arg,ABA, 0.736; Gln,Arg,Leu, 0.735; Ala,Arg,Leu, 0.735; Arg,Pro,Val, 0.735; His,Arg,Leu, 0.734; Arg,Val,Lys, 0.734; Glu,Arg,Tyr, 0.734; Arg,Pro,Tyr, 0.734; Gln,Arg,Lys, 0.734; Arg,Tyr,Leu, 0.733; Arg,Val,Leu, 0.733; Asn,Arg,Tyr, 0.733; Thr,Arg,ABA, 0.732; Gln,Arg,Val, 0.731; Glu,Ala,Arg, 0.731; Ala,Orn,Phe, 0.73; Thr,Arg,Leu, 0.73; Arg,Tyr,Val, 0.73; Ser,Arg,Tyr, 0.73; Glu,Gly,Arg, 0.73; Arg,Val,Trp, 0.729; Gln,Arg,Tyr, 0.729; Arg,ABA,Leu, 0.729; Ser,Gly,Arg, 0.729; Thr,Arg,Tyr, 0.729; Arg,ABA,Trp, 0.728; Arg,ABA,Lys, 0.728; Gly,Arg,Trp, 0.728; Cit,Arg,Tyr, 0.728; Ser,Arg,ABA, 0.728; Glu,Asn,Arg, 0.727; His,Arg,ABA, 0.727; Ala,Arg,Val, 0.726; Ala,Arg,ABA, 0.726; Glu,Arg,Trp, 0.725; Gly,Ala,Arg, 0.723; Asn,Arg,ABA, 0.722; Ala,Arg,Pro, 0.721
Glu,Arg,Met,Trp, 0.798; Gly,Arg,Met,Trp, 0.796; Gly,Ala,Arg,Met, 0.793; Ala,Arg,Met,Lys, 0.793; Glu,Ala,Arg,Met, 0.792; Ala,Arg,Met,Trp, 0.79; Ala,Arg,Met,Leu, 0.789; His,Arg,Tyr,Met, 0.789; Gly,His,Arg,Met, 0.788; His,Arg,Met,Orn, 0.788; Arg,Met,Phe,Trp, 0.787; Ala,Arg,Met,Phe, 0.787; Thr,Ala,Arg,Met, 0.787; Arg,Met,Ile,Trp, 0.786; Gln,His,Arg,Met, 0.786; Ala,Arg,Val,Met, 0.785; Ala,Arg,Tyr,Met, 0.785; Ala,Cit,Arg,Met, 0.784; Ala,Arg,Tyr,Phe, 0.784; Ala,Arg,ABA,Met, 0.783; Gln,Ala,Arg,Met, 0.783; Ala,Arg,Pro,Met, 0.783; Arg,Val,Met,Trp, 0.782; Arg,Met,Lys,Trp, 0.782; His,Arg,Pro,Met, 0.782; Arg,Met,Leu,Phe, 0.781; His,Arg,Met,Leu, 0.781; Gly,Arg,Val,Met, 0.781; Gly,Arg,Met,Leu, 0.779; Gln,Arg,Met,Phe, 0.779; Asn,Arg,Met,Leu, 0.779; Glu,Arg,Val,Met, 0.778; Arg,Tyr,Met,Trp, 0.777; Gln,His,Arg,Phe, 0.777; Thr,Arg,Met,Trp, 0.776; Glu,Arg,Tyr,Met, 0.776; Gly,Arg,Met,Lys, 0.776; Glu,Arg,Met,Phe, 0.775; Ala,Arg,ABA,Phe, 0.775; Arg,ABA,Met,Phe, 0.774; Asn,Arg,Met,Ile, 0.773; Gly,Ala,Arg,Phe, 0.773; Asn,Gln,Arg,Met, 0.772; Glu,Asn,Arg,Met, 0.772; Gly,Arg,Tyr,Met, 0.772; Gln,Thr,Arg,Phe, 0.772; Asn,Arg,Val,Met, 0.771; Arg,Met,Ile,Phe, 0.771; Gln,Arg,Val,Phe, 0.771; Gly,Arg,ABA,Met, 0.771; Gly,Thr,Arg,Met, 0.77; Asn,Arg,Met,Orn, 0.77; Glu,Ala,Arg,Phe, 0.77; Arg,Val,Met,Orn, 0.769; Ser,Arg,Pro,Phe, 0.769; Gly,Arg,Val,Phe, 0.769; Asn,Arg,Pro,Met, 0.768; Ala,Arg,Orn,Phe, 0.768; Glu,Gln,Arg,Met, 0.768; Glu,Arg,Met,Orn, 0.768; Thr,Arg,Val,Phe, 0.768; Ser,Arg,Phe,Trp, 0.767; Arg,Pro,Met,Phe, 0.767; Arg,Val,Leu,Phe, 0.767; Gly,Arg,Pro,Met, 0.767; Glu,Cit,Arg,Met, 0.767; Arg,Val,Met,Ile, 0.767; Ala,Cit,Arg,Phe, 0.767; Gln,Arg,Val,Met, 0.767; Gln,Arg,Met,Lys, 0.766; Ser,Arg,Tyr,Met, 0.765; Arg,Val,Orn,Phe, 0.765; Arg,Pro,ABA,Met, 0.764; Gln,Arg,Met,Ile, 0.764; Asn,Gln,Arg,Phe, 0.764; Glu,Thr,Arg,Met, 0.763; Arg,Tyr,Met,Ile, 0.763; Ser,Arg,Met,Lys, 0.763; Thr,Arg,ABA,Met, 0.763; Thr,Arg,Met,Leu, 0.763; Arg,Pro,Tyr,Met, 0.763; Arg,ABA,Met,Orn, 0.763; Ser,Arg,Met,Leu, 0.763; Gln,Arg,Met,Orn, 0.763; Gln,Cit,Arg,Met, 0.763; Cit,Arg,Val,Phe, 0.763; Ser,Thr,Arg,Met, 0.762; Arg,Val,Phe,Trp, 0.762; Thr,Arg,Phe,Trp, 0.761; Arg,Met,Orn,Lys, 0.761; Thr,Arg,Pro,Met, 0.76; Arg,Pro,Phe,Trp, 0.759; Arg,ABA,Phe,Trp, 0.755; Gln,Arg,Pro,Met, 0.755; Arg,Tyr,Phe,Trp, 0.754; Arg,Orn,Lys,Phe, 0.753; Arg,Orn,Phe,Trp, 0.752; Arg,Lys,Phe,Trp, 0.751; Arg,Lys,Ile,Phe, 0.747; Arg,Tyr,Ile,Trp, 0.741
Ala,Arg,Met,Leu,Phe, 0.805; Ala,Arg,Met,Lys,Trp, 0.805; Ala,Arg,Val,Met,Phe, 0.803; Gly,Ala,Arg,Met,Ile, 0.8; Gln,Ala,Arg,Met,Phe, 0.796; Ala,Arg,Met,Phe,Trp, 0.796; Asn,Ala,Arg,Met,Trp, 0.796; Arg,Met,Lys,Phe,Trp, 0.796; Ser,Gly,Arg,Met,Trp, 0.796; Gly,Ala,Arg,Met,Trp, 0.795; Ala,Arg,Pro,Met,Trp, 0.795; Gln,His,Arg,Met,Trp, 0.795; Ser,Ala,Arg,Met,Trp, 0.794; Arg,Val,Met,Phe,Trp, 0.794; Glu,Gly,Ala,Arg,Met, 0.794; His,Cit,Arg,Met,Orn, 0.794; Ala,Arg,Met,Leu,Trp, 0.793; Arg,ABA,Met,Phe,Trp, 0.793; His,Cit,Arg,Met,Phe, 0.793; Ala,Arg,Met,Lys,Phe, 0.792; Ala,Cit,Arg,Met,Trp, 0.792; Gln,Ala,Arg,Met,Trp, 0.792; Arg,Met,Leu,Phe,Trp, 0.792; Cit,Arg,Met,Phe,Trp, 0.792; Gly,His,Arg,Met,Trp, 0.792; His,Ala,Arg,Met,Phe, 0.792; Ala,Arg,Val,Met,Lys, 0.792; His,Ala,Arg,Met,Trp, 0.791; Gln,Arg,Met,Phe,Trp, 0.791; Ala,Arg,Tyr,Val,Met, 0.791; Gln,Ala,Arg,Met,Leu, 0.79; Ala,Cit,Arg,Met,Ile, 0.79; Asn,Ala,Arg,Met,Phe, 0.789; Ala,Arg,Tyr,Met,Lys, 0.789; Asn,His,Arg,Tyr,Met, 0.789; Glu,Gly,Arg,Val,Met, 0.789; Ser,Arg,Met,Phe,Trp, 0.788; Ala,Arg,Met,Ile,Leu, 0.788; Thr,Ala,Arg,ABA,Met, 0.788; Ser,Ala,Arg,Met,Leu, 0.788; Glu,His,Arg,Met,Ile, 0.788; Thr,Ala,Arg,Met,Phe, 0.787; Ser,Ala,Arg,Met,Phe, 0.787; Glu,His,Arg,Met,Phe, 0.787; His,Arg,ABA,Met,Leu, 0.787; Ser,Ala,Arg,Met,Ile, 0.786; Arg,ABA,Val,Met,Trp, 0.786; Ala,Arg,ABA,Met,Phe, 0.785; Ser,His,Ala,Arg,Met, 0.785; His,Ala,Cit,Arg,Met, 0.785; Gly,Gln,Arg,Val,Met, 0.785; Glu,Ser,His,Arg,Met, 0.784; Asn,Arg,Pro,Met,Trp, 0.783; Arg,Met,Orn,Lys,Trp, 0.783; Glu,His,Arg,Met,Lys, 0.783; Arg,Val,Ile,Phe,Trp, 0.782; Asn,Arg,Val,Met,Trp, 0.782; Gln,Arg,Met,Leu,Trp, 0.782; His,Ala,Arg,Pro,Met, 0.782; Ser,Gln,Ala,Arg,Phe, 0.782; His,Arg,Met,Orn,Leu, 0.782; Arg,Tyr,Met,Leu,Trp, 0.78; Gln,Arg,Met,Orn,Phe, 0.779; Gln,Arg,Met,Ile,Phe, 0.779; Cit,Arg,Val,Ile,Phe, 0.778; His,Thr,Arg,Val,Met, 0.778; Glu,Arg,Tyr,Met,Phe, 0.778; Asn,His,Arg,Pro,Met, 0.778; Gly,Arg,Tyr,Val,Met, 0.778; Glu,Arg,Met,Orn,Phe, 0.778; Ala,Arg,Pro,Val,Phe, 0.777; Asn,Arg,Tyr,Val,Met, 0.777; Asn,Gly,Arg,ABA,Met, 0.776; Ser,Arg,Ile,Phe,Trp, 0.775; Ala,Arg,Orn,Ile,Phe, 0.775; Arg,Pro,Ile,Leu,Phe, 0.774; Gln,Ala,Arg,Val,Phe, 0.773; Asn,Thr,Arg,Met,Orn, 0.773; Ser,Thr,Arg,Met,Phe, 0.773; Thr,Ala,Arg,Phe,Trp, 0.772; Ala,Arg,Pro,Phe,Trp, 0.772; Gly,His,Thr,Arg,Met, 0.771; Asn,Thr,Arg,Met,Ile, 0.771; Thr,Arg,ABA,Met,Leu, 0.77; Ala,Arg,Orn,Lys,Phe, 0.769; Thr,Arg,Lys,Phe,Trp, 0.769; Asn,Ala,Arg,Val,Phe, 0.769; Glu,Asn,Thr,Arg,Met, 0.769; Arg,Tyr,Ile,Leu,Phe, 0.768; Thr,Cit,Arg,Met,Phe, 0.768; Glu,Thr,Arg,ABA,Met, 0.767; Ala,Arg,Lys,Phe,Trp, 0.766; Asn,Ala,Arg,Lys,Phe, 0.765; Thr,Arg,ABA,Met,Orn, 0.765; Arg,Val,Lys,Phe,Trp, 0.761; Thr,Arg,Tyr,Phe,Trp, 0.761; Thr,Arg,Val,Met,Lys, 0.76; Thr,Ala,Arg,Lys,Phe, 0.758; Arg,Orn,Lys,Phe,Trp, 0.753; His,Arg,Lys,Phe,Trp, 0.752
Glu,Ala,Arg,Met,Leu,Phe, 0.821; His,Arg,Val,Met,Lys,Phe, 0.82; Gly,Ala,Arg,Val,Met,Phe, 0.817; Glu,Ala,Arg,Val,Met,Phe, 0.813; Glu,Asn,Ala,Arg,Met,Trp, 0.811; Gly,Ala,Arg,Val,Met,Lys, 0.81; Ala,Arg,Val,Met,Lys,Phe, 0.809; Ala,Arg,Val,Met,Orn,Phe, 0.809; Gly,His,Ala,Arg,Met,Leu, 0.809; Ala,Arg,Val,Met,Phe,Trp, 0.808; Glu,Ala,Cit,Arg,Met,Trp, 0.806; Glu,Ala,Arg,Tyr,Met,Trp, 0.806; Glu,Ala,Arg,Met,Phe,Trp, 0.804; Gly,Ala,Arg,Met,Phe,Trp, 0.803; Ser,Ala,Arg,Val,Met,Phe, 0.803; Gly,Ala,Cit,Arg,Val,Met, 0.803; Thr,Ala,Arg,Met,Phe,Trp, 0.802; Glu,Ala,Arg,Pro,Met,Phe, 0.802; Ala,Arg,Met,Ile,Phe,Trp, 0.801; Glu,Ser,Ala,Arg,Met,Trp, 0.801; Gly,Gln,Ala,Arg,Met,Lys, 0.801; Gly,Ala,Arg,Met,Leu,Trp, 0.8; Glu,Arg,Met,Orn,Phe,Trp, 0.8; Ala,Arg,Pro,Ile,Leu,Phe, 0.8; Gln,Ala,Arg,Met,Phe,Trp, 0.799; Ser,Ala,Arg,Met,Phe,Trp, 0.799; Glu,Asn,Arg,Met,Phe,Trp, 0.799; Glu,Arg,Tyr,Met,Orn,Trp, 0.799; Glu,Gln,Arg,Met,Lys,Trp, 0.799; Gly,Ala,Arg,Pro,Met,Trp, 0.798; Glu,Ser,Ala,Arg,Met,Phe, 0.798; Glu,Gln,His,Arg,Met,Trp, 0.798; His,Ala,Arg,Met,Phe,Trp, 0.797; Gly,Gln,Ala,Arg,Met,Trp, 0.797; Glu,Arg,Met,Ile,Phe,Trp, 0.797; Glu,Ala,Arg,ABA,Met,Orn, 0.797; Arg,ABA,Met,Leu,Phe,Trp, 0.796; Glu,Arg,ABA,Met,Orn,Trp, 0.796; Ala,Arg,ABA,Met,Lys,Phe, 0.796; Gly,Gln,Thr,Ala,Arg,Met, 0.796; Ala,Arg,Val,Met,Lys,Leu, 0.796; Ser,Ala,Arg,Met,Lys,Trp, 0.795; Ala,Cit,Arg,Val,Met,Trp, 0.795; Gly,Gln,Arg,Met,Phe,Trp, 0.795; Ser,Ala,Arg,Val,Met,Trp, 0.795; Arg,Pro,Met,Lys,Phe,Trp, 0.795; Glu,Asn,Gly,Arg,Met,Trp, 0.795; Glu,Asn,Ala,Arg,Met,Ile, 0.795; Ser,Ala,Arg,Val,Met,Lys, 0.795; Gln,Ala,Arg,Met,Lys,Leu, 0.795; Ala,Arg,Val,Met,Lys,Ile, 0.795; Ala,Arg,Tyr,Met,Phe,Trp, 0.794; Gly,Ala,Cit,Arg,Met,Trp, 0.794; Gly,Thr,Ala,Arg,Met,Ile, 0.794; Ala,Arg,Pro,Val,Met,Trp, 0.794; Gly,Thr,Ala,Arg,Tyr,Met, 0.794; His,Arg,Tyr,Met,Lys,Trp, 0.794; Glu,Ser,Arg,Met,Ile,Trp, 0.794; Glu,Ala,Arg,Met,Lys,Phe, 0.793; Ala,Cit,Arg,Pro,Met,Trp, 0.793; Glu,His,Ala,Arg,Met,Phe, 0.793; Gln,Ala,Arg,Val,Ile,Phe, 0.793; Glu,Asn,Ala,Arg,ABA,Met, 0.793; Thr,Cit,Arg,Met,Phe,Trp, 0.792; Ala,Cit,Arg,Val,Met,Lys, 0.792; Asn,Ala,Arg,Met,Ile,Phe, 0.791; Gln,Ala,Arg,Met,Ile,Trp, 0.791; Ala,Arg,Tyr,Val,Met,Lys, 0.791; His,Ala,Arg,Val,Met,Trp, 0.79; Gln,Arg,Met,Orn,Phe,Trp, 0.79; Arg,Pro,ABA,Met,Phe,Trp, 0.79; His,Thr,Ala,Arg,Tyr,Met, 0.789; Gln,Thr,Ala,Arg,Met,Trp, 0.788; Asn,Gln,Arg,ABA,Met,Trp, 0.788; Ser,His,Arg,Met,Ile,Trp, 0.788; Glu,Ser,Ala,Cit,Arg,Met, 0.788; Thr,Arg,Met,Ile,Phe,Trp, 0.788; Gln,His,Thr,Ala,Arg,Met, 0.788; Thr,Ala,Arg,Pro,Tyr,Met, 0.788; Asn,Gln,Ala,Arg,Met,Leu, 0.788; Thr,Ala,Arg,Tyr,Met,Ile, 0.787; Ser,Ala,Arg,Val,Lys,Phe, 0.787; Gln,Thr,Ala,Arg,Met,Ile, 0.786; Thr,Ala,Arg,Tyr,Met,Lys, 0.786; Asn,Arg,ABA,Tyr,Met,Trp, 0.786; Ser,Ala,Arg,Val,Met,Ile, 0.786; Ala,Arg,ABA,Val,Lys,Phe, 0.785; His,Arg,Tyr,Val,Met,Trp, 0.785; Thr,Ala,Arg,Val,Lys,Phe, 0.784; Ala,Arg,Val,Lys,Leu,Phe, 0.784; Asn,Gln,Ala,Arg,Met,Orn, 0.784; Asn,Thr,Arg,Pro,Met,Trp, 0.783; Ser,Asn,Arg,Val,Met,Trp, 0.782; Asn,Gly,Arg,Pro,Met,Trp, 0.781; Ala,Arg,Val,Lys,Phe,Trp, 0.78; Gly,Ala,Arg,Val,Lys,Phe, 0.78; Ser,Asn,Thr,Arg,Met,Trp, 0.778; Thr,Arg,Tyr,Met,Ile,Trp, 0.778; Thr,Arg,Pro,Met,Ile,Trp, 0.774; Ser,Arg,Pro,Met,Lys,Trp, 0.773
Arg,Kyn, 0.771; Arg,hKyn, 0.741; Cit,QA, 0.738; Arg,Lys, 0.737; His,QA, 0.736; Arg,QA, 0.735; hKyn,AnthA, 0.731; His,hKyn, 0.729; Gly,Arg, 0.729; Arg,hAnthA, 0.728; His,AnthA, 0.726; Cit,hKyn, 0.722; His,Kyn, 0.722; Arg,NP, 0.721; Thr,Arg, 0.72; AnthA,Kyn, 0.72; Trp,hKyn, 0.719; AnthA,QA, 0.716; Arg,AnthA, 0.715; Cit,Kyn, 0.713; hTrp,AnthA, 0.712; His,hTrp, 0.712; His,hAnthA, 0.711; Cit,NP, 0.71; Ala,hKyn, 0.709; Ala,Kyn, 0.708; Ala,AnthA, 0.707; Asn,Arg, 0.706; Arg,hTrp, 0.704; Arg,Trp, 0.703; Ser,Arg, 0.702; Gly,His, 0.701; Lys,hKyn, 0.7; His,Arg, 0.699; AnthA,NP, 0.699; Ala,Arg, 0.697; Cit,Arg, 0.697; Thr,hKyn, 0.697; His,NP, 0.697; Arg,Orn, 0.696; Ala,QA, 0.695; Gly,Cit, 0.695; Trp,Kyn, 0.694; Gly,Trp, 0.691; His,Orn, 0.691; Trp,hAnthA, 0.689; Gly,hKyn, 0.689; hKyn,hTrp, 0.689; Orn,hKyn, 0.689; hKyn,NP, 0.688; Gly,Ala, 0.687; His,Cit, 0.687; Ala,Cit, 0.686; Cit,hTrp, 0.686; Cit,hAnthA, 0.685; Cit,AnthA, 0.684; Trp,AnthA, 0.683; Asn,hKyn, 0.681; Cit,Trp, 0.68; Lys,AnthA, 0.68; Ser,hKyn, 0.679; His,Thr, 0.679; Gly,AnthA, 0.679; Ala,hAnthA, 0.678; Ser,Cit, 0.678; hTrp,QA, 0.677; Thr,QA, 0.676; hKyn,QA, 0.673; His,Trp, 0.673; Trp,QA, 0.673; Gly,QA, 0.671; hAnthA,AnthA, 0.671; Asn,AnthA, 0.671; Orn,NP, 0.67; Ala,NP, 0.669; Thr,Kyn, 0.669; Ser,AnthA, 0.668; hTrp,NP, 0.668; Ala,Orn, 0.667; hKyn,hAnthA, 0.667; Ala,hTrp, 0.664; hKyn,Kyn, 0.664; Ser,Ala, 0.661; Thr,Cit, 0.661; Thr,AnthA, 0.659; Gly,NP, 0.658; Ser,Trp, 0.657; Thr,hAnthA, 0.654; Lys,hAnthA, 0.654; Ala,Trp, 0.653; Trp,hTrp, 0.651; Thr,NP, 0.649; Orn,Trp, 0.648; Thr,Ala, 0.647; Cit,Lys, 0.645; Thr,Trp, 0.642; Lys,Trp, 0.641; Asn,Trp, 0.636; Thr,hTrp, 0.631; hAnthA,NP, 0.62
Thr,Arg,Kyn, 0.771; Arg,Kyn,NP, 0.771; Arg,Lys,Kyn, 0.77; Arg,AnthA,Kyn, 0.769; His,Arg,Kyn, 0.769; Asn,Arg,Kyn, 0.769; Arg,hTrp,Kyn, 0.768; Gly,Arg,Kyn, 0.767; Arg,Orn,Kyn, 0.767; Ala,Arg,Kyn, 0.766; Arg,Kyn,QA, 0.766; Ser,Arg,Kyn, 0.763; Thr,Arg,QA, 0.763; Arg,hKyn,Kyn, 0.761; Ala,hKyn,AnthA, 0.76; Arg,hAnthA,Kyn, 0.757; Arg,Lys,QA, 0.757; Trp,hKyn,AnthA, 0.755; Arg,hKyn,AnthA, 0.754; Arg,hAnthA,QA, 0.753; Arg,hTrp,QA, 0.75; Gly,Thr,Arg, 0.748; Arg,Lys,hKyn, 0.747; Asn,Arg,QA, 0.746; Thr,Arg,hKyn, 0.746; Cit,AnthA,QA, 0.746; Arg,hKyn,QA, 0.745; Arg,Trp,QA, 0.745; Gly,Arg,hKyn, 0.744; Ala,Cit,Kyn, 0.744; Arg,AnthA,QA, 0.743; Arg,hKyn,hAnthA, 0.742; Arg,Lys,NP, 0.742; Arg,hKyn,hTrp, 0.741; Arg,Orn,hKyn, 0.741; Arg,hKyn,NP, 0.741; His,Arg,hKyn, 0.741; Ala,Arg,hAnthA, 0.74; Cit,hKyn,AnthA, 0.74; Arg,Lys,hTrp, 0.74; Cit,hAnthA,QA, 0.74; Arg,Lys,AnthA, 0.739; Cit,Arg,hKyn, 0.739; Cit,Arg,QA, 0.739; Arg,Lys,Trp, 0.739; His,Arg,Lys, 0.738; Arg,hAnthA,AnthA, 0.738; Thr,Arg,hAnthA, 0.738; Ser,Arg,QA, 0.737; Ala,Arg,QA, 0.737; Arg,Orn,QA, 0.737; Thr,Arg,Lys, 0.737; His,Arg,QA, 0.736; Arg,Orn,Lys, 0.736; Arg,hAnthA,NP, 0.735; Arg,QA,NP, 0.735; Thr,Arg,NP, 0.735; Ser,Arg,Lys, 0.735; Ser,Arg,hAnthA, 0.734; Asn,Gly,Arg, 0.734; Asn,Arg,Lys, 0.734; Cit,hKyn,QA, 0.733; Arg,hAnthA,hTrp, 0.732; Gly,Arg,AnthA, 0.732; Arg,AnthA,NP, 0.731; Gly,Arg,NP, 0.731; Gly,Arg,hAnthA, 0.73; Gly,Arg,hTrp, 0.73; Arg,Orn,hAnthA, 0.729; Thr,Arg,Trp, 0.729; Asn,Arg,hAnthA, 0.729; Ser,Gly,Arg, 0.729; Asn,Arg,AnthA, 0.728; Gly,Arg,Trp, 0.728; Thr,Arg,hTrp, 0.728; Gly,His,Arg, 0.728; Arg,hTrp,AnthA, 0.727; Thr,hKyn,AnthA, 0.727; Gly,Arg,Orn, 0.727; Ala,hAnthA,AnthA, 0.725; Cit,Arg,hAnthA, 0.724; Arg,hTrp,NP, 0.724; Gly,Ala,Arg, 0.723; Ala,Arg,AnthA, 0.721; Ser,Arg,NP, 0.721; Asn,Arg,NP, 0.72; Arg,Orn,AnthA, 0.717; Cit,Arg,AnthA, 0.717; Arg,Trp,NP, 0.717; Ser,Arg,AnthA, 0.715; His,Arg,AnthA, 0.715; Asn,Arg,hTrp, 0.714; Cit,Trp,hKyn, 0.714; His,Arg,hTrp, 0.711; Asn,Ala,Arg, 0.709; Ala,Arg,hTrp, 0.709; Arg,Trp,hTrp, 0.706; Asn,Arg,Trp, 0.704; Arg,Orn,hTrp, 0.702; Cit,Trp,hAnthA, 0.696
Ser,Gly,Arg,QA, 0.775; Thr,Arg,hTrp,Kyn, 0.773; His,Arg,AnthA,Kyn, 0.771; Ala,Arg,Lys,Kyn, 0.769; Ala,Arg,Lys,QA, 0.769; Ser,Arg,hTrp,Kyn, 0.768; Arg,Orn,hTrp,Kyn, 0.768; Thr,Arg,Lys,Kyn, 0.767; Ala,Arg,Orn,Kyn, 0.767; Asn,Gly,Arg,Kyn, 0.767; Ala,Arg,hAnthA,Kyn, 0.766; Arg,AnthA,Kyn,QA, 0.766; Asn,Arg,Trp,Kyn, 0.766; Thr,Arg,Kyn,QA, 0.766; Arg,hKyn,Kyn,NP, 0.766; Ala,Arg,Trp,Kyn, 0.766; Thr,Arg,Lys,QA, 0.765; Ser,Arg,hAnthA,QA, 0.764; Arg,Lys,AnthA,Kyn, 0.764; Thr,Arg,hAnthA,Kyn, 0.764; His,Arg,hTrp,Kyn, 0.764; Ser,Ala,Arg,Kyn, 0.764; Ser,Arg,AnthA,Kyn, 0.764; Arg,hKyn,hTrp,Kyn, 0.763; Arg,Orn,Lys,Kyn, 0.763; His,Arg,hKyn,Kyn, 0.763; Arg,hAnthA,hTrp,Kyn, 0.763; Arg,Lys,hKyn,Kyn, 0.763; Thr,Arg,hKyn,AnthA, 0.763; Ser,Arg,hAnthA,Kyn, 0.762; Arg,Lys,hAnthA,Kyn, 0.762; Gly,Arg,hKyn,AnthA, 0.761; Asn,Arg,hKyn,Kyn, 0.761; Gly,Cit,Arg,QA, 0.76; His,Arg,Lys,NP, 0.76; Arg,Lys,hKyn,AnthA, 0.759; Arg,Lys,AnthA,QA, 0.759; Cit,Arg,Lys,QA, 0.759; Ser,Arg,Kyn,QA, 0.759; Ala,Arg,Lys,AnthA, 0.758; Ala,Cit,hTrp,Kyn, 0.758; Thr,Arg,hKyn,hTrp, 0.758; Arg,Orn,hKyn,Kyn, 0.758; Arg,hAnthA,hTrp,QA, 0.757; Arg,Lys,hAnthA,QA, 0.757; Gly,Arg,hAnthA,Kyn, 0.757; Arg,hKyn,hAnthA,AnthA, 0.756; Ser,Arg,hKyn,AnthA, 0.756; Ser,Gly,Arg,hKyn, 0.756; Arg,hKyn,hTrp,AnthA, 0.755; Asn,Thr,Arg,QA, 0.755; Thr,Arg,hAnthA,NP, 0.754; His,Arg,hAnthA,Kyn, 0.754; Arg,hAnthA,AnthA,QA, 0.753; Arg,hTrp,AnthA,QA, 0.753; Arg,Lys,hKyn,hTrp, 0.752; Arg,hAnthA,Kyn,NP, 0.752; Gly,Arg,hKyn,hTrp, 0.752; Asn,Arg,hAnthA,QA, 0.751; Asn,Arg,hKyn,QA, 0.751; Arg,Trp,AnthA,QA, 0.751; Cit,Arg,hAnthA,Kyn, 0.75; Ser,Arg,hKyn,hAnthA, 0.75; Arg,Trp,hKyn,AnthA, 0.75; Asn,His,Arg,QA, 0.75; Cit,Arg,AnthA,Kyn, 0.749; Arg,Orn,Lys,hKyn, 0.748; His,Arg,AnthA,QA, 0.748; Ser,Arg,Lys,hKyn, 0.747; Asn,Ala,Arg,hKyn, 0.747; Ser,Cit,Arg,Kyn, 0.747; Arg,Lys,hAnthA,AnthA, 0.746; Arg,hKyn,hAnthA,hTrp, 0.746; His,Arg,hKyn,hTrp, 0.746; His,Cit,Arg,Kyn, 0.746; Ser,Asn,Arg,QA, 0.746; Ser,Arg,hAnthA,NP, 0.745; Arg,hKyn,hTrp,NP, 0.745; Ser,Cit,Arg,QA, 0.745; Cit,Arg,hKyn,QA, 0.744; Arg,AnthA,QA,NP, 0.744; Ala,Arg,AnthA,QA, 0.744; Asn,Arg,Lys,hKyn, 0.743; Ala,Arg,hAnthA,hTrp, 0.743; Ala,Arg,hAnthA,NP, 0.743; Ser,Gly,Arg,hAnthA, 0.743; Cit,Arg,AnthA,QA, 0.742; Cit,Arg,hKyn,hAnthA, 0.742; Ser,Cit,Arg,hKyn, 0.742; Gly,Ala,Arg,hAnthA, 0.742; Ser,Thr,Arg,hKyn, 0.742; Ser,Arg,Orn,hKyn, 0.741; Asn,Arg,hAnthA,AnthA, 0.74; Arg,Trp,hKyn,hTrp, 0.74; Arg,Lys,hAnthA,hTrp, 0.739; Asn,Arg,Trp,hAnthA, 0.735; Asn,Arg,hAnthA,hTrp, 0.735; Ser,Asn,Arg,hAnthA, 0.734; Ser,His,Arg,hAnthA, 0.734; Cit,Trp,hAnthA,AnthA, 0.713
Ser,Gly,Thr,Arg,QA, 0.797; Ser,Gly,Cit,Arg,QA, 0.782; Gly,Thr,Arg,Orn,QA, 0.779; Ser,Gly,Arg,hAnthA,QA, 0.777; Asn,Ala,Arg,Lys,Kyn, 0.777; Ser,Gly,Ala,Arg,QA, 0.776; Thr,Ala,Arg,hAnthA,Kyn, 0.775; Asn,Ala,Arg,AnthA,Kyn, 0.773; Arg,hKyn,hTrp,AnthA,Kyn, 0.773; Ala,Arg,hTrp,Kyn,NP, 0.773; Thr,Arg,hTrp,AnthA,QA, 0.772; Thr,Ala,Arg,AnthA,QA, 0.772; Ser,Arg,hAnthA,hTrp,Kyn, 0.771; Ser,Cit,Arg,hAnthA,QA, 0.771; Arg,hTrp,AnthA,Kyn,NP, 0.771; Gly,Ala,Arg,hTrp,Kyn, 0.77; Ala,Arg,hAnthA,Kyn,NP, 0.768; Asn,Arg,Lys,AnthA,Kyn, 0.768; Ser,Arg,hAnthA,Kyn,QA, 0.767; Ser,His,Arg,hAnthA,QA, 0.767; Ser,Arg,Orn,hAnthA,QA, 0.767; Ala,Cit,hAnthA,hTrp,Kyn, 0.766; Arg,Lys,hTrp,AnthA,QA, 0.766; Gly,Arg,hAnthA,hTrp,QA, 0.766; Arg,Lys,hAnthA,hTrp,Kyn, 0.765; Cit,Arg,Trp,hTrp,Kyn, 0.765; Cit,Arg,Trp,hTrp,QA, 0.765; Ser,Arg,hKyn,hAnthA,QA, 0.764; Ala,Arg,Trp,hAnthA,Kyn, 0.764; Ala,Cit,hAnthA,AnthA,QA, 0.764; Asn,His,Arg,AnthA,Kyn, 0.764; Arg,hAnthA,hTrp,AnthA,Kyn, 0.763; Asn,Ala,Arg,hKyn,AnthA, 0.763; Ala,Arg,hAnthA,Kyn,QA, 0.763; Arg,Orn,Lys,AnthA,QA, 0.763; Asn,Arg,hKyn,hAnthA,QA, 0.763; Ser,Arg,Lys,hKyn,AnthA, 0.763; Ser,Gly,Arg,hAnthA,Kyn, 0.763; Arg,Lys,Trp,AnthA,Kyn, 0.763; Ala,Arg,Lys,AnthA,NP, 0.763; Ser,Arg,Lys,AnthA,Kyn, 0.763; Gly,Ala,Arg,Lys,hKyn, 0.762; His,Ala,Arg,Lys,hKyn, 0.762; Thr,Arg,hAnthA,QA,NP, 0.762; Thr,Arg,hAnthA,Kyn,NP, 0.762; Ser,Arg,Lys,hAnthA,QA, 0.761; Cit,Arg,Orn,hTrp,Kyn, 0.761; Thr,Arg,Trp,hAnthA,QA, 0.761; Arg,Lys,hAnthA,hTrp,QA, 0.76; Asn,Arg,hAnthA,hTrp,Kyn, 0.76; Ala,Arg,Orn,Lys,hKyn, 0.76; Arg,Trp,hKyn,hAnthA,Kyn, 0.76; His,Thr,Arg,hAnthA,Kyn, 0.76; Thr,Ala,Arg,Lys,hAnthA, 0.76; Arg,Lys,Trp,hKyn,AnthA, 0.759; Cit,Arg,Lys,hKyn,QA, 0.759; Gly,Arg,hAnthA,Kyn,QA, 0.759; Gly,Arg,Lys,hKyn,Kyn, 0.759; Ser,Gly,Arg,Trp,Kyn, 0.759; Ser,Arg,hAnthA,AnthA,NP, 0.758; Ser,Gly,Arg,hAnthA,NP, 0.758; Ser,Asn,Arg,AnthA,QA, 0.758; Ala,Cit,Arg,Kyn,QA, 0.758; Ser,Arg,Orn,hAnthA,Kyn, 0.757; Arg,Trp,hAnthA,AnthA,QA, 0.756; Thr,Ala,Arg,hAnthA,NP, 0.756; Arg,Lys,hKyn,hAnthA,hTrp, 0.755; His,Arg,hKyn,hTrp,AnthA, 0.755; Asn,Gly,Arg,hAnthA,QA, 0.754; Arg,hKyn,hAnthA,AnthA,NP, 0.754; Gly,Arg,Lys,hAnthA,QA, 0.754; Ser,Arg,hKyn,hTrp,QA, 0.754; Arg,Orn,hKyn,hAnthA,AnthA, 0.754; Ser,Arg,Lys,hKyn,hTrp, 0.754; Arg,hAnthA,AnthA,Kyn,NP, 0.753; Arg,Lys,Trp,hKyn,QA, 0.753; Ala,Arg,Orn,hAnthA,QA, 0.753; Ser,His,Arg,hAnthA,NP, 0.752; Asn,Arg,Trp,hAnthA,Kyn, 0.751; Asn,Arg,Lys,hAnthA,QA, 0.751; Cit,Arg,hKyn,hAnthA,hTrp, 0.751; Ser,Cit,Arg,hTrp,QA, 0.751; Arg,Orn,Lys,hKyn,QA, 0.751; Thr,Arg,Lys,hAnthA,NP, 0.751; Asn,Ala,Arg,hAnthA,hTrp, 0.75; Ser,His,Arg,Lys,hKyn, 0.75; Ser,Arg,Lys,hKyn,hAnthA, 0.749; Arg,Lys,hKyn,hAnthA,QA, 0.748; Arg,Lys,Trp,hKyn,hTrp, 0.748; Ala,Arg,Trp,hAnthA,AnthA, 0.747; Ser,Ala,Arg,hAnthA,hTrp, 0.747; Ser,Arg,Orn,hAnthA,AnthA, 0.747; Ser,Gly,Arg,hKyn,hAnthA, 0.746; Ser,Gly,Arg,Trp,hAnthA, 0.746; Ser,Gly,Arg,hAnthA,hTrp, 0.746; Arg,Lys,Trp,hKyn,hAnthA, 0.746; Asn,Thr,Ala,Arg,hAnthA, 0.745; Ser,Asn,Ala,Arg,hAnthA, 0.738; Asn,Arg,Trp,hKyn,hAnthA, 0.738; Cit,Trp,hKyn,hAnthA,AnthA, 0.738
Ser,Asn,Gly,His,Arg,QA, 0.804; Ser,Asn,Gly,Arg,hTrp,QA, 0.796; Ser,Gly,Arg,Lys,hTrp,QA, 0.795; Ser,Asn,Gly,Thr,Arg,QA, 0.793; Asn,Gly,Thr,Ala,Arg,QA, 0.791; Thr,Ala,Arg,Lys,AnthA,QA, 0.79; Asn,Gly,Thr,Cit,Arg,QA, 0.789; Ser,Gly,Thr,Arg,hAnthA,QA, 0.788; Asn,Thr,Ala,Arg,hTrp,Kyn, 0.788; Ser,Asn,Ala,Arg,hAnthA,Kyn, 0.786; Gly,Thr,Arg,hAnthA,hTrp,QA, 0.786; Ser,Asn,Gly,Arg,Kyn,QA, 0.786; Ser,Gly,Arg,hAnthA,hTrp,QA, 0.785; Ser,Asn,Gly,Arg,QA,NP, 0.785; Ser,Asn,Gly,Arg,hAnthA,QA, 0.783; Ser,Gly,Ala,Arg,Kyn,QA, 0.783; Ser,Gly,His,Arg,Lys,QA, 0.783; Ser,Gly,Arg,Orn,Lys,QA, 0.783; Ser,Gly,His,Arg,hTrp,QA, 0.782; Ser,Ala,Arg,hAnthA,Kyn,QA, 0.781; Thr,Arg,Lys,Trp,AnthA,Kyn, 0.781; Ser,Gly,Cit,Arg,hAnthA,QA, 0.78; Ser,Arg,hKyn,hAnthA,hTrp,QA, 0.78; Asn,Ala,Arg,Lys,AnthA,Kyn, 0.779; Ser,Gly,Ala,Arg,hAnthA,QA, 0.779; Gly,Thr,Arg,hAnthA,AnthA,QA, 0.779; Asn,Thr,Arg,hTrp,AnthA,QA, 0.779; Ser,Gly,Arg,hKyn,hAnthA,QA, 0.779; Ser,Gly,Arg,hAnthA,QA,NP, 0.779; Asn,Ala,Arg,hAnthA,AnthA,NP, 0.779; Asn,Ala,Arg,hAnthA,Kyn,NP, 0.779; Ser,Ala,Arg,hKyn,hAnthA,Kyn, 0.779; Asn,Gly,Ala,Cit,Arg,QA, 0.779; Asn,Arg,hTrp,AnthA,Kyn,QA, 0.779; Ser,Arg,hAnthA,hTrp,AnthA,QA, 0.778; Asn,Ala,Arg,AnthA,Kyn,NP, 0.778; Ser,Gly,Arg,Trp,hAnthA,QA, 0.777; Ala,Cit,Arg,Lys,hTrp,Kyn, 0.777; Ser,His,Arg,hAnthA,hTrp,QA, 0.777; Ser,His,Ala,Arg,hAnthA,Kyn, 0.777; Asn,Cit,Arg,hTrp,Kyn,QA, 0.777; Thr,Arg,hKyn,hTrp,AnthA,QA, 0.777; Ser,Gly,Arg,hAnthA,Kyn,QA, 0.776; Ser,Gly,Arg,Lys,hAnthA,QA, 0.776; Ser,Arg,Orn,hAnthA,hTrp,QA, 0.776; Asn,Ala,Arg,hTrp,AnthA,QA, 0.776; Ala,Cit,Arg,Lys,Kyn,QA, 0.776; Asn,Ala,Arg,Lys,AnthA,QA, 0.774; Thr,Ala,Arg,Lys,hAnthA,NP, 0.774; Ala,Arg,Lys,hAnthA,hTrp,Kyn, 0.773; Gly,Ala,Arg,Lys,Kyn,QA, 0.773; Ala,Cit,Arg,Lys,Kyn,NP, 0.773; Thr,Ala,Arg,Lys,hKyn,QA, 0.773; Asn,Cit,Arg,AnthA,Kyn,QA, 0.773; Asn,His,Arg,hAnthA,AnthA,Kyn, 0.772; Gly,Ala,Arg,Lys,hAnthA,Kyn, 0.771; Thr,Arg,Lys,AnthA,Kyn,QA, 0.771; Gly,Ala,Cit,Arg,Lys,Kyn, 0.771; Ser,Arg,Lys,hTrp,Kyn,QA, 0.771; Arg,Orn,Lys,Trp,AnthA,Kyn, 0.771; Ala,Cit,Arg,Lys,hAnthA,Kyn, 0.771; Ser,Arg,hAnthA,AnthA,Kyn,QA, 0.771; Asn,Ala,Arg,hKyn,AnthA,QA, 0.771; His,Thr,Arg,Lys,hTrp,QA, 0.768; Gly,His,Ala,Arg,Lys,Kyn, 0.767; His,Ala,Arg,Lys,AnthA,QA, 0.766; Asn,His,Cit,Arg,hAnthA,QA, 0.766; Arg,Orn,Lys,hKyn,AnthA,NP, 0.766; Arg,Lys,Trp,hKyn,hAnthA,AnthA, 0.765; Ser,Ala,Arg,hAnthA,AnthA,NP, 0.765; Ser,Ala,Arg,Orn,hAnthA,QA, 0.765; Thr,Ala,Cit,hAnthA,hTrp,Kyn, 0.765; Arg,Lys,hAnthA,hTrp,Kyn,NP, 0.765; Thr,Arg,Lys,hKyn,hAnthA,AnthA, 0.764; Ser,Arg,Orn,hAnthA,AnthA,Kyn, 0.764; His,Arg,hAnthA,hTrp,AnthA,QA, 0.763; Ser,Arg,Orn,hAnthA,hTrp,NP, 0.763; Asn,Arg,Trp,hKyn,AnthA,NP, 0.763; Arg,Lys,hAnthA,AnthA,Kyn,QA, 0.763; Cit,Arg,Lys,hKyn,hTrp,AnthA, 0.763; Asn,Ala,Arg,Lys,AnthA,NP, 0.763; Gly,Arg,Lys,hKyn,AnthA,NP, 0.763; Arg,Lys,Trp,hKyn,hTrp,AnthA, 0.762; Cit,Arg,hAnthA,hTrp,AnthA,Kyn, 0.762; Gly,Arg,hAnthA,hTrp,AnthA,QA, 0.762; Ala,Cit,Trp,hAnthA,hTrp,Kyn, 0.761; Thr,Ala,Arg,hAnthA,AnthA,NP, 0.761; His,Arg,Lys,hKyn,hTrp,AnthA, 0.76; Gly,Arg,Lys,Trp,hKyn,AnthA, 0.759; Arg,Orn,hAnthA,AnthA,Kyn,QA, 0.759; Arg,Lys,Trp,hAnthA,AnthA,Kyn, 0.758; Cit,Arg,hKyn,hAnthA,hTrp,QA, 0.757; Ala,Arg,Orn,hAnthA,AnthA,QA, 0.757; Ser,Cit,Arg,hAnthA,Kyn,NP, 0.756; Ser,Gly,Ala,Arg,hAnthA,NP, 0.756; Ala,Cit,Arg,hAnthA,hTrp,AnthA, 0.754; Ala,Arg,Orn,hAnthA,hTrp,AnthA, 0.754; Asn,Arg,Trp,hKyn,hAnthA,Kyn, 0.754; Asn,Thr,Arg,Trp,hAnthA,AnthA, 0.753; Asn,His,Arg,Lys,hKyn,AnthA, 0.752
Leu,Phe, 0.783; Orn,Trp, 0.783; Val,Phe, 0.767; Met,Phe, 0.758; Phe,Trp, 0.754; Val,Orn, 0.749; Ser,Val, 0.749; Pro,Val, 0.747; Asn,Val, 0.747; Ala,Val, 0.743; Cit,Val, 0.741; Val,Trp, 0.741; Gly,Val, 0.741; Tyr,Val, 0.741; Glu,Val, 0.741; Val,Met, 0.741; Arg,Val, 0.737; Cit,Trp, 0.737; Gln,Val, 0.737; Orn,Leu, 0.737; ABA,Val, 0.735; His,Phe, 0.735; Asn,Leu, 0.733; Arg,Leu, 0.73; Arg,Trp, 0.73; Val,Ile, 0.73; Ser,Leu, 0.73; His,Orn, 0.728; Thr,Cit, 0.726; Ile,Phe, 0.726; Leu,Trp, 0.726; Gly,Leu, 0.726; Cit,Leu, 0.724; Val,Lys, 0.72; Met,Orn, 0.72; Arg,Orn, 0.718; Arg,ABA, 0.718; Ile,Trp, 0.716; Gln,Leu, 0.716; Ala,Leu, 0.716; ABA,Leu, 0.716; Thr,Val, 0.715; His,Val, 0.715; Lys,Trp, 0.715; His,Leu, 0.715; Lys,Leu, 0.715; Thr,Trp, 0.713; Val,Leu, 0.713; Thr,Leu, 0.713; Thr,Orn, 0.711; Asn,Arg, 0.711; His,Cit, 0.711; Ile,Leu, 0.711; Glu,Leu, 0.711; Arg,Met, 0.709; Pro,Leu, 0.709; Cit,Tyr, 0.707; Tyr,Leu, 0.707; Thr,Phe, 0.705; His,Trp, 0.703; Asn,Trp, 0.703; Arg,Ile, 0.701; Cit,Arg, 0.701; Cit,Met, 0.701; Glu,Trp, 0.699; Pro,Trp, 0.699; His,Ile, 0.699; His,Thr, 0.698; His,Arg, 0.698; Met,Leu, 0.698; Gly,Trp, 0.696; Ser,Trp, 0.696; Gln,Trp, 0.696; Ala,Trp, 0.694; Met,Trp, 0.694; Thr,Ile, 0.694; ABA,Trp, 0.692; Tyr,Trp, 0.692; Thr,Ala, 0.692; Glu,Arg, 0.69; Arg,Phe, 0.69; Arg,Tyr, 0.69; Thr,Lys, 0.69; Thr,Met, 0.69; Arg,Pro, 0.69; Cit,ABA, 0.69; Gln,Thr, 0.688; Thr,Tyr, 0.688; Cit,Ile, 0.688; Thr,Pro, 0.686; Gln,Arg, 0.684; Ala,Arg, 0.682; Glu,Thr, 0.682; Thr,ABA, 0.682; Arg,Lys, 0.682; Asn,Thr, 0.681; Ser,Arg, 0.679; Gly,Thr, 0.679; Gly,Arg, 0.677; Ser,Thr, 0.669
Orn,Leu,Phe, 0.832; Cit,Leu,Phe, 0.813; Arg,Leu,Phe, 0.803; Pro,Leu,Phe, 0.802; Gly,Leu,Phe, 0.798; Ile,Leu,Phe, 0.796; Val,Leu,Phe, 0.794; Lys,Leu,Phe, 0.794; Val,Orn,Phe, 0.792; Orn,Leu,Trp, 0.792; Glu,Leu,Phe, 0.79; Gly,Orn,Trp, 0.79; Arg,Phe,Trp, 0.79; Pro,Val,Phe, 0.788; Ser,Leu,Phe, 0.788; Tyr,Orn,Trp, 0.788; His,Leu,Phe, 0.786; Thr,Leu,Phe, 0.786; Ala,Orn,Trp, 0.786; Cit,Orn,Trp, 0.786; Orn,Phe,Trp, 0.784; Gln,Orn,Trp, 0.784; Val,Phe,Trp, 0.783; Asn,Leu,Phe, 0.783; Met,Orn,Trp, 0.783; Arg,Orn,Trp, 0.783; Asn,Orn,Trp, 0.783; ABA,Orn,Trp, 0.783; Cit,Val,Phe, 0.781; ABA,Leu,Phe, 0.781; Pro,Orn,Trp, 0.781; Ser,Orn,Trp, 0.781; Arg,Val,Phe, 0.779; His,Orn,Trp, 0.779; Val,Met,Phe, 0.777; Cit,Phe,Trp, 0.777; Thr,Orn,Trp, 0.777; Tyr,Val,Phe, 0.773; Val,Lys,Phe, 0.771; Val,Orn,Trp, 0.771; Thr,Phe,Trp, 0.769; Glu,Val,Phe, 0.767; Ala,Val,Phe, 0.767; Ser,Val,Phe, 0.767; Asn,Val,Phe, 0.767; Gln,Phe,Trp, 0.767; Ser,Phe,Trp, 0.766; Lys,Phe,Trp, 0.764; Gln,Orn,Leu, 0.764; Val,Ile,Phe, 0.76; Arg,Val,Orn, 0.76; Pro,Val,Orn, 0.76; Arg,ABA,Phe, 0.76; Tyr,Phe,Trp, 0.758; Cit,Met,Phe, 0.758; Val,Orn,Lys, 0.758; His,Ile,Phe, 0.756; Tyr,Val,Orn, 0.756; Pro,Phe,Trp, 0.754; Asn,Phe,Trp, 0.754; His,Phe,Trp, 0.752; Cit,Val,Trp, 0.752; Thr,Val,Orn, 0.752; Gly,Cit,Val, 0.752; Arg,Pro,Val, 0.75; Val,Orn,Ile, 0.75; Gly,Val,Orn, 0.75; Arg,Orn,Leu, 0.749; Cit,Val,Orn, 0.749; Cit,Arg,Leu, 0.749; Glu,Cit,Val, 0.749; Ser,Cit,Val, 0.747; Val,Orn,Leu, 0.747; Ala,Val,Orn, 0.747; Ser,Val,Orn, 0.745; Cit,Val,Ile, 0.745; Arg,Val,Trp, 0.745; Ser,Cit,Leu, 0.743; Cit,Lys,Trp, 0.743; Cit,Pro,Trp, 0.743; Arg,Val,Lys, 0.741; Thr,Cit,Val, 0.741; Asn,Arg,Leu, 0.741; Thr,Cit,Phe, 0.737; Thr,Orn,Leu, 0.737; Arg,Val,Ile, 0.737; Arg,ABA,Orn, 0.737; Glu,Cit,Trp, 0.735; Gln,Cit,Trp, 0.733; Asn,Cit,Trp, 0.732; Arg,Val,Met, 0.73; Arg,Pro,Leu, 0.728; Arg,Lys,Leu, 0.726; Thr,Cit,Arg, 0.726; Gly,Arg,Leu, 0.724; Arg,Met,Leu, 0.724; Ser,Arg,Leu, 0.722; Glu,Arg,Val, 0.72; Glu,Arg,Trp, 0.72; Glu,Arg,Leu, 0.705
Gln,Orn,Leu,Phe, 0.834; Val,Orn,Leu,Phe, 0.832; Met,Orn,Leu,Phe, 0.83; Cit,Pro,Leu,Phe, 0.828; Arg,Orn,Leu,Phe, 0.828; Arg,Pro,Leu,Phe, 0.824; Cit,Orn,Leu,Phe, 0.82; Cit,Lys,Leu,Phe, 0.82; Cit,ABA,Leu,Phe, 0.817; Cit,Tyr,Leu,Phe, 0.815; Cit,Met,Leu,Phe, 0.813; Cit,Val,Leu,Phe, 0.813; Pro,Leu,Phe,Trp, 0.813; Pro,Lys,Leu,Phe, 0.811; Arg,Ile,Leu,Phe, 0.809; Cit,Ile,Leu,Phe, 0.809; Asn,Cit,Leu,Phe, 0.809; Glu,Cit,Leu,Phe, 0.809; Ala,Pro,Leu,Phe, 0.807; Arg,Leu,Phe,Trp, 0.805; Arg,ABA,Leu,Phe, 0.805; Pro,Ile,Leu,Phe, 0.805; Asn,Pro,Leu,Phe, 0.805; Pro,Tyr,Leu,Phe, 0.805; Pro,Val,Phe,Trp, 0.805; Gly,Orn,Phe,Trp, 0.803; Glu,Pro,Leu,Phe, 0.803; Val,Met,Orn,Phe, 0.803; Thr,Met,Leu,Phe, 0.803; Arg,Lys,Leu,Phe, 0.802; Gln,Arg,Leu,Phe, 0.802; Pro,Tyr,Val,Phe, 0.802; Val,Met,Leu,Phe, 0.802; Arg,Tyr,Leu,Phe, 0.8; Gln,Lys,Leu,Phe, 0.8; Ala,Met,Leu,Phe, 0.8; Gly,Met,Leu,Phe, 0.8; Asn,Arg,Leu,Phe, 0.798; Gln,Pro,Leu,Phe, 0.798; Gly,Pro,Leu,Phe, 0.798; Gln,Val,Leu,Phe, 0.798; Glu,Gly,Leu,Phe, 0.798; Gly,Lys,Leu,Phe, 0.798; Glu,Asn,Leu,Phe, 0.798; Gly,Ala,Leu,Phe, 0.798; Pro,Val,Orn,Phe, 0.796; Orn,Ile,Phe,Trp, 0.796; Gln,Ala,Leu,Phe, 0.796; Tyr,Val,Leu,Phe, 0.796; ABA,Lys,Leu,Phe, 0.796; Glu,Gln,Leu,Phe, 0.794; Tyr,Lys,Leu,Phe, 0.794; Ile,Leu,Phe,Trp, 0.792; Asn,Val,Orn,Phe, 0.792; His,Met,Leu,Phe, 0.792; Thr,Lys,Leu,Phe, 0.792; Tyr,Orn,Lys,Trp, 0.792; Ser,Orn,Phe,Trp, 0.79; Ser,Pro,Val,Phe, 0.79; Cit,Val,Orn,Phe, 0.79; Gly,Gln,Leu,Phe, 0.79; Gln,Val,Orn,Phe, 0.79; Cit,ABA,Val,Phe, 0.79; Glu,His,Leu,Phe, 0.79; Ala,Ile,Leu,Phe, 0.79; Cit,Pro,Val,Phe, 0.788; Val,Orn,Lys,Phe, 0.788; His,Arg,Val,Phe, 0.788; Gln,Val,Phe,Trp, 0.788; Tyr,Ile,Leu,Phe, 0.788; Ser,Lys,Leu,Phe, 0.788; Thr,Tyr,Leu,Phe, 0.788; Ser,Tyr,Val,Phe, 0.788; Lys,Ile,Leu,Phe, 0.786; His,Lys,Leu,Phe, 0.786; Gln,Orn,Lys,Trp, 0.786; Glu,Val,Phe,Trp, 0.784; Asn,Val,Phe,Trp, 0.784; ABA,Tyr,Leu,Phe, 0.784; Asn,ABA,Leu,Phe, 0.784; Tyr,Orn,Phe,Trp, 0.783; Orn,Lys,Leu,Trp, 0.783; Glu,Asn,Val,Phe, 0.783; Asn,Tyr,Leu,Phe, 0.781; Cit,Val,Lys,Phe, 0.779; Ala,Arg,Val,Phe, 0.779; Arg,Val,Met,Phe, 0.779; His,Tyr,Val,Phe, 0.779; Gln,Tyr,Val,Phe, 0.779; Asn,Pro,Val,Phe, 0.777; Ser,Val,Met,Phe, 0.777; Gly,Val,Met,Phe, 0.775; Gly,Thr,Val,Phe, 0.773; Ser,Thr,Val,Phe, 0.773; Val,Met,Ile,Phe, 0.773; Gln,Thr,Val,Phe, 0.773; His,Val,Lys,Phe, 0.769; Thr,Ala,Val,Phe, 0.767; Gly,Val,Lys,Phe, 0.76; Ala,Val,Ile,Phe, 0.76
Arg,Orn,Leu,Phe,Trp, 0.853; Gln,Pro,Orn,Leu,Phe, 0.847; Thr,Arg,Pro,Leu,Phe, 0.843; Pro,Orn,Leu,Phe,Trp, 0.839; Pro,Tyr,Orn,Leu,Phe, 0.839; Ser,Pro,Orn,Leu,Phe, 0.839; Val,Orn,Leu,Phe,Trp, 0.837; Pro,Val,Orn,Leu,Phe, 0.837; Asn,Pro,Orn,Leu,Phe, 0.837; Pro,Orn,Lys,Leu,Phe, 0.836; Gln,His,Orn,Leu,Phe, 0.836; Ala,Arg,Orn,Leu,Phe, 0.834; Ser,Thr,Orn,Leu,Phe, 0.834; Cit,Pro,Orn,Leu,Phe, 0.832; Ala,Orn,Ile,Leu,Phe, 0.832; Arg,Pro,Orn,Leu,Phe, 0.83; Thr,Arg,Orn,Leu,Phe, 0.83; Arg,Orn,Ile,Leu,Phe, 0.828; Cit,Arg,Pro,Leu,Phe, 0.828; Val,Orn,Lys,Leu,Phe, 0.828; Cit,Pro,Ile,Leu,Phe, 0.826; Arg,Met,Orn,Leu,Phe, 0.826; Cit,Arg,Orn,Leu,Phe, 0.826; Gln,Arg,Pro,Leu,Phe, 0.824; Ser,Pro,Leu,Phe,Trp, 0.824; Cit,Pro,Tyr,Leu,Phe, 0.822; Ser,Cit,Orn,Leu,Phe, 0.822; Arg,Pro,Val,Leu,Phe, 0.82; His,Arg,Pro,Leu,Phe, 0.82; Ser,Cit,Pro,Leu,Phe, 0.82; Met,Orn,Lys,Leu,Phe, 0.82; Cit,Val,Orn,Leu,Phe, 0.82; His,Val,Orn,Leu,Phe, 0.82; Thr,Pro,Leu,Phe,Trp, 0.819; Arg,Pro,Leu,Phe,Trp, 0.817; Gln,Cit,Leu,Phe,Trp, 0.817; Arg,Pro,Met,Leu,Phe, 0.815; Cit,Arg,Leu,Phe,Trp, 0.815; Cit,Arg,Met,Leu,Phe, 0.815; His,Ala,Orn,Leu,Phe, 0.815; Asn,Pro,Leu,Phe,Trp, 0.815; His,Cit,Lys,Leu,Phe, 0.815; Ser,Tyr,Leu,Phe,Trp, 0.815; Gln,Val,Orn,Phe,Trp, 0.813; Ala,Val,Orn,Phe,Trp, 0.813; Gln,Cit,Lys,Leu,Phe, 0.813; Ala,Pro,Met,Leu,Phe, 0.813; Cit,Met,Leu,Phe,Trp, 0.811; Ser,Cit,Lys,Leu,Phe, 0.811; Gly,His,Cit,Leu,Phe, 0.811; Arg,Ile,Leu,Phe,Trp, 0.809; Glu,Ser,Cit,Leu,Phe, 0.809; Asn,Thr,Cit,Leu,Phe, 0.809; Cit,Val,Lys,Leu,Phe, 0.809; ABA,Tyr,Leu,Phe,Trp, 0.809; Ser,ABA,Leu,Phe,Trp, 0.809; Gln,Lys,Leu,Phe,Trp, 0.807; His,ABA,Leu,Phe,Trp, 0.807; Pro,Tyr,Val,Leu,Phe, 0.807; Ala,Arg,ABA,Leu,Phe, 0.805; Gly,Lys,Leu,Phe,Trp, 0.805; Pro,ABA,Tyr,Leu,Phe, 0.805; Asn,Pro,ABA,Leu,Phe, 0.805; Glu,His,Leu,Phe,Trp, 0.803; Ala,Arg,Val,Orn,Phe, 0.803; Ser,Arg,Val,Orn,Phe, 0.803; Gln,Ala,Met,Leu,Phe, 0.803; Cit,Val,Ile,Leu,Phe, 0.802; Asn,His,Arg,Leu,Phe, 0.802; Thr,Ile,Leu,Phe,Trp, 0.802; Ser,Gly,Orn,Phe,Trp, 0.802; Gln,Pro,Val,Leu,Phe, 0.802; Glu,Pro,Tyr,Leu,Phe, 0.802; Tyr,Ile,Leu,Phe,Trp, 0.8; Gln,Pro,Ile,Leu,Phe, 0.8; Glu,Asn,Val,Orn,Phe, 0.8; Arg,Pro,Val,Ile,Phe, 0.798; Ser,ABA,Orn,Phe,Trp, 0.798; Glu,Arg,Ile,Leu,Phe, 0.796; His,Pro,Val,Orn,Phe, 0.796; Tyr,Met,Ile,Leu,Phe, 0.796; Gly,ABA,Val,Orn,Phe, 0.796; Ser,Ala,Orn,Phe,Trp, 0.794; Ser,Met,Ile,Leu,Phe, 0.794; His,Arg,Tyr,Leu,Phe, 0.792; Ser,Cit,Orn,Phe,Trp, 0.792; Ser,Asn,Orn,Phe,Trp, 0.792; Cit,Pro,Val,Ile,Phe, 0.79; Thr,Tyr,Val,Orn,Phe, 0.79; Arg,Tyr,Orn,Phe,Trp, 0.786; His,Arg,Val,Lys,Phe, 0.786; Gly,Tyr,Val,Orn,Phe, 0.786; Tyr,Val,Ile,Leu,Phe, 0.786; Asn,His,Cit,Val,Phe, 0.784; Glu,Arg,Met,Leu,Phe, 0.783; Orn,Lys,Ile,Phe,Trp, 0.783; Glu,Arg,Tyr,Leu,Phe, 0.781; Ser,Gln,Cit,Val,Phe, 0.779; Gly,Gln,Arg,Val,Phe, 0.777; Asn,Gln,Cit,Val,Phe, 0.777
Arg,Orn,Lys,Leu,Phe,Trp, 0.854; Thr,Orn,Lys,Leu,Phe,Trp, 0.853; Ser,Val,Orn,Leu,Phe,Trp, 0.847; Ala,Pro,Orn,Leu,Phe,Trp, 0.845; Pro,ABA,Orn,Ile,Leu,Phe, 0.843; Ala,Pro,Tyr,Orn,Leu,Phe, 0.843; Thr,Ala,Pro,Orn,Leu,Phe, 0.843; Pro,Tyr,Orn,Leu,Phe,Trp, 0.841; Ala,Pro,Val,Orn,Leu,Phe, 0.841; Glu,Met,Orn,Ile,Leu,Phe, 0.837; Glu,Cit,Arg,Pro,Leu,Phe, 0.836; Cit,Arg,Pro,Orn,Leu,Phe, 0.836; Glu,Thr,Pro,Orn,Leu,Phe, 0.836; Gln,Orn,Ile,Leu,Phe,Trp, 0.834; Ser,Ala,Orn,Leu,Phe,Trp, 0.834; Thr,Ala,Orn,Ile,Leu,Phe, 0.834; Gln,Arg,Pro,Orn,Leu,Phe, 0.832; Cit,Arg,Pro,Ile,Leu,Phe, 0.832; Ala,Arg,Pro,Orn,Leu,Phe, 0.832; Glu,Gly,Cit,Pro,Leu,Phe, 0.832; Gln,Pro,Orn,Ile,Leu,Phe, 0.832; Thr,Cit,Arg,Orn,Leu,Phe, 0.832; Asn,Gly,Arg,Orn,Leu,Phe, 0.832; Glu,Pro,ABA,Orn,Leu,Phe, 0.832; His,Orn,Ile,Leu,Phe,Trp, 0.83; Arg,Pro,Orn,Leu,Phe,Trp, 0.83; Cit,Arg,Pro,Met,Leu,Phe, 0.83; Cit,Pro,ABA,Orn,Leu,Phe, 0.83; Asn,Arg,ABA,Orn,Leu,Phe, 0.83; Gly,Arg,Pro,Orn,Leu,Phe, 0.828; Gly,Cit,Arg,Pro,Leu,Phe, 0.828; Asn,Cit,Arg,Pro,Leu,Phe, 0.828; Cit,Arg,Pro,Leu,Phe,Trp, 0.828; Glu,Asn,Cit,Pro,Leu,Phe, 0.828; Arg,Pro,ABA,Orn,Leu,Phe, 0.826; His,Arg,Pro,Orn,Leu,Phe, 0.826; Cit,Arg,Pro,Tyr,Leu,Phe, 0.826; Glu,Cit,Pro,Ile,Leu,Phe, 0.826; Gln,Arg,Pro,Leu,Phe,Trp, 0.826; Cit,Pro,ABA,Met,Leu,Phe, 0.826; Asn,Cit,Pro,Ile,Leu,Phe, 0.826; Thr,Ala,Cit,Pro,Leu,Phe, 0.826; Cit,Pro,Orn,Lys,Leu,Phe, 0.826; Glu,Cit,Arg,Orn,Leu,Phe, 0.826; Glu,Arg,Pro,Orn,Leu,Phe, 0.824; Cit,Arg,Pro,Lys,Leu,Phe, 0.824; Ser,Cit,Pro,Met,Leu,Phe, 0.824; Glu,Ser,Cit,Pro,Leu,Phe, 0.824; Asn,Cit,Arg,Ile,Leu,Phe, 0.824; Glu,Arg,ABA,Orn,Leu,Phe, 0.824; Ala,Cit,Pro,Leu,Phe,Trp, 0.822; Glu,His,Cit,Pro,Leu,Phe, 0.822; Thr,Cit,Pro,Val,Leu,Phe, 0.822; Ser,Thr,Cit,Pro,Leu,Phe, 0.822; Thr,Arg,Val,Orn,Leu,Phe, 0.822; Ser,His,Arg,Orn,Leu,Phe, 0.822; Glu,Cit,Pro,Leu,Phe,Trp, 0.82; Gln,Arg,Pro,Ile,Leu,Phe, 0.82; Ala,Arg,Orn,Lys,Leu,Phe, 0.82; Arg,Pro,ABA,Tyr,Leu,Phe, 0.82; Glu,Gly,Thr,Arg,Leu,Phe, 0.82; Glu,Gln,Arg,Pro,Leu,Phe, 0.819; Glu,Cit,Arg,Ile,Leu,Phe, 0.819; Glu,Cit,Arg,Leu,Phe,Trp, 0.819; Ala,Arg,Pro,Leu,Phe,Trp, 0.817; Ser,Arg,Tyr,Orn,Leu,Phe, 0.817; Glu,Cit,Arg,ABA,Leu,Phe, 0.817; His,Arg,Pro,Lys,Leu,Phe, 0.815; Arg,Pro,Met,Lys,Leu,Phe, 0.815; Arg,Pro,Met,Ile,Leu,Phe, 0.815; Gly,Cit,Pro,Leu,Phe,Trp, 0.815; Glu,Cit,Pro,Val,Leu,Phe, 0.815; Thr,Arg,Tyr,Lys,Leu,Phe, 0.815; Glu,Arg,Pro,ABA,Leu,Phe, 0.813; Gly,Cit,Met,Ile,Leu,Phe, 0.813; Glu,Ala,Cit,Arg,Leu,Phe, 0.813; His,Cit,Pro,Val,Phe,Trp, 0.811; Glu,Cit,ABA,Ile,Leu,Phe, 0.809; Gln,Cit,Lys,Ile,Leu,Phe, 0.809; His,Ala,Cit,Leu,Phe,Trp, 0.809; Glu,Arg,Pro,Met,Leu,Phe, 0.805; Gly,His,Arg,Ile,Leu,Phe, 0.805; Glu,Arg,Pro,Leu,Phe,Trp, 0.803; Glu,Thr,Cit,Arg,Leu,Phe, 0.803; Glu,His,Cit,Arg,Leu,Phe, 0.803; Gly,Cit,Lys,Ile,Leu,Phe, 0.803; Gln,Arg,Pro,Val,Ile,Phe, 0.802; Gly,His,Arg,Tyr,Leu,Phe, 0.802; Gln,Arg,ABA,Ile,Leu,Phe, 0.8; Asn,Ala,Cit,Pro,Val,Phe, 0.8; Glu,Cit,Arg,Met,Leu,Phe, 0.798; Gly,Cit,Pro,Val,Phe,Trp, 0.796; Asn,Ala,Orn,Lys,Phe,Trp, 0.796; Ser,Arg,Val,Lys,Leu,Phe, 0.796; His,Arg,ABA,Ile,Leu,Phe, 0.792; Glu,Ala,Arg,Ile,Leu,Phe, 0.792; Glu,Cit,Arg,Pro,Val,Phe, 0.79; Gly,Cit,Pro,Val,Orn,Phe, 0.79; Thr,Cit,Pro,Val,Ile,Phe, 0.79; Cit,Pro,ABA,Val,Ile,Phe, 0.788
Trp,Kyn, 0.8; Val,Kyn, 0.788; Leu,hKyn, 0.788; Leu,NP, 0.788; AnthA,NP, 0.786; Val,NP, 0.786; Cit,NP, 0.784; Leu,Kyn, 0.784; Leu,AnthA, 0.784; Orn,Trp, 0.783; Orn,NP, 0.781; Val,hKyn, 0.781; Ile,Kyn, 0.781; Cit,QA, 0.779; AnthA,QA, 0.777; Leu,QA, 0.777; Thr,Kyn, 0.777; ABA,QA, 0.777; hKyn,XA, 0.777; Met,Kyn, 0.773; Arg,NP, 0.773; Thr,NP, 0.773; Val,QA, 0.771; Ile,AnthA, 0.769; Cit,Kyn, 0.769; Val,AnthA, 0.767; QA,NP, 0.766; QA,XA, 0.764; Ile,QA, 0.762; XA,NP, 0.762; Met,QA, 0.76; hKyn,NP, 0.758; Ile,NP, 0.756; His,Kyn, 0.756; Trp,QA, 0.754; Kyn,NP, 0.754; Orn,QA, 0.754; Thr,AnthA, 0.752; Trp,NP, 0.752; ABA,NP, 0.752; Thr,QA, 0.75; Trp,hKyn, 0.75; Asn,NP, 0.75; Arg,Kyn, 0.749; Val,Orn, 0.749; Cit,hKyn, 0.749; Ser,Val, 0.749; Gln,NP, 0.747; ABA,Kyn, 0.747; His,hKyn, 0.745; Tyr,AnthA, 0.743; Asn,QA, 0.743; Ser,NP, 0.743; Ala,NP, 0.743; Tyr,NP, 0.743; Lys,NP, 0.743; Kyn,XA, 0.743; Asn,hKyn, 0.743; Trp,AnthA, 0.741; hKyn,AnthA, 0.741; Cit,Val, 0.741; Val,Trp, 0.741; Tyr,Val, 0.741; Arg,QA, 0.739; Tyr,QA, 0.739; Lys,QA, 0.739; Met,NP, 0.739; His,QA, 0.737; Arg,Val, 0.737; Cit,Trp, 0.737; Ile,hKyn, 0.737; Gln,Val, 0.737; Orn,Leu, 0.737; His,NP, 0.735; Val,XA, 0.732; Arg,Leu, 0.73; Thr,hKyn, 0.73; Arg,Trp, 0.73; Val,Ile, 0.73; Met,hKyn, 0.728; Thr,Cit, 0.726; Leu,Trp, 0.726; Kyn,QA, 0.726; Cit,Leu, 0.724; hKyn,QA, 0.722; Ser,QA, 0.72; Arg,hKyn, 0.718; Arg,Orn, 0.718; Arg,AnthA, 0.715; Ala,QA, 0.715; Thr,Val, 0.715; His,Val, 0.715; Thr,Trp, 0.713; Val,Leu, 0.713; Gln,QA, 0.711; Thr,Orn, 0.711; Asn,Arg, 0.711; Thr,Arg, 0.709; AnthA,Kyn, 0.709; Arg,Ile, 0.701
ABA,Orn,QA, 0.83; Orn,Trp,Kyn, 0.82; Orn,Trp,QA, 0.813; Cit,Val,Kyn, 0.813; Leu,AnthA,Kyn, 0.809; Cit,Leu,QA, 0.807; Cit,Tyr,QA, 0.807; Orn,Trp,NP, 0.807; Cit,ABA,QA, 0.805; Val,hKyn,AnthA, 0.805; Orn,Leu,hKyn, 0.805; Ile,AnthA,Kyn, 0.803; Ile,Trp,Kyn, 0.803; Trp,AnthA,Kyn, 0.802; Val,Orn,Kyn, 0.802; Leu,Kyn,NP, 0.802; Cit,AnthA,NP, 0.802; Leu,AnthA,NP, 0.802; Val,AnthA,Kyn, 0.8; Val,Trp,Kyn, 0.8; Cit,Ile,QA, 0.8; Trp,Kyn,XA, 0.8; Cit,hKyn,NP, 0.8; Cit,Val,NP, 0.8; Cit,Tyr,Kyn, 0.8; Cit,Met,QA, 0.798; Thr,AnthA,Kyn, 0.798; Val,Kyn,XA, 0.798; ABA,Trp,Kyn, 0.798; Arg,Val,Kyn, 0.796; Ser,Val,Kyn, 0.796; Ser,Trp,Kyn, 0.796; Asn,Trp,Kyn, 0.796; Thr,Leu,Kyn, 0.796; hKyn,AnthA,XA, 0.794; Cit,Leu,NP, 0.794; Orn,Ile,QA, 0.794; Thr,Val,Kyn, 0.792; Met,Trp,Kyn, 0.792; hKyn,AnthA,NP, 0.792; Thr,Trp,Kyn, 0.792; Orn,Leu,Trp, 0.792; Asn,Val,Kyn, 0.79; Tyr,Val,Kyn, 0.79; Orn,Lys,Trp, 0.79; His,Ile,Kyn, 0.79; Val,Met,Kyn, 0.788; Val,Kyn,QA, 0.788; ABA,AnthA,QA, 0.788; Kyn,XA,NP, 0.788; Tyr,Orn,Trp, 0.788; Tyr,AnthA,QA, 0.786; Arg,Trp,Kyn, 0.786; Ile,AnthA,QA, 0.786; Orn,XA,NP, 0.786; Cit,Trp,hKyn, 0.786; Val,Ile,Kyn, 0.784; Tyr,AnthA,Kyn, 0.784; Val,Kyn,NP, 0.783; Arg,Orn,Trp, 0.783; Thr,Cit,QA, 0.781; Cit,Arg,QA, 0.781; Met,Kyn,NP, 0.781; Val,Leu,Kyn, 0.779; Orn,QA,NP, 0.779; Cit,Lys,QA, 0.779; His,Cit,QA, 0.779; Val,AnthA,XA, 0.777; Val,Ile,AnthA, 0.777; Arg,AnthA,NP, 0.777; Val,Orn,hKyn, 0.775; AnthA,QA,NP, 0.775; Cit,QA,XA, 0.775; Thr,Arg,Kyn, 0.775; Ala,Val,AnthA, 0.775; AnthA,Kyn,NP, 0.773; Met,AnthA,QA, 0.773; Val,Met,AnthA, 0.773; Arg,Kyn,XA, 0.773; Arg,QA,XA, 0.773; Arg,Met,Kyn, 0.773; Thr,AnthA,QA, 0.771; Val,Orn,AnthA, 0.771; Val,Orn,Trp, 0.771; Arg,Val,AnthA, 0.769; Thr,hKyn,AnthA, 0.769; Cit,Val,AnthA, 0.769; Thr,Val,AnthA, 0.769; Arg,Trp,QA, 0.769; His,Orn,QA, 0.766; Arg,Kyn,NP, 0.764; ABA,Val,AnthA, 0.764; Ala,AnthA,QA, 0.764; Trp,AnthA,QA, 0.762; His,AnthA,QA, 0.76; Asn,Arg,Kyn, 0.76; Thr,Orn,QA, 0.758; Arg,AnthA,Kyn, 0.758; Arg,Orn,QA, 0.75; Thr,Cit,AnthA, 0.75
Cit,Leu,hKyn,Kyn, 0.834; Cit,ABA,Ile,Kyn, 0.834; Asn,ABA,Orn,QA, 0.832; ABA,Orn,Trp,Kyn, 0.83; ABA,Orn,Trp,QA, 0.828; ABA,Tyr,Orn,QA, 0.828; Ala,ABA,Orn,QA, 0.826; Gln,Cit,Trp,Kyn, 0.824; Cit,Tyr,Val,Kyn, 0.824; Ala,Orn,Trp,Kyn, 0.822; Orn,Lys,Trp,Kyn, 0.822; Ser,Orn,Trp,QA, 0.82; Cit,Leu,hKyn,QA, 0.819; Val,Orn,AnthA,QA, 0.817; Tyr,AnthA,Kyn,XA, 0.817; His,Orn,Trp,hKyn, 0.817; Tyr,Leu,AnthA,Kyn, 0.817; Asn,Orn,Leu,hKyn, 0.817; Tyr,Orn,Trp,QA, 0.815; Thr,Orn,Trp,Kyn, 0.815; Cit,Tyr,QA,NP, 0.815; Gln,ABA,Orn,QA, 0.815; His,Cit,Trp,QA, 0.815; Lys,Leu,AnthA,QA, 0.815; Orn,Leu,hKyn,XA, 0.815; Val,Lys,AnthA,Kyn, 0.813; Cit,ABA,Lys,QA, 0.813; Thr,Cit,Val,Kyn, 0.813; Cit,ABA,Val,QA, 0.813; Asn,Orn,Trp,hKyn, 0.813; Arg,Orn,Trp,hKyn, 0.813; Thr,Orn,Trp,hKyn, 0.813; Cit,Lys,Leu,QA, 0.813; ABA,Leu,AnthA,Kyn, 0.813; Met,Orn,Kyn,NP, 0.813; Orn,Leu,QA,XA, 0.813; Val,hKyn,AnthA,Kyn, 0.811; Orn,Trp,hKyn,AnthA, 0.811; Ala,Cit,Trp,Kyn, 0.811; Ala,Orn,Trp,hKyn, 0.811; Asn,Val,Orn,Kyn, 0.811; Orn,Trp,AnthA,QA, 0.809; Cit,Tyr,AnthA,QA, 0.809; Val,Orn,hKyn,AnthA, 0.809; Leu,hKyn,AnthA,NP, 0.809; His,Cit,Leu,QA, 0.809; Val,Orn,QA,XA, 0.809; Cit,Tyr,Ile,QA, 0.809; Thr,ABA,Orn,QA, 0.809; Val,AnthA,Kyn,NP, 0.807; Val,Orn,AnthA,NP, 0.807; Cit,Val,Trp,QA, 0.807; Val,Orn,Lys,QA, 0.807; Cit,Leu,AnthA,NP, 0.807; ABA,Val,Orn,QA, 0.805; Orn,hKyn,AnthA,NP, 0.805; Cit,ABA,Ile,QA, 0.803; Ser,Trp,AnthA,Kyn, 0.803; Val,Orn,Ile,QA, 0.803; ABA,Leu,hKyn,AnthA, 0.803; Val,AnthA,Kyn,XA, 0.802; Val,Met,AnthA,Kyn, 0.802; Cit,Val,hKyn,AnthA, 0.802; Arg,Leu,AnthA,Kyn, 0.8; Gln,Val,AnthA,Kyn, 0.8; Val,Ile,AnthA,Kyn, 0.8; Met,Orn,Trp,hKyn, 0.8; Ser,Cit,Val,QA, 0.8; Trp,AnthA,Kyn,XA, 0.8; Tyr,Orn,QA,XA, 0.8; Cit,QA,XA,NP, 0.8; Asn,Arg,Leu,Kyn, 0.798; Val,AnthA,QA,XA, 0.798; Gln,Cit,Tyr,QA, 0.798; Arg,Val,AnthA,Kyn, 0.796; Arg,Ile,AnthA,Kyn, 0.796; ABA,Val,hKyn,AnthA, 0.796; Val,Trp,AnthA,QA, 0.796; Asn,Cit,Val,hKyn, 0.796; Ser,Cit,Trp,QA, 0.796; Tyr,Val,Orn,hKyn, 0.796; Arg,Val,hKyn,AnthA, 0.794; Arg,Val,Kyn,XA, 0.794; Arg,Ile,AnthA,QA, 0.792; Arg,ABA,Leu,Kyn, 0.79; Arg,Val,Trp,Kyn, 0.79; Gln,Arg,Val,Kyn, 0.79; Asn,Leu,hKyn,AnthA, 0.79; Val,Ile,hKyn,AnthA, 0.786; Arg,Tyr,AnthA,Kyn, 0.786; Thr,Cit,Kyn,QA, 0.786; Ser,Val,Orn,hKyn, 0.786; Arg,Val,Lys,Kyn, 0.784; Thr,Tyr,AnthA,QA, 0.784; Arg,Val,AnthA,QA, 0.783; His,Val,Kyn,NP, 0.783; Thr,Arg,Leu,Kyn, 0.781; Gln,Arg,Leu,Kyn, 0.781; Thr,Arg,AnthA,QA, 0.775; Tyr,Trp,AnthA,QA, 0.769
Cit,Lys,Leu,hKyn,AnthA, 0.845; Cit,ABA,Orn,Ile,QA, 0.834; Cit,Tyr,Lys,Leu,QA, 0.834; Ser,Orn,Lys,Trp,Kyn, 0.834; Ala,Val,Lys,AnthA,Kyn, 0.832; Thr,Cit,ABA,Kyn,QA, 0.832; Ser,Tyr,Orn,Trp,Kyn, 0.832; His,Cit,Val,Kyn,NP, 0.83; Cit,ABA,Kyn,QA,NP, 0.83; Gln,Cit,Trp,hKyn,Kyn, 0.83; His,Cit,Val,Trp,Kyn, 0.828; Ser,Met,Orn,Trp,Kyn, 0.828; Val,Lys,hKyn,AnthA,NP, 0.826; Ala,Cit,ABA,Trp,Kyn, 0.826; Asn,Cit,Trp,Kyn,XA, 0.826; Cit,Arg,Leu,Kyn,NP, 0.824; Gln,Orn,Trp,Kyn,QA, 0.824; Asn,Orn,Trp,Kyn,QA, 0.824; Cit,Tyr,Ile,Trp,Kyn, 0.824; Val,Met,Lys,AnthA,Kyn, 0.822; Asn,Gln,Cit,Trp,Kyn, 0.822; Cit,ABA,Val,Met,Kyn, 0.822; Val,Orn,Ile,Trp,Kyn, 0.822; Ala,Cit,Leu,Trp,Kyn, 0.82; Cit,ABA,Val,Trp,Kyn, 0.82; Ser,Met,Orn,Trp,QA, 0.82; Thr,Cit,Leu,Kyn,QA, 0.82; Tyr,Orn,Trp,hKyn,Kyn, 0.82; Leu,AnthA,Kyn,QA,NP, 0.82; Val,Orn,Trp,AnthA,QA, 0.819; Cit,Tyr,Val,AnthA,QA, 0.819; Gln,Cit,Val,AnthA,Kyn, 0.819; Cit,Val,Ile,Kyn,NP, 0.819; Thr,Cit,ABA,Trp,Kyn, 0.819; His,Orn,Ile,Trp,QA, 0.819; Cit,Lys,Leu,Trp,Kyn, 0.819; Asn,Cit,Val,Orn,Kyn, 0.819; Leu,AnthA,Kyn,XA,NP, 0.819; Orn,Leu,AnthA,QA,XA, 0.819; Orn,Lys,Trp,hKyn,AnthA, 0.817; Val,Orn,hKyn,AnthA,NP, 0.817; Cit,Leu,Trp,AnthA,Kyn, 0.817; Cit,Leu,hKyn,AnthA,QA, 0.817; Ser,Val,Lys,AnthA,Kyn, 0.817; Ser,Orn,Trp,QA,XA, 0.817; His,Orn,Trp,QA,XA, 0.817; Ala,Tyr,Orn,Trp,QA, 0.817; Ala,Orn,Ile,Trp,QA, 0.817; Met,Orn,Trp,QA,NP, 0.817; His,Cit,Val,Kyn,QA, 0.817; Arg,Lys,Trp,AnthA,Kyn, 0.817; Gln,Val,Lys,AnthA,Kyn, 0.815; Tyr,Val,hKyn,AnthA,Kyn, 0.815; Orn,Ile,Trp,QA,NP, 0.815; Cit,Orn,Lys,Trp,hKyn, 0.815; Ala,Orn,Trp,AnthA,QA, 0.813; Cit,Tyr,Val,Trp,Kyn, 0.813; Ser,Val,Ile,AnthA,Kyn, 0.813; Gln,Tyr,Orn,Trp,QA, 0.813; Asn,Cit,Trp,Kyn,NP, 0.813; Asn,Thr,Cit,Trp,Kyn, 0.813; His,Ala,Val,AnthA,Kyn, 0.811; Val,Orn,Leu,Kyn,NP, 0.811; Thr,Arg,Orn,Trp,QA, 0.811; Thr,Cit,Trp,Kyn,NP, 0.811; Cit,Val,Met,AnthA,Kyn, 0.809; Arg,Val,Lys,hKyn,AnthA, 0.809; Thr,Cit,Leu,AnthA,QA, 0.809; Ala,ABA,Val,AnthA,Kyn, 0.809; Arg,Val,Lys,AnthA,Kyn, 0.807; Arg,Val,AnthA,Kyn,NP, 0.807; Arg,Orn,Trp,AnthA,QA, 0.807; Gln,Val,AnthA,Kyn,NP, 0.807; Val,Orn,Leu,Trp,QA, 0.807; Arg,ABA,Val,Orn,QA, 0.807; Thr,Cit,Ile,AnthA,Kyn, 0.805; His,Arg,Val,AnthA,Kyn, 0.803; Gln,Arg,Val,AnthA,Kyn, 0.803; Arg,Orn,Leu,hKyn,AnthA, 0.803; Thr,Cit,Trp,Kyn,QA, 0.803; Arg,Val,Lys,Kyn,NP, 0.803; Arg,Val,Lys,AnthA,QA, 0.802; Ser,Arg,Val,AnthA,Kyn, 0.802; Thr,Cit,Ile,Trp,Kyn, 0.802; His,Cit,Arg,Val,Kyn, 0.802; Arg,Lys,Ile,AnthA,Kyn, 0.802; Arg,Val,AnthA,Kyn,QA, 0.8; Arg,Tyr,Lys,AnthA,QA, 0.8; Arg,ABA,Val,Orn,Kyn, 0.8; Arg,ABA,Val,AnthA,Kyn, 0.798; Thr,Arg,Val,AnthA,Kyn, 0.798; Arg,Val,Leu,AnthA,Kyn, 0.798; Asn,Val,Ile,AnthA,Kyn, 0.798; Gln,Val,Ile,AnthA,Kyn, 0.798; Arg,Val,Ile,AnthA,Kyn, 0.796; Arg,Val,AnthA,Kyn,XA, 0.796; Ala,Arg,Val,Lys,Kyn, 0.796; Arg,Val,Orn,Lys,Kyn, 0.796; Thr,Cit,hKyn,AnthA,QA, 0.792; Arg,Val,Lys,AnthA,XA, 0.784;
Cit,ABA,Tyr,Lys,AnthA,QA, 0.858; Cit,Tyr,Lys,Trp,AnthA,QA, 0.851; Cit,Tyr,Lys,AnthA,QA,XA, 0.849; Ser,Cit,Tyr,Lys,AnthA,QA, 0.847; Cit,Tyr,Lys,AnthA,Kyn,QA, 0.847; Cit,Tyr,Lys,AnthA,QA,NP, 0.845; Gln,Ala,Cit,Lys,Trp,Kyn, 0.845; Met,Orn,Leu,AnthA,Kyn,NP, 0.843; Ser,Cit,ABA,Tyr,Lys,QA, 0.843; Cit,Tyr,Lys,Ile,AnthA,QA, 0.841; Cit,Tyr,Orn,Lys,AnthA,QA, 0.841; Cit,ABA,Lys,Ile,Trp,Kyn, 0.841; Cit,ABA,Met,Lys,Kyn,QA, 0.836; Cit,ABA,Tyr,Kyn,XA,NP, 0.836; Cit,ABA,Ile,Leu,Kyn,QA, 0.834; Gln,Cit,ABA,AnthA,Kyn,QA, 0.834; Gln,Cit,Met,Trp,Kyn,NP, 0.834; Tyr,Val,Orn,Lys,AnthA,QA, 0.832; Gln,His,Cit,Val,Trp,Kyn, 0.832; Gln,Cit,ABA,Val,Kyn,XA, 0.832; Ala,Orn,Lys,Trp,AnthA,Kyn, 0.83; Cit,Tyr,Orn,Lys,Trp,QA, 0.83; Ala,Cit,Leu,AnthA,Kyn,QA, 0.83; Asn,Gln,Orn,Lys,Trp,QA, 0.828; His,Cit,Trp,AnthA,Kyn,NP, 0.828; Cit,Arg,ABA,Tyr,Lys,QA, 0.828; His,Orn,Lys,Leu,QA,NP, 0.828; Gln,Cit,ABA,Tyr,AnthA,QA, 0.826; His,Orn,Trp,AnthA,Kyn,QA, 0.826; Thr,Val,Orn,Ile,Kyn,NP, 0.826; Thr,Orn,Leu,hKyn,AnthA,Kyn, 0.826; His,Cit,ABA,Orn,QA,NP, 0.826; Cit,Tyr,Orn,Trp,Kyn,XA, 0.826; Ser,Tyr,Trp,AnthA,Kyn,XA, 0.826; Arg,ABA,Orn,Lys,QA,XA, 0.824; Arg,Orn,Trp,hKyn,Kyn,QA, 0.824; Ser,Asn,Thr,Orn,Trp,QA, 0.824; Ser,Asn,Tyr,Orn,Trp,QA, 0.824; Ala,Cit,Val,Ile,Kyn,XA, 0.824; Cit,ABA,Tyr,Orn,AnthA,QA, 0.822; ABA,Orn,Trp,hKyn,AnthA,QA, 0.822; Orn,Leu,Trp,Kyn,QA,NP, 0.822; Cit,ABA,Val,Lys,AnthA,QA, 0.82; Cit,ABA,Tyr,Ile,AnthA,QA, 0.82; Cit,Tyr,Met,AnthA,QA,NP, 0.82; Cit,Tyr,Met,AnthA,Kyn,QA, 0.82; Cit,Ile,Trp,AnthA,Kyn,NP, 0.82; Ala,Val,hKyn,AnthA,Kyn,QA, 0.82; Cit,Tyr,Val,Kyn,QA,XA, 0.82; Thr,Orn,Trp,hKyn,Kyn,NP, 0.82; Val,Orn,Leu,hKyn,AnthA,NP, 0.819; Val,Orn,Leu,hKyn,AnthA,QA, 0.819; Cit,Tyr,Met,Trp,AnthA,QA, 0.817; Cit,ABA,Tyr,hKyn,AnthA,QA, 0.817; Gln,Cit,Tyr,Trp,AnthA,QA, 0.817; Ala,Cit,Met,Trp,Kyn,NP, 0.817; Cit,ABA,Leu,AnthA,QA,XA, 0.815; Thr,Cit,Leu,Trp,Kyn,NP, 0.815; His,Val,Ile,hKyn,AnthA,Kyn, 0.815; Gln,ABA,Val,Lys,AnthA,Kyn, 0.815; Cit,Val,Leu,Trp,hKyn,Kyn, 0.815; Arg,ABA,Val,Lys,AnthA,Kyn, 0.813; Asn,Cit,Arg,Leu,AnthA,Kyn, 0.813; Asn,Cit,Leu,hKyn,AnthA,NP, 0.813; Ser,Thr,Val,Trp,AnthA,Kyn, 0.813; Ala,Cit,Orn,Trp,QA,NP, 0.813; Arg,Tyr,Lys,Leu,AnthA,QA, 0.811; Asn,Cit,Val,Lys,Ile,hKyn, 0.811; Cit,ABA,Val,Trp,AnthA,QA, 0.811; Gln,Val,Trp,AnthA,Kyn,NP, 0.811; Thr,ABA,Val,Orn,hKyn,AnthA, 0.811; Ser,Asn,Thr,Val,AnthA,Kyn, 0.811; Asn,His,Cit,Leu,QA,XA, 0.811; Cit,Ile,Leu,Trp,hKyn,AnthA, 0.811; Cit,Ile,Leu,Trp,hKyn,Kyn, 0.809; Ser,Cit,Leu,Trp,hKyn,Kyn, 0.809; Cit,Tyr,Orn,Trp,hKyn,AnthA, 0.809; Ala,Val,Lys,Leu,AnthA,QA, 0.809; Arg,Lys,Leu,Trp,AnthA,Kyn, 0.807; Ser,Arg,Leu,AnthA,Kyn,NP, 0.807; His,Ala,Arg,Leu,AnthA,Kyn, 0.807; Ser,Thr,Orn,Trp,hKyn,AnthA, 0.807; Arg,ABA,Val,Lys,AnthA,NP, 0.805; Arg,Tyr,AnthA,Kyn,XA,NP, 0.805; Gln,Ala,ABA,Val,AnthA,Kyn, 0.805; Cit,Met,Leu,Trp,hKyn,Kyn, 0.805; Asn,Arg,ABA,Val,Lys,Kyn, 0.803; Thr,Cit,Ile,AnthA,Kyn,QA, 0.803; Asn,Orn,Trp,hKyn,AnthA,NP, 0.803; Arg,Orn,Ile,Leu,AnthA,QA, 0.802; Thr,Tyr,Val,AnthA,Kyn,NP, 0.802; Arg,Tyr,Met,Leu,hKyn,AnthA, 0.8; Ser,Arg,Met,Leu,AnthA,Kyn, 0.798; Arg,ABA,Val,Ile,AnthA,Kyn, 0.796; Asn,Arg,Val,Lys,Kyn,XA, 0.794; Ser,Gln,Val,Ile,AnthA,Kyn, 0.794; Thr,Val,Ile,AnthA,Kyn,QA, 0.794; Asn,Ala,Val,Leu,AnthA,Kyn, 0.792; Thr,Arg,ABA,Lys,AnthA,QA, 0.786; Asn,Gln,Arg,Val,Lys,hKyn, 0.779
Ala,Arg, 0.825; Asn,Ala, 0.819; His,Ala, 0.819; Ala,Cit, 0.817; Ala,Orn, 0.817; Ala,Ile, 0.817; Ala,Pro, 0.817; Gln,Ala, 0.817; Ala,Val, 0.817; Ala,Lys, 0.817; Glu,Ala, 0.817; Ala,Met, 0.816; Ala,Trp, 0.816; Ala,Phe, 0.816; Ala,Leu, 0.816; Gly,Ala, 0.814; Ala,Tyr, 0.814; Thr,Ala, 0.813; Ala,ABA, 0.813; Ser,Ala, 0.805; Pro,Lys, 0.766; Orn,Trp, 0.751; His,Pro, 0.746; Arg,Pro, 0.745; Pro,Trp, 0.738; Arg,Trp, 0.738; Lys,Trp, 0.734; Glu,Lys, 0.731; Arg,Orn, 0.729; His,Trp, 0.726; Gly,Lys, 0.726; Thr,Pro, 0.726; His,Arg, 0.726; Orn,Lys, 0.723; Asn,Pro, 0.723; Ser,Lys, 0.723; Gln,Lys, 0.721; His,Lys, 0.721; Pro,Val, 0.721; Arg,Tyr, 0.72; Val,Lys, 0.72; His,Tyr, 0.72; Arg,Val, 0.718; ABA,Lys, 0.718; Asn,Trp, 0.717; Ser,Arg, 0.717; Thr,Lys, 0.715; Thr,Trp, 0.714; Glu,Arg, 0.714; Pro,Tyr, 0.712; Pro,Met, 0.712; Glu,Asn, 0.712; Glu,Trp, 0.711; Cit,Lys, 0.711; Lys,Phe, 0.711; Arg,Ile, 0.711; Pro,ABA, 0.711; Gln,Pro, 0.711; Tyr,Lys, 0.709; Gly,Trp, 0.709; Val,Trp, 0.709; Arg,Lys, 0.707; Tyr,Trp, 0.707; Ile,Trp, 0.707; Ser,Trp, 0.707; Lys,Leu, 0.707; Lys,Ile, 0.707; Asn,Lys, 0.706; Met,Trp, 0.704; Gln,Trp, 0.703; Met,Lys, 0.703; Arg,Leu, 0.703; Phe,Trp, 0.701; Arg,ABA, 0.701; Gln,Arg, 0.701; Gly,Arg, 0.701; Cit,Trp, 0.698; Cit,Arg, 0.698; Gly,Pro, 0.698; Arg,Met, 0.698; Arg,Phe, 0.698; Ser,Pro, 0.698; Val,Leu, 0.698; Cit,Tyr, 0.698; ABA,Trp, 0.697; Thr,Arg, 0.697; Pro,Leu, 0.695; Pro,Ile, 0.693; Leu,Trp, 0.692; Glu,Pro, 0.692; Pro,Phe, 0.69; Thr,Tyr, 0.689; Pro,Orn, 0.687; Cit,Pro, 0.681; Gly,Tyr, 0.678; Asn,Tyr, 0.675; Gln,Tyr, 0.675; Tyr,Orn, 0.675; Asn,Val, 0.666; Tyr,Phe, 0.638
Ala,Arg,Met, 0.833; Asn,Ala,Arg, 0.828; His,Ala,Arg, 0.828; Ala,Arg,Leu, 0.828; Ala,Arg,Val, 0.827; Glu,Ala,Arg, 0.827; Ala,Arg,Phe, 0.825; Ala,Arg,Lys, 0.825; Ala,Arg,Pro, 0.825; Ala,Cit,Met, 0.824; Asn,Ala,Cit, 0.824; Ala,Arg,Trp, 0.824; Ala,Arg,Ile, 0.824; Gly,Ala,Arg, 0.824; Glu,Asn,Ala, 0.822; Asn,Ala,Phe, 0.82; Ala,Met,Leu, 0.82; Ala,Cit,Arg, 0.82; His,Ala,Pro, 0.82; Gln,His,Ala, 0.82; Ala,ABA,Met, 0.819; His,Ala,Met, 0.819; Asn,Ala,Pro, 0.819; Ala,Orn,Trp, 0.819; Asn,Gln,Ala, 0.819; Asn,Ala,Leu, 0.819; Ala,Arg,ABA, 0.819; Gly,Thr,Ala, 0.819; Thr,Ala,Phe, 0.819; His,Ala,Val, 0.819; Ala,Met,Trp, 0.817; Ala,Cit,Trp, 0.817; Gly,Ala,Cit, 0.817; Ala,Cit,Lys, 0.817; Glu,Ala,Cit, 0.817; Ala,Leu,Trp, 0.817; Ala,Phe,Trp, 0.817; His,Ala,Orn, 0.817; His,Ala,Leu, 0.817; Ala,Pro,Trp, 0.817; Ala,Ile,Trp, 0.817; Glu,Ala,Orn, 0.817; Gln,Ala,Orn, 0.817; Asn,Thr,Ala, 0.816; Glu,Ala,Met, 0.816; Gly,His,Ala, 0.816; Gln,Thr,Ala, 0.816; Thr,Ala,Arg, 0.814; Asn,Ala,ABA, 0.814; His,Ala,Cit, 0.814; Ala,Val,Met, 0.814; Ala,Pro,Met, 0.814; Ala,Cit,Pro, 0.814; Thr,Ala,Lys, 0.814; Ala,Tyr,Phe, 0.814; Ala,Orn,Phe, 0.814; Gly,Gln,Ala, 0.814; Ala,Val,Orn, 0.814; Ala,Val,Ile, 0.814; Asn,Ala,Trp, 0.813; Ala,ABA,Trp, 0.813; Thr,Ala,Orn, 0.813; Glu,Ala,ABA, 0.813; Gly,Ala,Orn, 0.813; Ala,Tyr,Orn, 0.813; Ala,Pro,Orn, 0.813; Ala,Tyr,Leu, 0.813; Ala,Pro,Phe, 0.813; Gln,Ala,Phe, 0.813; Glu,Ala,Phe, 0.813; Ala,Cit,Orn, 0.811; Asn,His,Ala, 0.811; Asn,Ala,Ile, 0.811; Ser,Ala,Pro, 0.811; Ala,Cit,Ile, 0.811; His,Ala,ABA, 0.811; His,Ala,Lys, 0.811; Gly,Ala,ABA, 0.811; Ala,Lys,Trp, 0.811; Ala,ABA,Tyr, 0.811; Ala,ABA,Ile, 0.811; Gly,Ala,Tyr, 0.811; Ser,Ala,Lys, 0.81; Ala,ABA,Leu, 0.81; Thr,Ala,Val, 0.81; Gln,Ala,ABA, 0.81; His,Thr,Ala, 0.808; Ala,ABA,Phe, 0.808; Ala,Ile,Phe, 0.808; Ala,Tyr,Met, 0.807; Thr,Ala,Trp, 0.807; Ser,Ala,Phe, 0.805; Ser,His,Ala, 0.805; Ser,Ala,Leu, 0.805; Ala,Cit,ABA, 0.805; Ser,Ala,Ile, 0.805; Ser,Ala,Arg, 0.803; Ser,Ala,Trp, 0.803; Ser,Ala,Met, 0.803; Glu,Ser,Ala, 0.802
Ala,Arg,Met,Leu, 0.834; His,Ala,Arg,Met, 0.833; Gly,Ala,Arg,Met, 0.831; Ala,Arg,Met,Ile, 0.83; Ala,Arg,Met,Lys, 0.83; His,Ala,Arg,Ile, 0.83; Gln,Ala,Arg,Met, 0.828; Ala,Arg,Orn,Lys, 0.828; Asn,Gly,Thr,Ala, 0.828; Ala,Arg,Val,Met, 0.827; Asn,Ala,Arg,Tyr, 0.827; Thr,Ala,Arg,Orn, 0.825; Thr,Ala,Arg,Met, 0.825; Ala,Cit,Arg,Met, 0.825; Asn,Ala,Cit,Phe, 0.825; Ala,Arg,Tyr,Orn, 0.825; Gly,Ala,Arg,Orn, 0.825; Glu,His,Ala,Arg, 0.825; Glu,Ala,Cit,Met, 0.824; Asn,Ala,Cit,Pro, 0.824; Asn,Ala,Cit,Leu, 0.824; Ala,Arg,Orn,Ile, 0.824; Ala,Arg,Tyr,Met, 0.822; Ala,Arg,ABA,Met, 0.822; Ala,Cit,Met,Trp, 0.822; Ala,Arg,Met,Phe, 0.822; Thr,Ala,Cit,Met, 0.822; Ala,Cit,Pro,Met, 0.822; Asn,Gly,Ala,Val, 0.822; Asn,Gly,Ala,Phe, 0.822; Asn,Gly,His,Ala, 0.82; Asn,Ala,ABA,Leu, 0.819; His,Ala,ABA,Met, 0.819; Asn,Ala,Orn,Lys, 0.819; Asn,Ala,Val,Lys, 0.819; His,Ala,Met,Orn, 0.819; Thr,Ala,Arg,Ile, 0.817; Ala,Cit,Orn,Trp, 0.817; Glu,Thr,Ala,Arg, 0.817; Asn,Ala,Met,Leu, 0.817; Gln,His,Ala,Met, 0.817; Gly,Ala,Met,Ile, 0.816; Asn,Ala,ABA,Trp, 0.816; Ser,Ala,Orn,Trp, 0.816; His,Ala,Cit,Trp, 0.816; Glu,Asn,Ala,Met, 0.816; Asn,Ala,Tyr,Orn, 0.816; Ala,Val,Met,Orn, 0.816; Asn,Gln,Thr,Ala, 0.816; Ala,Cit,Met,Ile, 0.814; His,Ala,Met,Trp, 0.814; Ala,Met,Lys,Ile, 0.814; Thr,Ala,Cit,Pro, 0.814; Asn,His,Ala,Trp, 0.813; Ala,Cit,Val,Orn, 0.813; His,Ala,Cit,Ile, 0.813; Asn,Ala,Val,Leu, 0.813; Asn,Ala,Tyr,Ile, 0.813; His,Ala,ABA,Trp, 0.813; Gly,Thr,Ala,Leu, 0.813; Glu,Ala,Pro,Met, 0.813; Ser,Ala,Arg,Met, 0.811; Thr,Ala,Arg,Leu, 0.811; Thr,Ala,Arg,Pro, 0.811; Gln,Ala,Arg,Lys, 0.811; Ser,His,Ala,Arg, 0.81; Asn,Thr,Ala,Trp, 0.81; Ser,Ala,Tyr,Met, 0.81; Ala,Met,Ile,Phe, 0.81; Ser,Ala,Lys,Leu, 0.81; His,Ala,Lys,Trp, 0.81; Ala,Cit,ABA,Val, 0.81; Glu,Thr,Ala,ABA, 0.81; Thr,Ala,ABA,Val, 0.81; Ser,His,Ala,Cit, 0.808; Glu,Ala,Cit,Orn, 0.808; Ala,Tyr,Ile,Leu, 0.808; His,Ala,Pro,Met, 0.807; Asn,His,Ala,Phe, 0.807; Asn,Ala,Pro,Ile, 0.807; Ser,His,Ala,Leu, 0.807; Ser,Ala,Arg,Phe, 0.805; Ala,Pro,Tyr,Met, 0.805; Ser,Asn,Ala,Tyr, 0.805; Glu,Gln,Ala,Cit, 0.805; Ala,Cit,ABA,Lys, 0.805; Ser,His,Ala,Trp, 0.803; Ser,Ala,Cit,Pro, 0.803; Ser,Ala,Pro,Trp, 0.803; Ser,Asn,His,Ala, 0.803; Ser,Ala,Lys,Phe, 0.803; Ser,Ala,ABA,Orn, 0.803; Gln,Ala,Cit,Leu, 0.803; Ser,Ala,Val,Ile, 0.803; Ser,Gln,Ala,Arg, 0.802; His,Thr,Ala,Val, 0.802; Ser,Ala,Arg,Trp, 0.8; Ser,Ala,Ile,Phe, 0.8; Ser,Asn,Ala,Ile, 0.8; Ser,Ala,Cit,Leu, 0.797
Glu,Asn,Ala,Arg,Orn, 0.841; Glu,Ala,Arg,Met,Orn, 0.836; Glu,Ala,Arg,Met,Leu, 0.833; Asn,Gly,Thr,Ala,Arg, 0.831; Ala,Arg,Tyr,Met,Ile, 0.828; Thr,Ala,Arg,Met,Orn, 0.828; Asn,Gly,Ala,Met,Trp, 0.828; His,Ala,Arg,Pro,Phe, 0.828; Ala,Arg,Orn,Leu,Phe, 0.828; Asn,Gly,Ala,Pro,Met, 0.827; Ala,Arg,Val,Met,Ile, 0.825; Ala,Arg,ABA,Met,Orn, 0.825; His,Ala,Arg,Met,Orn, 0.825; Asn,Ala,Cit,ABA,Ile, 0.825; Ser,Asn,Ala,Cit,Ile, 0.825; His,Ala,Cit,Arg,Tyr, 0.825; His,Ala,Arg,Met,Leu, 0.824; Asn,His,Ala,Cit,Phe, 0.824; Asn,Ala,Cit,Pro,ABA, 0.824; Ala,Arg,Tyr,Met,Orn, 0.822; Ser,Thr,Ala,Arg,Orn, 0.822; His,Thr,Ala,Arg,Orn, 0.822; Glu,Ala,Arg,ABA,Met, 0.822; Asn,His,Ala,Cit,Trp, 0.822; Ala,Cit,Met,Lys,Leu, 0.822; Asn,Ala,Pro,Orn,Trp, 0.822; Asn,Gly,Thr,Ala,Lys, 0.822; Asn,Gly,Ala,Pro,Lys, 0.822; Asn,Ala,Cit,ABA,Orn, 0.82; Thr,Ala,Arg,Ile,Phe, 0.82; Gly,Ala,Met,Orn,Trp, 0.82; Asn,Ala,Arg,Tyr,Ile, 0.82; Asn,Ala,Tyr,Lys,Phe, 0.82; Ser,Asn,Gly,Ala,Arg, 0.819; Ala,Cit,Met,Leu,Trp, 0.819; Asn,Thr,Ala,Cit,Tyr, 0.819; Asn,Gly,Ala,Tyr,Met, 0.819; Gln,His,Ala,Arg,Trp, 0.819; Ala,Cit,Orn,Ile,Trp, 0.817; Glu,Gln,Ala,Cit,Met, 0.817; Ala,ABA,Val,Ile,Leu, 0.817; His,Ala,Cit,Tyr,Trp, 0.817; Glu,Ser,Ala,Arg,Met, 0.816; Asn,His,Ala,Cit,Met, 0.816; Asn,Gln,Ala,Met,Trp, 0.816; Glu,Asn,Ala,Val,Trp, 0.816; Thr,Ala,Arg,Lys,Phe, 0.816; Ser,Asn,Ala,Lys,Leu, 0.816; Ser,Ala,Arg,Orn,Lys, 0.814; Ser,Asn,Gly,Ala,Ile, 0.814; Thr,Ala,Arg,Val,Trp, 0.814; Asn,Ala,Met,Lys,Trp, 0.814; Gly,Ala,Cit,Orn,Phe, 0.814; Gly,Ala,ABA,Met,Orn, 0.814; His,Ala,Orn,Lys,Trp, 0.814; Ser,Ala,Arg,Met,Orn, 0.813; Ser,Gly,Ala,Arg,Met, 0.813; Asn,Thr,Ala,Lys,Trp, 0.813; Asn,Ala,ABA,Met,Leu, 0.813; Asn,His,Ala,Val,Phe, 0.813; Ser,Asn,His,Ala,Trp, 0.811; Ala,ABA,Met,Leu,Trp, 0.811; Thr,Ala,Arg,Pro,Lys, 0.811; Asn,Ala,ABA,Val,Ile, 0.811; Glu,Ala,Cit,Orn,Lys, 0.811; Ala,ABA,Ile,Leu,Phe, 0.811; Gln,His,Ala,Orn,Trp, 0.811; Gly,Ala,Tyr,Met,Ile, 0.81; Glu,Ser,Gly,Ala,Cit, 0.81; Ala,Tyr,Ile,Leu,Trp, 0.81; Glu,Ser,Ala,Orn,Trp, 0.81; His,Ala,Pro,Met,Lys, 0.81; Ser,Asn,Gly,Ala,Phe, 0.808; Asn,Thr,Ala,Pro,Trp, 0.808; Ser,Gly,Ala,Val,Lys, 0.808; Ser,Thr,Ala,Cit,Val, 0.808; Ser,Ala,Tyr,Met,Orn, 0.808; Gln,Thr,Ala,Met,Ile, 0.808; Ser,Ala,Arg,Ile,Leu, 0.807; Asn,Ala,Val,Ile,Trp, 0.807; Ala,ABA,Tyr,Met,Phe, 0.807; Ser,Ala,Pro,Tyr,Met, 0.807; Asn,Ala,Pro,Met,Ile, 0.807; Ser,Ala,Met,Orn,Trp, 0.805; His,Thr,Ala,Leu,Trp, 0.805; Ser,Gly,Thr,Ala,Leu, 0.805; Ser,Ala,ABA,Met,Orn, 0.805; Asn,His,Ala,Pro,Lys, 0.805; Ser,Ala,Tyr,Leu,Phe, 0.805; Ser,Ala,Cit,Pro,Phe, 0.803; Glu,Ser,Ala,Met,Trp, 0.802; Glu,Ser,Gln,Ala,Arg, 0.802; His,Thr,Ala,Orn,Trp, 0.802; Thr,Ala,Pro,ABA,Phe, 0.802; Ser,Asn,Ala,Pro,Phe, 0.802; Ser,Gln,His,Ala,Trp, 0.8; Ser,Ala,Met,Orn,Ile, 0.8; Thr,Ala,Ile,Leu,Trp, 0.799; Ser,Asn,His,Ala,Pro, 0.799; Ser,Asn,Ala,ABA,Phe, 0.794
Asn,Ala,Arg,Orn,Ile,Trp, 0.837; Ala,Arg,Met,Orn,Ile,Trp, 0.836; Glu,Ala,Arg,Met,Orn,Ile, 0.834; Gly,His,Ala,Arg,ABA,Met, 0.834; Asn,Gly,Ala,Arg,Met,Trp, 0.834; Asn,Ala,Arg,ABA,Tyr,Met, 0.833; Glu,Ala,Arg,Val,Met,Orn, 0.833; Gly,Ala,Arg,Tyr,Val,Met, 0.831; Thr,Ala,Arg,ABA,Met,Ile, 0.83; Asn,Ala,Cit,Arg,ABA,Orn, 0.83; Asn,His,Thr,Ala,Arg,Leu, 0.828; Ala,Arg,Pro,ABA,Met,Ile, 0.827; Ser,Asn,Gly,Ala,Cit,Trp, 0.827; Ser,Asn,Ala,Arg,Pro,Orn, 0.827; Glu,Thr,Ala,Arg,ABA,Orn, 0.827; Asn,Ala,Cit,Met,Lys,Trp, 0.827; Asn,Thr,Ala,Arg,Met,Leu, 0.827; Asn,Gln,Thr,Ala,Arg,ABA, 0.827; Asn,Gln,Thr,Ala,Arg,Ile, 0.827; Ser,Asn,Ala,Cit,ABA,Trp, 0.827; His,Ala,Arg,Val,Met,Ile, 0.825; His,Ala,Arg,Met,Ile,Phe, 0.825; Glu,Ala,Arg,Tyr,Met,Trp, 0.825; Asn,Gly,Ala,ABA,Tyr,Trp, 0.825; Gly,Gln,His,Ala,Met,Trp, 0.825; Ser,Asn,Gly,Ala,ABA,Trp, 0.824; His,Ala,Cit,Arg,Met,Phe, 0.824; Asn,Gly,Ala,Pro,ABA,Trp, 0.824; Asn,His,Thr,Ala,Cit,Met, 0.824; Gly,Ala,Cit,ABA,Tyr,Met, 0.822; Ser,Asn,Gly,Ala,Cit,ABA, 0.822; Thr,Ala,Arg,Pro,Orn,Phe, 0.822; Asn,His,Ala,Cit,Arg,Phe, 0.822; Thr,Ala,Arg,Met,Ile,Leu, 0.82; His,Ala,Cit,Arg,Met,Ile, 0.82; Ala,Cit,ABA,Tyr,Met,Leu, 0.82; Gln,Thr,Ala,Arg,Tyr,Met, 0.82; Ser,His,Ala,Cit,Met,Ile, 0.82; Gly,Ala,Cit,ABA,Val,Met, 0.82; Gln,Thr,Ala,Arg,Ile,Phe, 0.82; His,Ala,Cit,Arg,Tyr,Met, 0.819; Glu,His,Thr,Ala,Arg,Ile, 0.819; Thr,Ala,Arg,Pro,Met,Phe, 0.819; Glu,Gly,Ala,Tyr,Met,Trp, 0.819; Glu,Ala,Cit,Tyr,Met,Leu, 0.817; Glu,Thr,Ala,Arg,Tyr,Met, 0.817; Ser,Thr,Ala,Arg,Pro,Met, 0.817; Glu,Thr,Ala,Cit,Met,Trp, 0.817; Ser,Ala,Cit,ABA,Tyr,Met, 0.816; Ala,Cit,Pro,Met,Orn,Trp, 0.816; His,Ala,Cit,Orn,Ile,Trp, 0.816; Ser,Asn,His,Ala,Arg,Trp, 0.816; His,Ala,Cit,Tyr,Orn,Lys, 0.816; Gly,His,Thr,Ala,ABA,Trp, 0.816; Ala,Cit,Tyr,Met,Ile,Leu, 0.814; Ser,His,Ala,Arg,ABA,Met, 0.814; Ser,Ala,Arg,Orn,Leu,Phe, 0.814; Asn,Ala,Met,Ile,Phe,Trp, 0.814; Ser,Asn,Gly,Ala,Tyr,Trp, 0.813; Gln,Ala,Cit,Tyr,Met,Leu, 0.813; Ser,Asn,Gly,Ala,Pro,ABA, 0.813; Ala,Cit,Pro,Met,Orn,Phe, 0.813; Thr,Ala,Cit,Pro,Tyr,Orn, 0.813; Ser,Gly,Ala,Arg,Pro,Met, 0.811; Ala,Cit,Pro,Met,Ile,Leu, 0.811; Glu,Ser,Asn,His,Ala,Arg, 0.811; Ser,Gly,His,Ala,Lys,Trp, 0.811; Ser,Gly,Ala,Met,Lys,Ile, 0.811; Ser,Gly,Gln,Ala,ABA,Trp, 0.811; Ser,Gly,His,Ala,Ile,Trp, 0.811; Thr,Ala,Arg,ABA,Ile,Leu, 0.81; Ala,Cit,Met,Orn,Ile,Phe, 0.81; Ser,Gly,Gln,Ala,Arg,Phe, 0.81; Asn,Gln,Ala,ABA,Met,Trp, 0.81; Ser,Gly,Thr,Ala,Cit,Ile, 0.81; Ser,His,Thr,Ala,Cit,Lys, 0.81; Glu,Ser,Asn,Gly,Ala,Cit, 0.81; His,Ala,Cit,Tyr,Met,Leu, 0.808; Gln,Ala,Cit,ABA,Ile,Leu, 0.808; Thr,Ala,Arg,Pro,ABA,Lys, 0.808; Ser,Gly,Ala,Tyr,Met,Orn, 0.808; Thr,Ala,Arg,ABA,Tyr,Val, 0.808; Ser,Gly,Ala,Arg,Met,Orn, 0.807; Thr,Ala,Arg,Tyr,Ile,Leu, 0.807; Glu,Ser,Thr,Ala,Arg,Leu, 0.807; Glu,Asn,His,Ala,Pro,Trp, 0.807; Asn,Ala,Val,Met,Ile,Leu, 0.807; Glu,Ser,Ala,Arg,ABA,Phe, 0.805; Ser,Gly,Thr,Ala,ABA,Trp, 0.805; Ser,Thr,Ala,Arg,Lys,Trp, 0.805; Ser,His,Ala,Met,Lys,Trp, 0.805; Ser,Gly,Ala,Cit,ABA,Trp, 0.803; Glu,Ser,Ala,Arg,Val,Leu, 0.803; Glu,Ser,Gln,Ala,Met,Trp, 0.802; Ala,Pro,Tyr,Met,Ile,Trp, 0.802; Glu,Ser,Ala,Arg,Tyr,Phe, 0.8; Ser,Asn,Ala,ABA,Leu,Trp, 0.8; Ser,Asn,Ala,ABA,Val,Trp, 0.8; Ser,Ala,Val,Ile,Leu,Phe, 0.8; Ser,His,Ala,Cit,Orn,Leu, 0.793
Ala,hTrp, 0.83; Ala,Arg, 0.825; Ala,hKyn, 0.824; Ala,Serot, 0.82; Asn,Ala, 0.819; His,Ala, 0.819; Ala,Cit, 0.817; Ala,Ile, 0.817; Ala,Pro, 0.817; Gln,Ala, 0.817; Ala,Val, 0.817; Ala,Lys, 0.817; Ala,Met, 0.816; Ala,NP, 0.816; Ala,Trp, 0.816; Ala,XA, 0.816; Ala,Tyr, 0.814; His,hTrp, 0.786; Pro,hTrp, 0.783; His,hKyn, 0.779; Asn,hTrp, 0.762; Lys,hTrp, 0.759; Pro,hKyn, 0.752; Lys,hKyn, 0.752; Arg,hTrp, 0.748; Lys,Serot, 0.748; His,Pro, 0.746; Arg,Pro, 0.745; Arg,Serot, 0.741; Pro,Trp, 0.738; Arg,Trp, 0.738; Trp,hTrp, 0.737; hKyn,XA, 0.735; Lys,Trp, 0.734; Trp,hKyn, 0.729; Trp,Serot, 0.729; His,Trp, 0.726; Lys,XA, 0.726; Thr,Pro, 0.726; His,Arg, 0.726; Val,hKyn, 0.723; Asn,Pro, 0.723; Met,hTrp, 0.721; Gln,Lys, 0.721; His,Lys, 0.721; Pro,Val, 0.721; Arg,hKyn, 0.72; Pro,NP, 0.72; Arg,Tyr, 0.72; Val,Lys, 0.72; Gln,hTrp, 0.72; His,Tyr, 0.72; Asn,Trp, 0.717; Thr,Lys, 0.715; Thr,Trp, 0.714; Pro,Serot, 0.712; Pro,Tyr, 0.712; Arg,NP, 0.712; Pro,Met, 0.712; Thr,hTrp, 0.711; Arg,XA, 0.711; Arg,Ile, 0.711; Gln,Pro, 0.711; Tyr,Lys, 0.709; Val,Trp, 0.709; Arg,Lys, 0.707; Thr,hKyn, 0.707; Tyr,Trp, 0.707; Lys,Ile, 0.707; Asn,Arg, 0.707; Trp,NP, 0.706; Trp,XA, 0.706; Asn,Lys, 0.706; Ile,hTrp, 0.704; Met,Trp, 0.704; Gln,Trp, 0.703; Met,Lys, 0.703; Tyr,hTrp, 0.701; Gln,Arg, 0.701; Tyr,Serot, 0.7; Cit,Trp, 0.698; Val,hTrp, 0.698; Cit,Arg, 0.698; Arg,Met, 0.698; Tyr,hKyn, 0.697; Ile,hKyn, 0.697; Met,hKyn, 0.697; Thr,Arg, 0.697; Asn,hKyn, 0.695; Pro,XA, 0.695; Lys,NP, 0.693; Pro,Ile, 0.693; Met,Serot, 0.692; Cit,Pro, 0.681; hTrp,XA, 0.675; Asn,Tyr, 0.675; hTrp,Serot, 0.672; hKyn,Serot, 0.67; hTrp,NP, 0.67; Tyr,NP, 0.663
Ala,hTrp,Serot, 0.854; Gln,Ala,hTrp, 0.841; Ala,Arg,Serot, 0.836; Ala,Pro,hTrp, 0.834; Ala,hTrp,NP, 0.833; Ala,Arg,Met, 0.833; Ala,Arg,hTrp, 0.831; Ala,Lys,hTrp, 0.831; Ala,Tyr,hTrp, 0.831; Ala,Cit,hTrp, 0.83; Ala,Val,hTrp, 0.83; Ala,Lys,hKyn, 0.83; Ala,hKyn,hTrp, 0.828; Ala,Trp,hTrp, 0.828; Asn,Ala,Arg, 0.828; Ala,hTrp,XA, 0.827; Ala,Trp,hKyn, 0.827; Ala,Met,hKyn, 0.827; Thr,Ala,hKyn, 0.827; Ala,Arg,Val, 0.827; His,Ala,hTrp, 0.825; Ala,Met,Serot, 0.825; Ala,Arg,Lys, 0.825; Ala,Arg,XA, 0.825; Ala,Arg,Pro, 0.825; Ala,Cit,hKyn, 0.824; Ala,Cit,Met, 0.824; Asn,Ala,Cit, 0.824; His,Ala,NP, 0.824; Ala,Arg,Ile, 0.824; Ala,Arg,Tyr, 0.824; His,Ala,hKyn, 0.822; Ala,Pro,Serot, 0.822; Gln,Ala,hKyn, 0.822; Ala,Met,hTrp, 0.82; His,Ala,Serot, 0.82; Ala,Tyr,Serot, 0.82; Ala,Lys,Serot, 0.82; Ala,Cit,Arg, 0.82; His,Ala,Pro, 0.82; Gln,His,Ala, 0.82; Ala,Val,Serot, 0.819; His,Ala,Met, 0.819; Gln,Ala,Arg, 0.819; Asn,Gln,Ala, 0.819; His,Ala,Tyr, 0.819; His,Ala,Val, 0.819; His,Ala,XA, 0.819; Thr,Ala,hTrp, 0.817; Asn,Ala,hTrp, 0.817; Thr,Ala,Serot, 0.817; Ala,Ile,Serot, 0.817; Ala,Met,Trp, 0.817; Ala,Met,NP, 0.817; Ala,Arg,NP, 0.817; Asn,Ala,XA, 0.817; Ala,Met,Lys, 0.817; Ala,Cit,Trp, 0.817; Ala,Pro,NP, 0.817; Ala,Cit,Val, 0.817; Ala,Cit,Lys, 0.817; His,Ala,Ile, 0.817; Ala,Ile,Trp, 0.817; Ala,Trp,XA, 0.817; Gln,Ala,Tyr, 0.817; Ala,hKyn,XA, 0.816; Ala,Trp,Serot, 0.816; Asn,Ala,Tyr, 0.816; Gln,Thr,Ala, 0.816; Ala,Tyr,Trp, 0.816; Gln,Ala,Ile, 0.816; Thr,Ala,Arg, 0.814; Asn,Ala,NP, 0.814; His,Ala,Cit, 0.814; Ala,Val,Met, 0.814; Ala,Pro,Met, 0.814; Ala,XA,NP, 0.814; Ala,Cit,Tyr, 0.814; Ala,Cit,Pro, 0.814; Thr,Ala,XA, 0.814; Gln,Ala,Trp, 0.814; Ala,Val,Ile, 0.814; Ala,Pro,Ile, 0.814; Asn,Ala,Trp, 0.813; Ala,Cit,NP, 0.813; Ala,Ile,NP, 0.813; Ala,Trp,NP, 0.813; Ala,Tyr,NP, 0.813; Asn,His,Ala, 0.811; Asn,Ala,Ile, 0.811; Ala,Cit,Ile, 0.811; Ala,Lys,Trp, 0.811; Thr,Ala,NP, 0.81; Thr,Ala,Val, 0.81; Pro,hKyn,XA, 0.808; His,Thr,Ala, 0.808; Ala,Tyr,Met, 0.807; Pro,hKyn,hTrp, 0.802; Thr,Ala,Tyr, 0.8; Thr,Ala,Ile, 0.799
Ala,Cit,hTrp,Serot, 0.865; Ala,Pro,hTrp,Serot, 0.859; Ala,hKyn,hTrp,Serot, 0.858; Ala,Val,hTrp,Serot, 0.854; Ala,hTrp,Serot,NP, 0.854; Ala,Tyr,hTrp,Serot, 0.854; Thr,Ala,hTrp,Serot, 0.853; Ala,hTrp,Serot,XA, 0.853; Ala,Ile,hTrp,Serot, 0.853; Ala,Trp,hTrp,Serot, 0.853; His,Ala,hTrp,Serot, 0.85; Ala,Met,hTrp,Serot, 0.85; Ala,Lys,hTrp,Serot, 0.85; Gln,Ala,hKyn,hTrp, 0.842; Ala,Cit,Pro,hTrp, 0.842; Ala,Cit,Val,hTrp, 0.841; Asn,Ala,hTrp,Serot, 0.839; Ala,Cit,hTrp,NP, 0.839; Ala,Cit,Lys,hTrp, 0.839; Gln,Ala,hTrp,NP, 0.839; Gln,Ala,Val,hTrp, 0.839; His,Ala,Arg,Serot, 0.839; Ala,Arg,Tyr,Serot, 0.839; Asn,Gln,Ala,hTrp, 0.837; Gln,Ala,Cit,hTrp, 0.837; Ala,Pro,Val,hTrp, 0.837; Ala,Pro,hTrp,NP, 0.837; Ala,Tyr,hKyn,Serot, 0.837; Ala,Arg,Lys,Serot, 0.837; Ala,Arg,Pro,Serot, 0.837; Ala,Arg,Lys,hTrp, 0.836; Ala,Arg,Serot,XA, 0.836; Ala,Pro,Tyr,hTrp, 0.834; Ala,Pro,Ile,hTrp, 0.834; Gln,Ala,Arg,Serot, 0.834; Ala,Val,hTrp,XA, 0.833; Ala,Arg,hKyn,hTrp, 0.833; Ala,Cit,Tyr,hTrp, 0.833; Gln,Thr,Ala,hTrp, 0.831; Ala,Tyr,hTrp,NP, 0.831; Ala,Tyr,Trp,hTrp, 0.831; Ala,Cit,Ile,hTrp, 0.83; Ala,Met,hTrp,NP, 0.83; Ala,Ile,hTrp,NP, 0.83; Ala,Arg,Met,Ile, 0.83; Ala,Ile,hKyn,hTrp, 0.828; His,Ala,Met,hTrp, 0.828; Ala,Lys,hKyn,hTrp, 0.828; Ala,Ile,hTrp,XA, 0.828; Asn,Ala,Cit,Serot, 0.828; His,Ala,Serot,NP, 0.828; Ala,Cit,Lys,Serot, 0.828; His,Ala,Tyr,hTrp, 0.827; His,Ala,Ile,hTrp, 0.827; His,Ala,Lys,hTrp, 0.827; Ala,Arg,hTrp,XA, 0.827; Ala,Val,Met,hTrp, 0.827; Ala,Met,Serot,NP, 0.827; Ala,Lys,Trp,Serot, 0.827; Asn,Ala,hTrp,NP, 0.825; Ala,Met,Lys,hTrp, 0.825; Ala,Met,Trp,hKyn, 0.825; Asn,Ala,hKyn,XA, 0.824; Asn,Ala,Pro,Serot, 0.824; Asn,Ala,Trp,hKyn, 0.824; Thr,Ala,Lys,Serot, 0.824; Thr,Ala,Trp,Serot, 0.822; Asn,Gln,Ala,Serot, 0.822; Asn,Ala,Tyr,hKyn, 0.822; Gln,His,Ala,hKyn, 0.822; Thr,Ala,hKyn,hTrp, 0.82; Thr,Ala,Pro,hTrp, 0.82; Ala,Tyr,Met,hTrp, 0.82; Thr,Ala,Val,hTrp, 0.82; His,Ala,Val,hKyn, 0.82; Ala,Tyr,Met,hKyn, 0.82; Ala,Pro,Ile,hKyn, 0.82; Gln,His,Ala,Serot, 0.82; Asn,His,Ala,hTrp, 0.819; Asn,Ala,Trp,hTrp, 0.819; Thr,Ala,Met,Serot, 0.819; Ala,Val,Met,hKyn, 0.819; Thr,Ala,Met,hTrp, 0.817; Asn,Ala,Lys,hTrp, 0.817; Thr,Ala,Serot,NP, 0.817; Gln,Thr,Ala,Serot, 0.817; Ala,Lys,Ile,hKyn, 0.817; Gln,Ala,Cit,hKyn, 0.816; Gln,Ala,Trp,Serot, 0.816; Ala,Val,Trp,Serot, 0.816; Thr,Ala,Trp,hTrp, 0.814; Gln,Ala,hKyn,XA, 0.814; Thr,Ala,Pro,Serot, 0.814; Ala,Arg,Ile,hKyn, 0.814; Ala,Trp,Serot,NP, 0.814; Ala,Tyr,hKyn,XA, 0.813; Thr,Ala,Ile,Serot, 0.811; Thr,Ala,Tyr,Serot, 0.811; Gln,Ala,Ile,hKyn, 0.811; Thr,Ala,Tyr,hTrp, 0.808
Ala,Cit,hKyn,hTrp,Serot, 0.87; Gln,Ala,Cit,hTrp,Serot, 0.865; Ala,Cit,Arg,hTrp,Serot, 0.865; Ala,Cit,Tyr,hTrp,Serot, 0.865; Ala,hKyn,hTrp,Serot,XA, 0.864; His,Ala,Pro,hTrp,Serot, 0.864; Ala,Arg,hKyn,hTrp,Serot, 0.864; Ala,Arg,Met,hTrp,Serot, 0.862; Ala,Cit,Val,hTrp,Serot, 0.861; His,Ala,hKyn,hTrp,Serot, 0.859; Ala,Pro,Tyr,hTrp,Serot, 0.859; Ala,Pro,Lys,hTrp,Serot, 0.858; Ala,hTrp,Serot,XA,NP, 0.856; Ala,Val,hTrp,Serot,NP, 0.856; Ala,Tyr,Ile,hTrp,Serot, 0.856; Thr,Ala,Pro,hTrp,Serot, 0.854; His,Ala,hTrp,Serot,XA, 0.854; Thr,Ala,Cit,hTrp,Serot, 0.853; Asn,Ala,Cit,hTrp,Serot, 0.853; His,Ala,Tyr,hTrp,Serot, 0.853; Thr,Ala,Met,hTrp,Serot, 0.851; Thr,Ala,hTrp,Serot,XA, 0.85; Ala,Trp,hTrp,Serot,XA, 0.85; Pro,Val,hKyn,hTrp,XA, 0.85; Ala,Met,hTrp,Serot,XA, 0.848; Thr,Ala,Trp,hTrp,Serot, 0.845; Thr,Ala,Tyr,hTrp,Serot, 0.844; Asn,His,Ala,hTrp,Serot, 0.844; Gln,His,Ala,Arg,hTrp, 0.842; Gln,His,Ala,Tyr,hTrp, 0.842; Gln,Ala,Arg,hKyn,hTrp, 0.842; Ala,Arg,Tyr,Met,Serot, 0.842; Ala,Val,Met,hKyn,Serot, 0.842; Gln,Ala,Ile,hTrp,XA, 0.841; Thr,Ala,Arg,Met,Serot, 0.841; His,Ala,Cit,Met,hTrp, 0.839; Ala,Arg,Tyr,Lys,hTrp, 0.839; Ala,Met,hKyn,Serot,XA, 0.839; Ala,Lys,hKyn,Serot,XA, 0.839; Ala,Cit,Arg,Met,Serot, 0.839; His,Ala,Tyr,hKyn,Serot, 0.839; Asn,Ala,Pro,hKyn,hTrp, 0.837; His,Ala,Tyr,Val,hTrp, 0.837; Gln,Ala,Val,Met,hTrp, 0.837; Ala,Pro,Lys,Ile,hTrp, 0.837; Thr,Ala,Arg,Serot,XA, 0.837; His,Ala,Met,hKyn,Serot, 0.837; Ala,Lys,hTrp,XA,NP, 0.836; Ala,Pro,Trp,hTrp,NP, 0.836; Gln,Ala,Ile,hTrp,NP, 0.836; Thr,Ala,Arg,Tyr,Serot, 0.836; Ala,Val,hKyn,Serot,XA, 0.836; Asn,Ala,Arg,Pro,Serot, 0.836; Gln,Ala,Met,Trp,hTrp, 0.834; Ala,Tyr,Lys,hTrp,NP, 0.834; Thr,Ala,Cit,Arg,Serot, 0.834; Thr,Ala,Cit,hKyn,hTrp, 0.833; Thr,Ala,Cit,hTrp,NP, 0.833; His,Ala,Pro,Tyr,hTrp, 0.833; Gln,Ala,Arg,Met,hTrp, 0.833; Ala,Cit,Trp,hTrp,NP, 0.833; Ala,Tyr,Trp,hKyn,hTrp, 0.833; Ala,Arg,Pro,Ile,hTrp, 0.833; Asn,Ala,Cit,hKyn,Serot, 0.833; Thr,Ala,hKyn,Serot,XA, 0.833; Ala,Ile,hKyn,Serot,XA, 0.833; Ala,Tyr,hKyn,Serot,XA, 0.833; His,Ala,Pro,hTrp,NP, 0.831; Ala,Arg,Met,hTrp,NP, 0.831; His,Ala,Val,Met,hTrp, 0.831; Ala,Lys,Trp,hTrp,NP, 0.831; Ala,Val,hKyn,hTrp,XA, 0.83; His,Ala,Pro,Lys,hTrp, 0.83; Ala,Pro,Val,Ile,hTrp, 0.83; Ala,Tyr,Val,hKyn,hTrp, 0.83; Ala,Pro,Val,Met,hTrp, 0.83; Asn,Ala,Pro,Met,hTrp, 0.828; Ala,Met,Trp,hTrp,NP, 0.828; Ala,Cit,hKyn,Serot,XA, 0.828; Asn,His,Ala,Arg,hTrp, 0.827; Ala,Val,Met,hKyn,hTrp, 0.827; Ala,Lys,Trp,hTrp,XA, 0.827; Ala,Val,Met,Trp,hTrp, 0.827; Thr,Ala,Met,hTrp,NP, 0.825; Asn,Ala,Val,Met,hTrp, 0.825; Asn,His,Ala,Cit,Serot, 0.825; Ala,Tyr,Met,hKyn,XA, 0.825; Thr,Ala,Cit,hTrp,XA, 0.822; Thr,Ala,Val,Met,hTrp, 0.822; Asn,Ala,hTrp,XA,NP, 0.82; Asn,Ala,Ile,Trp,hTrp, 0.82; Ala,Cit,Met,Ile,hKyn, 0.819; Thr,Ala,hTrp,XA,NP, 0.817; Asn,His,Ala,Ile,hTrp, 0.817; Thr,Ala,Pro,Lys,hTrp, 0.816; Asn,Ala,Tyr,hTrp,XA, 0.814; Ala,Pro,Met,Ile,hTrp, 0.813; Asn,His,Ala,Trp,Serot, 0.813; Thr,Ala,Ile,Trp,hTrp, 0.81; Thr,Ala,Tyr,Trp,hTrp, 0.808
His,Ala,Arg,hTrp,Serot,XA, 0.865; Ala,Cit,Val,hKyn,hTrp,Serot, 0.865; Ala,Cit,Pro,hTrp,Serot,XA, 0.865; Gln,Thr,Ala,Arg,hTrp,Serot, 0.862; Thr,Ala,Cit,hKyn,hTrp,Serot, 0.862; Ala,Arg,Pro,Met,hTrp,Serot, 0.862; Asn,His,Ala,Arg,hTrp,Serot, 0.861; Ala,Cit,Met,Lys,hTrp,Serot, 0.859; Ala,Arg,Tyr,Trp,hTrp,Serot, 0.859; Ala,Pro,Tyr,hTrp,Serot,NP, 0.859; Thr,Ala,Arg,Ile,hTrp,Serot, 0.858; Ala,Cit,Arg,hKyn,hTrp,Serot, 0.858; Gln,Ala,Lys,hKyn,hTrp,Serot, 0.858; Gln,Thr,Ala,Ile,hTrp,Serot, 0.856; Ala,Val,hKyn,hTrp,Serot,XA, 0.856; Ala,Tyr,Val,Trp,hTrp,Serot, 0.856; Thr,Ala,Arg,Pro,hTrp,Serot, 0.854; Ala,Met,Lys,hKyn,hTrp,Serot, 0.854; Thr,Ala,hTrp,Serot,XA,NP, 0.853; Thr,Ala,Trp,hKyn,hTrp,Serot, 0.853; Asn,Ala,Trp,hKyn,hTrp,Serot, 0.853; Ala,Met,Trp,hTrp,Serot,XA, 0.853; Ala,Val,Ile,hTrp,Serot,NP, 0.853; Thr,Ala,Arg,Met,hTrp,Serot, 0.851; Ala,Tyr,Met,hKyn,hTrp,Serot, 0.851; Asn,Gln,Ala,Val,hTrp,Serot, 0.851; His,Ala,Lys,hTrp,Serot,NP, 0.851; His,Ala,Pro,hKyn,hTrp,XA, 0.85; Ala,Met,Lys,Trp,hTrp,Serot, 0.85; Ala,Lys,Trp,hTrp,Serot,NP, 0.85; Thr,Ala,Arg,Val,hTrp,Serot, 0.848; Ala,Arg,Met,Ile,hTrp,Serot, 0.848; Thr,Ala,Ile,hKyn,hTrp,Serot, 0.848; Ala,Pro,Met,Trp,hTrp,Serot, 0.848; His,Thr,Ala,Arg,Ile,Serot, 0.848; Ala,Lys,Ile,Trp,hTrp,Serot, 0.848; Ala,Arg,Met,Ile,hKyn,Serot, 0.848; Gln,Ala,Pro,Val,hTrp,XA, 0.848; Ala,Tyr,Met,hTrp,Serot,NP, 0.847; Ala,Cit,Tyr,Met,hKyn,hTrp, 0.847; His,Thr,Ala,Ile,hTrp,Serot, 0.845; Ala,Cit,Arg,Tyr,Met,hTrp, 0.845; Asn,Ala,Cit,Tyr,hKyn,hTrp, 0.845; Thr,Ala,Ile,hTrp,Serot,XA, 0.844; Asn,Thr,Ala,Arg,Ile,Serot, 0.844; Gln,Ala,Cit,Met,hKyn,hTrp, 0.844; His,Ala,Arg,Pro,Ile,hTrp, 0.844; Ala,Cit,Pro,hTrp,XA,NP, 0.844; Asn,Gln,Ala,Pro,hKyn,hTrp, 0.842; Thr,Ala,Met,Ile,hTrp,Serot, 0.841; Asn,Ala,Lys,hTrp,Serot,XA, 0.841; Asn,Gln,His,Thr,Ala,hTrp, 0.841; Asn,Ala,Cit,Met,hKyn,hTrp, 0.841; Asn,Gln,Ala,Val,hTrp,XA, 0.841; Thr,Ala,Ile,Trp,hTrp,Serot, 0.839; Ala,Arg,Lys,hKyn,hTrp,XA, 0.839; Ala,Cit,Val,Ile,hTrp,XA, 0.839; Ala,Pro,Tyr,Val,hTrp,XA, 0.839; Asn,Thr,Ala,Arg,Val,Serot, 0.839; Thr,Ala,Arg,Tyr,Ile,Serot, 0.839; His,Ala,Cit,Arg,Ile,hTrp, 0.837; Gln,Thr,Ala,Arg,Ile,Serot, 0.837; His,Ala,Met,Lys,hKyn,hTrp, 0.836; Thr,Ala,Arg,Ile,Serot,NP, 0.836; Thr,Ala,Arg,Val,Met,Serot, 0.836; Asn,Ala,Cit,Arg,hTrp,NP, 0.836; Ala,Pro,Val,Ile,Trp,hTrp, 0.836; Ala,Met,Ile,hTrp,Serot,NP, 0.834; Thr,Ala,Cit,Met,hTrp,NP, 0.834; Thr,Ala,Cit,Arg,hTrp,NP, 0.834; Asn,Gln,Ala,Ile,hKyn,hTrp, 0.834; Thr,Ala,Arg,Val,Ile,Serot, 0.834; Asn,His,Ala,Pro,Val,hTrp, 0.834; Asn,His,Ala,Lys,hKyn,Serot, 0.834; His,Thr,Ala,Cit,Lys,hTrp, 0.833; Thr,Ala,Cit,Arg,Met,hTrp, 0.833; Ala,Cit,Trp,hKyn,hTrp,XA, 0.831; His,Ala,Lys,hTrp,XA,NP, 0.831; Ala,Arg,Trp,hKyn,hTrp,XA, 0.83; Thr,Ala,Cit,Arg,Trp,hTrp, 0.828; Ala,Tyr,Val,Ile,hKyn,hTrp, 0.828; Ala,Val,Ile,Trp,hTrp,XA, 0.828; Thr,Ala,Cit,Pro,Lys,hTrp, 0.827; Thr,Ala,Arg,Tyr,Val,hTrp, 0.827; Asn,His,Ala,Pro,hTrp,XA, 0.827; His,Ala,Val,Met,hTrp,XA, 0.825; His,Thr,Ala,Met,hKyn,hTrp, 0.822; Asn,Thr,Ala,Arg,Tyr,hTrp, 0.822; His,Thr,Ala,Tyr,hKyn,hTrp, 0.82; Thr,Ala,Arg,Lys,Trp,hTrp, 0.82; Thr,Ala,Arg,Val,Ile,hTrp, 0.819; Thr,Ala,Arg,Ile,hKyn,hTrp, 0.819; Thr,Ala,Cit,Lys,hTrp,XA, 0.819; His,Thr,Ala,Trp,hTrp,NP, 0.819; Asn,Ala,Val,Ile,Trp,hTrp, 0.816; His,Thr,Ala,Tyr,Trp,hTrp, 0.816; Asn,His,Ala,Met,hTrp,XA, 0.816; Thr,Ala,Ile,Trp,hTrp,NP, 0.811; Thr,Ala,Ile,Trp,hKyn,hTrp, 0.81; Thr,Ala,Val,Met,Ile,hTrp, 0.808
Arg,Met, 0.784; Arg,Phe, 0.756; Arg,Ile, 0.749; Arg,Leu, 0.743; Thr,Arg, 0.733; Ser,Arg, 0.729; Arg,Orn, 0.727; Cit,Arg, 0.727; His,Arg, 0.727; Arg,Pro, 0.727; Arg,Trp, 0.727; Asn,Arg, 0.725; Gln,Arg, 0.719; Ala,Arg, 0.71; Arg,Lys, 0.71; Tyr,Phe, 0.689; His,Ile, 0.684; Phe,Trp, 0.681; Ser,His, 0.681; His,Phe, 0.679; His,Leu, 0.678; His,Val, 0.676; His,Cit, 0.675; His,Met, 0.673; His,Orn, 0.671; His,Tyr, 0.668; His,Pro, 0.665; Met,Trp, 0.662; His,Thr, 0.657; His,Trp, 0.651; Ser,Thr, 0.651; Gln,His, 0.651; Ser,Ala, 0.649; Ser,Trp, 0.648; Ser,Pro, 0.646; Ala,Phe, 0.644; Asn,His, 0.643; Val,Phe, 0.64; Val,Trp, 0.638; Tyr,Trp, 0.637; Thr,Met, 0.637; Gly,His, 0.635; Thr,Ile, 0.633; Thr,Cit, 0.633; Ala,Met, 0.632; Cit,Trp, 0.632; Leu,Trp, 0.629; Thr,Phe, 0.627; Gly,Trp, 0.627; Ile,Trp, 0.627; Thr,Lys, 0.625; Pro,Trp, 0.625; Orn,Trp, 0.625; Gly,Ala, 0.624; Thr,Pro, 0.624; Ser,Lys, 0.622; Asn,Trp, 0.622; Gly,Lys, 0.621; Ala,Cit, 0.621; Gln,Trp, 0.621; Gln,Ala, 0.619; Ala,Leu, 0.619; His,Lys, 0.619; Thr,Tyr, 0.619; Ala,Ile, 0.617; His,Ala, 0.617; Gly,Thr, 0.617; Thr,Leu, 0.617; Thr,Trp, 0.616; Lys,Ile, 0.614; Ala,Val, 0.613; Cit,Lys, 0.611; Gln,Thr, 0.611; Ser,Asn, 0.608; Asn,Thr, 0.608; Ala,Trp, 0.606; Lys,Trp, 0.606; Leu,Phe, 0.606; Ala,Pro, 0.603; Asn,Ala, 0.603; Pro,Phe, 0.602; Pro,Lys, 0.6; Lys,Leu, 0.598; Ala,Tyr, 0.594; Asn,Phe, 0.594; Ala,Lys, 0.592; Gly,Val, 0.584; Val,Lys, 0.583; Asn,Lys, 0.583; Orn,Lys, 0.583; Asn,Gly, 0.581; Gln,Lys, 0.579; Met,Phe, 0.575; Met,Lys, 0.57; Tyr,Lys, 0.567; Gly,Met, 0.557; Gly,Pro, 0.543; Gly,Leu, 0.543; Gly,Ile, 0.54
His,Arg,Met, 0.789; Cit,Arg,Met, 0.786; Arg,Pro,Met, 0.786; Arg,Val,Met, 0.783; Arg,Met,Ile, 0.781; Ala,Arg,Met, 0.776; Ser,Arg,Phe, 0.77; Arg,Met,Leu, 0.768; Gln,Arg,Met, 0.768; Gly,Arg,Met, 0.765; Thr,Arg,Phe, 0.765; His,Arg,Phe, 0.76; Arg,Val,Phe, 0.759; Arg,Ile,Phe, 0.756; Gln,Arg,Phe, 0.756; Ser,Thr,Arg, 0.751; Thr,Arg,Ile, 0.749; Arg,Val,Ile, 0.749; Arg,Ile,Trp, 0.749; Gly,Arg,Ile, 0.748; Ala,Arg,Phe, 0.748; Cit,Arg,Leu, 0.746; Asn,Arg,Phe, 0.746; Arg,Ile,Leu, 0.744; Thr,Arg,Trp, 0.743; Thr,Cit,Arg, 0.743; Gln,Arg,Ile, 0.743; Arg,Lys,Phe, 0.743; Cit,Arg,Val, 0.741; Asn,Arg,Ile, 0.741; Arg,Val,Leu, 0.74; Ser,Arg,Ile, 0.738; Asn,Arg,Val, 0.737; Gln,Arg,Leu, 0.737; Arg,Pro,Ile, 0.735; His,Arg,Ile, 0.735; His,Cit,Arg, 0.732; His,Thr,Arg, 0.732; Arg,Pro,Val, 0.732; Gly,Arg,Val, 0.732; Gly,Arg,Leu, 0.732; Cit,Arg,Pro, 0.73; Asn,Gly,Arg, 0.729; Gly,Cit,Arg, 0.729; His,Arg,Val, 0.729; Asn,Cit,Arg, 0.727; Gly,Gln,Arg, 0.727; Asn,Arg,Orn, 0.725; Thr,Arg,Orn, 0.725; Ala,Arg,Leu, 0.725; Arg,Tyr,Val, 0.724; Cit,Arg,Lys, 0.722; Gln,Cit,Arg, 0.722; Arg,Orn,Trp, 0.721; Ser,Arg,Orn, 0.721; Ser,Gly,Arg, 0.721; Arg,Orn,Leu, 0.721; Gly,Arg,Trp, 0.719; His,Arg,Leu, 0.719; Ser,Arg,Lys, 0.717; His,Arg,Orn, 0.714; Thr,Arg,Tyr, 0.711; Ala,Arg,Trp, 0.706; Gln,Arg,Orn, 0.705; His,Ala,Arg, 0.705; Gln,Arg,Tyr, 0.702; His,Val,Phe, 0.684; His,Arg,Tyr, 0.684; Ile,Phe,Trp, 0.681; Leu,Phe,Trp, 0.679; Arg,Tyr,Trp, 0.679; Ser,Phe,Trp, 0.675; Gly,Phe,Trp, 0.67; Pro,Val,Phe, 0.662; Ala,Phe,Trp, 0.66; Ala,Val,Phe, 0.66; Ala,Orn,Phe, 0.659; Lys,Phe,Trp, 0.657; Ala,Cit,Phe, 0.657; Gln,Phe,Trp, 0.656; Cit,Lys,Phe, 0.654; Gly,Val,Phe, 0.651; Thr,Ala,Phe, 0.651; Ser,Gly,Ala, 0.648; Ala,Pro,Phe, 0.644; Asn,Ala,Phe, 0.644; Ala,Tyr,Trp, 0.64; Thr,Lys,Phe, 0.64; Pro,Lys,Phe, 0.64; Ala,Tyr,Phe, 0.638; Gly,Ala,Phe, 0.635; Gly,Ala,Trp, 0.63; Gly,Ala,Pro, 0.629; Asn,Gly,Ala, 0.627; Val,Lys,Phe, 0.627; Gly,Ala,Orn, 0.625; Gly,Lys,Phe, 0.625; Gly,His,Ala, 0.622; Ser,Ala,Tyr, 0.619; Gln,Ala,Tyr, 0.587
Cit,Arg,Met,Phe, 0.787; His,Arg,Met,Orn, 0.783; Gly,Arg,Met,Trp, 0.783; Asn,Arg,Met,Trp, 0.781; Ala,Arg,Met,Leu, 0.781; His,Arg,Met,Phe, 0.781; Thr,Arg,Met,Phe, 0.775; Thr,Cit,Arg,Phe, 0.771; His,Cit,Arg,Phe, 0.771; Ser,Ala,Arg,Met, 0.771; Arg,Met,Ile,Phe, 0.77; Gln,Arg,Met,Phe, 0.768; Cit,Arg,Ile,Phe, 0.767; Cit,Arg,Tyr,Phe, 0.767; Arg,Met,Lys,Trp, 0.765; Gly,Cit,Arg,Phe, 0.765; Thr,Arg,Ile,Phe, 0.765; Gln,Ala,Arg,Met, 0.765; Ala,Arg,Met,Phe, 0.765; Cit,Arg,Val,Phe, 0.762; His,Thr,Arg,Phe, 0.76; Arg,Val,Ile,Phe, 0.76; Ser,Arg,Met,Lys, 0.759; His,Arg,Ile,Phe, 0.759; Arg,Tyr,Ile,Phe, 0.757; Arg,Pro,Leu,Phe, 0.756; Asn,Arg,Met,Lys, 0.754; Gln,Arg,Val,Phe, 0.754; Ser,Arg,Val,Phe, 0.752; Gly,Arg,Phe,Trp, 0.752; Thr,Ala,Arg,Phe, 0.752; Thr,Arg,Met,Lys, 0.751; His,Arg,Lys,Phe, 0.751; Gln,Ala,Arg,Phe, 0.751; Ala,Arg,Lys,Phe, 0.751; Ala,Arg,Pro,Phe, 0.751; Arg,Ile,Phe,Trp, 0.749; Arg,Val,Lys,Phe, 0.748; Arg,Tyr,Val,Phe, 0.748; Ala,Arg,Val,Phe, 0.748; Arg,Lys,Ile,Phe, 0.746; Gly,Ala,Arg,Phe, 0.746; Ala,Arg,Phe,Trp, 0.746; His,Arg,Tyr,Phe, 0.741; Gly,Arg,Lys,Phe, 0.741; Cit,Arg,Lys,Phe, 0.74; Gly,Cit,Arg,Tyr, 0.738; Ser,Arg,Lys,Phe, 0.738; Arg,Pro,Tyr,Phe, 0.727; Asn,Arg,Tyr,Phe, 0.722; Cit,Arg,Tyr,Trp, 0.717; Ala,Arg,Tyr,Phe, 0.717; His,Ala,Arg,Tyr, 0.706; Ser,Arg,Tyr,Orn, 0.705; Arg,Tyr,Phe,Trp, 0.705; Ala,Arg,Pro,Tyr, 0.7; His,Arg,Tyr,Orn, 0.698; Ala,Arg,Tyr,Ile, 0.698; Ala,Arg,Tyr,Leu, 0.694; Ala,Arg,Tyr,Lys, 0.69; Gly,Ala,Arg,Tyr, 0.69; Asn,Arg,Tyr,Orn, 0.689; Gln,Ala,Arg,Tyr, 0.689; Gln,Arg,Tyr,Orn, 0.687; Arg,Tyr,Ile,Trp, 0.686; Ala,Ile,Leu,Phe, 0.681; Gly,Arg,Tyr,Lys, 0.678; Ala,Cit,Val,Phe, 0.678; Ala,Orn,Leu,Phe, 0.676; Ala,Cit,Leu,Phe, 0.676; Ser,Ala,Leu,Phe, 0.675; Ala,Val,Ile,Phe, 0.675; Ser,Ala,Orn,Phe, 0.671; His,Ala,Orn,Phe, 0.668; Ala,Met,Phe,Trp, 0.662; Gln,Ala,Orn,Phe, 0.662; Ser,Ala,Phe,Trp, 0.662; His,Ala,Cit,Phe, 0.659; Thr,Ala,Met,Phe, 0.657; His,Ala,Met,Phe, 0.656; Ala,Pro,Orn,Phe, 0.656; Ser,Ala,Pro,Phe, 0.654; Thr,Ala,Leu,Phe, 0.654; His,Thr,Ala,Phe, 0.652; Ala,Cit,Lys,Phe, 0.652; Gln,Ala,Phe,Trp, 0.651; Ala,Cit,Tyr,Phe, 0.651; Gly,Thr,Ala,Phe, 0.649; Asn,Gln,Ala,Phe, 0.644; Ser,Ala,Tyr,Phe, 0.644; Ala,Tyr,Leu,Phe, 0.641; Ala,Pro,Tyr,Phe, 0.64; Ala,Pro,Met,Phe, 0.64; Ala,Lys,Ile,Phe, 0.64; Gln,Ala,Tyr,Phe, 0.637; Gln,Ala,Ile,Phe, 0.637; Gly,Ala,Pro,Phe, 0.635; Gly,Ala,Lys,Phe, 0.635; Gly,Ala,Tyr,Phe, 0.624; Ala,Tyr,Ile,Phe, 0.622
His,Cit,Arg,Met,Phe, 0.802; His,Arg,Val,Met,Phe, 0.794; Ala,Arg,Ile,Leu,Phe, 0.783; Ala,Arg,Val,Met,Phe, 0.781; His,Ala,Arg,Met,Ile, 0.779; Thr,Arg,Val,Met,Phe, 0.776; Gly,Ala,Arg,Met,Leu, 0.776; Arg,Tyr,Val,Met,Phe, 0.775; Arg,Met,Ile,Phe,Trp, 0.775; Ser,Ala,Arg,Val,Met, 0.775; Arg,Val,Met,Phe,Trp, 0.775; Thr,Arg,Met,Phe,Trp, 0.773; Ser,Thr,Ala,Arg,Met, 0.773; Ala,Cit,Arg,Met,Phe, 0.773; Gly,Ala,Cit,Arg,Met, 0.771; His,Ala,Arg,Pro,Met, 0.77; Arg,Val,Met,Lys,Phe, 0.77; Ala,Arg,Met,Lys,Phe, 0.77; His,Ala,Arg,Val,Met, 0.768; Ser,Thr,Arg,Phe,Trp, 0.768; Cit,Arg,Val,Ile,Phe, 0.768; Thr,Ala,Arg,Met,Phe, 0.768; Arg,Val,Met,Orn,Phe, 0.767; Ala,Arg,Val,Met,Trp, 0.765; Asn,Ala,Arg,Met,Phe, 0.765; His,Ala,Arg,Val,Phe, 0.763; Asn,Gln,Ala,Arg,Met, 0.762; Arg,Val,Met,Leu,Phe, 0.762; Thr,Ala,Arg,Met,Orn, 0.76; Asn,Arg,Val,Ile,Phe, 0.76; Thr,Ala,Arg,Phe,Trp, 0.759; Ala,Arg,Met,Orn,Phe, 0.759; Asn,His,Ala,Arg,Phe, 0.754; Ala,Cit,Arg,Ile,Phe, 0.752; His,Ala,Arg,Leu,Phe, 0.752; Ala,Arg,Pro,Lys,Phe, 0.752; Gly,Gln,Ala,Arg,Phe, 0.751; His,Ala,Arg,Ile,Phe, 0.751; Ala,Arg,Lys,Phe,Trp, 0.749; Ala,Cit,Arg,Phe,Trp, 0.749; His,Ala,Arg,Lys,Phe, 0.749; Ser,Ala,Cit,Arg,Phe, 0.746; Arg,Orn,Ile,Phe,Trp, 0.743; Gln,Arg,Orn,Phe,Trp, 0.74; His,Arg,Tyr,Val,Phe, 0.74; Ala,Cit,Arg,Val,Phe, 0.74; Arg,Orn,Leu,Phe,Trp, 0.738; Ala,Cit,Arg,Leu,Phe, 0.738; Thr,Arg,Orn,Lys,Phe, 0.735; His,Ala,Arg,Tyr,Met, 0.729; Ala,Arg,Tyr,Met,Phe, 0.727; Arg,Tyr,Orn,Ile,Phe, 0.724; Cit,Arg,Tyr,Lys,Phe, 0.717; Ala,Arg,Tyr,Val,Phe, 0.714; Gly,His,Ala,Arg,Tyr, 0.713; Ala,Arg,Tyr,Leu,Phe, 0.71; Ser,Asn,Ala,Arg,Tyr, 0.706; Arg,Tyr,Orn,Phe,Trp, 0.706; Ala,Arg,Tyr,Orn,Phe, 0.706; Ala,Arg,Tyr,Lys,Trp, 0.703; Asn,Ala,Cit,Arg,Tyr, 0.703; Arg,Pro,Tyr,Orn,Phe, 0.703; Asn,Ala,Arg,Pro,Tyr, 0.7; Asn,Ala,Arg,Tyr,Val, 0.695; Thr,Ala,Arg,Tyr,Lys, 0.694; Ser,Ala,Ile,Leu,Phe, 0.692; Ala,Pro,Ile,Leu,Phe, 0.69; Ala,Met,Ile,Leu,Phe, 0.69; Gln,Ala,Arg,Tyr,Trp, 0.689; Gln,Ala,Cit,Arg,Tyr, 0.686; Arg,Tyr,Orn,Ile,Trp, 0.684; Ala,Cit,Leu,Phe,Trp, 0.679; Gly,Ala,Arg,Tyr,Orn, 0.679; Gln,Ala,Arg,Tyr,Orn, 0.678; Asn,Gly,Ala,Val,Phe, 0.678; Ala,Val,Met,Orn,Phe, 0.676; Thr,Ala,Cit,Leu,Phe, 0.676; Asn,Thr,Ala,Cit,Phe, 0.675; His,Ala,Orn,Leu,Phe, 0.673; Ala,Val,Orn,Leu,Phe, 0.67; Asn,Thr,Ala,Lys,Phe, 0.668; Asn,Ala,Val,Met,Phe, 0.667; Asn,Gln,Ala,Phe,Trp, 0.667; Thr,Ala,Leu,Phe,Trp, 0.663; His,Ala,Val,Leu,Phe, 0.662; Gln,Ala,Val,Leu,Phe, 0.66; His,Ala,Val,Lys,Phe, 0.659; Ala,Cit,Pro,Phe,Trp, 0.659; Ala,Pro,Val,Met,Phe, 0.657; Gln,Thr,Ala,Cit,Phe, 0.657; Gly,Thr,Ala,Cit,Phe, 0.657; Gly,Gln,Ala,Cit,Phe, 0.656; Gln,Ala,Cit,Pro,Phe, 0.656; Ala,Tyr,Val,Ile,Phe, 0.656; Asn,Ala,Pro,Leu,Phe, 0.654; Gly,Ala,Tyr,Val,Phe, 0.652; Asn,Ala,Lys,Leu,Phe, 0.651; Ala,Cit,Tyr,Orn,Phe, 0.648; Ser,Ala,Tyr,Phe,Trp, 0.638; Gln,Ala,Tyr,Leu,Phe, 0.637
His,Ala,Arg,Met,Leu,Phe, 0.803; Ala,Arg,Met,Ile,Leu,Phe, 0.8; Ala,Arg,Met,Lys,Leu,Phe, 0.797; Thr,Ala,Arg,Met,Leu,Phe, 0.795; Ala,Arg,Val,Met,Leu,Phe, 0.794; Ala,Arg,Met,Leu,Phe,Trp, 0.792; Asn,Ala,Arg,Met,Leu,Phe, 0.792; Gly,Ala,Arg,Met,Leu,Phe, 0.792; Ala,Arg,Met,Orn,Leu,Phe, 0.79; Ala,Arg,Pro,Met,Leu,Phe, 0.786; Ala,Arg,Orn,Ile,Leu,Phe, 0.783; Ala,Arg,Val,Ile,Leu,Phe, 0.783; Ala,Arg,Val,Met,Ile,Phe, 0.783; Gly,Ala,Arg,Pro,Met,Leu, 0.781; Ser,Ala,Arg,Ile,Leu,Phe, 0.779; Gly,Thr,Ala,Arg,Met,Leu, 0.776; His,Thr,Ala,Arg,Val,Phe, 0.773; Ser,Ala,Cit,Arg,Val,Met, 0.771; Ser,Thr,Ala,Arg,Val,Phe, 0.771; Gly,Ala,Arg,Pro,Met,Trp, 0.77; Ser,Asn,Ala,Arg,Val,Met, 0.768; His,Arg,Val,Orn,Ile,Phe, 0.768; Ser,Ala,Arg,Met,Ile,Leu, 0.768; Ser,Asn,Ala,Arg,Met,Orn, 0.767; Ala,Cit,Arg,Met,Lys,Phe, 0.767; Asn,Ala,Arg,Met,Lys,Phe, 0.767; Ala,Arg,Tyr,Met,Leu,Phe, 0.767; Asn,Ala,Arg,Met,Orn,Trp, 0.765; His,Thr,Ala,Arg,Pro,Phe, 0.762; Gln,Ala,Arg,Met,Ile,Phe, 0.762; Ala,Arg,Val,Ile,Phe,Trp, 0.76; His,Ala,Arg,Met,Ile,Phe, 0.76; Gln,Ala,Cit,Arg,Lys,Phe, 0.759; Ala,Arg,Pro,Met,Ile,Phe, 0.759; Gly,Ala,Arg,Met,Ile,Phe, 0.759; Gly,Thr,Arg,Val,Orn,Phe, 0.757; His,Ala,Arg,Pro,Lys,Phe, 0.757; Gln,Ala,Arg,Pro,Phe,Trp, 0.756; Asn,Ala,Arg,Val,Lys,Phe, 0.754; Gly,Gln,Ala,Arg,Pro,Phe, 0.752; Gly,Ala,Arg,Pro,Lys,Phe, 0.752; Gln,Ala,Arg,Lys,Leu,Phe, 0.751; Thr,Ala,Cit,Arg,Ile,Phe, 0.751; Gln,Thr,Arg,Val,Orn,Phe, 0.749; Ala,Arg,Tyr,Ile,Leu,Phe, 0.749; Ala,Arg,Val,Met,Lys,Ile, 0.748; Ser,Ala,Cit,Arg,Ile,Phe, 0.748; Ala,Cit,Arg,Pro,Phe,Trp, 0.748; Gly,Ala,Arg,Lys,Leu,Phe, 0.746; His,Ala,Arg,Val,Orn,Phe, 0.744; Ser,Gln,Ala,Arg,Ile,Phe, 0.744; Gly,Ala,Arg,Orn,Leu,Phe, 0.743; Gly,Ala,Arg,Val,Leu,Phe, 0.743; Asn,Gly,Ala,Arg,Orn,Phe, 0.743; Ala,Arg,Tyr,Met,Ile,Phe, 0.738; Ser,Ala,Arg,Pro,Ile,Phe, 0.737; Thr,Ala,Cit,Arg,Orn,Phe, 0.737; Ser,Ala,Arg,Pro,Orn,Phe, 0.735; Arg,Val,Orn,Lys,Leu,Phe, 0.732; His,Ala,Arg,Tyr,Met,Phe, 0.727; Asn,Ala,Arg,Tyr,Met,Leu, 0.725; Gly,Ala,Arg,Tyr,Met,Trp, 0.725; Ala,Arg,Pro,Tyr,Val,Met, 0.724; Gln,Ala,Arg,Tyr,Met,Orn, 0.722; Gly,Ala,Cit,Ile,Leu,Phe, 0.722; Thr,Ala,Arg,Tyr,Leu,Phe, 0.722; Ala,Cit,Arg,Pro,Tyr,Phe, 0.719; His,Ala,Cit,Arg,Tyr,Trp, 0.717; Ala,Arg,Pro,Tyr,Val,Phe, 0.717; Ser,Gly,Ala,Arg,Tyr,Phe, 0.716; Ala,Cit,Arg,Tyr,Leu,Phe, 0.716; Ala,Cit,Arg,Tyr,Ile,Leu, 0.713; Asn,Ala,Arg,Tyr,Orn,Phe, 0.713; Asn,Ala,Arg,Tyr,Phe,Trp, 0.711; Asn,Gly,Ala,Arg,Tyr,Val, 0.708; Asn,Ala,Arg,Tyr,Ile,Trp, 0.708; Ser,Asn,Ala,Arg,Tyr,Val, 0.706; Ala,Cit,Tyr,Ile,Leu,Phe, 0.705; Arg,Tyr,Orn,Lys,Ile,Phe, 0.702; Ser,Ala,Arg,Pro,Tyr,Ile, 0.697; Ser,Ala,Arg,Tyr,Ile,Trp, 0.695; Gln,Ala,Arg,Tyr,Val,Trp, 0.695; Gln,Ala,Cit,Arg,Pro,Tyr, 0.687; Asn,Gly,Gln,Ala,Leu,Phe, 0.686; Gln,His,Ala,Cit,Val,Phe, 0.686; Ala,Cit,Val,Ile,Phe,Trp, 0.684; Ala,Cit,Val,Met,Ile,Phe, 0.684; Thr,Ala,Cit,Val,Leu,Phe, 0.683; Asn,Gly,Ala,Val,Lys,Phe, 0.683; Asn,Gly,His,Ala,Val,Phe, 0.678; His,Ala,Cit,Pro,Val,Phe, 0.678; Ala,Cit,Val,Lys,Ile,Phe, 0.678; Asn,Gly,Ala,Pro,Val,Phe, 0.676; Ala,Cit,Tyr,Met,Leu,Phe, 0.675; Asn,Gly,Ala,Pro,Leu,Phe, 0.67; Gly,Ala,Pro,Val,Met,Phe, 0.668; Ser,Ala,Cit,Tyr,Leu,Phe, 0.667; Ala,Cit,Tyr,Leu,Phe,Trp, 0.665; Gln,Ala,Cit,Tyr,Val,Phe, 0.663; Gly,Ala,Tyr,Val,Orn,Phe, 0.656
Arg,Met, 0.784; Arg,NP, 0.779; Arg,KynA, 0.77; AnthA,NP, 0.77; hTrp,NP, 0.768; Arg,QA, 0.767; Arg,Kyn, 0.763; QA,NP, 0.76; Kyn,NP, 0.752; His,KynA, 0.74; Arg,AnthA, 0.737; Arg,hTrp, 0.737; Thr,NP, 0.737; Arg,hKyn, 0.737; Thr,Arg, 0.733; hKyn,NP, 0.732; Ser,Arg, 0.729; Arg,Trp, 0.727; Arg,Pro, 0.727; His,Arg, 0.727; Trp,NP, 0.727; Asn,Arg, 0.725; His,QA, 0.725; Gly,Arg, 0.725; His,Kyn, 0.724; Gln,Arg, 0.719; Ser,NP, 0.719; Met,NP, 0.719; KynA,NP, 0.717; Arg,Lys, 0.71; Ala,Arg, 0.71; Ala,Kyn, 0.71; His,AnthA, 0.71; Pro,NP, 0.706; Trp,KynA, 0.705; AnthA,KynA, 0.702; His,hKyn, 0.7; AnthA,QA, 0.698; hKyn,AnthA, 0.697; Gln,NP, 0.695; AnthA,Kyn, 0.694; Thr,KynA, 0.692; Asn,NP, 0.692; Ser,AnthA, 0.689; Pro,hKyn, 0.687; Ala,AnthA, 0.683; Ala,KynA, 0.679; Trp,Kyn, 0.678; Trp,hKyn, 0.678; Ala,NP, 0.678; Thr,hKyn, 0.676; Gly,NP, 0.675; Ala,hKyn, 0.675; Lys,hKyn, 0.67; hKyn,hTrp, 0.665; Lys,NP, 0.665; Thr,AnthA, 0.663; hTrp,QA, 0.663; Trp,AnthA, 0.663; hKyn,KynA, 0.663; Lys,AnthA, 0.662; Ala,QA, 0.662; Pro,Kyn, 0.66; Thr,QA, 0.657; Asn,Kyn, 0.656; Ser,hKyn, 0.654; Pro,AnthA, 0.652; hKyn,QA, 0.652; Met,hKyn, 0.652; Asn,hKyn, 0.651; Gln,QA, 0.649; Ser,Ala, 0.649; Asn,QA, 0.648; Lys,QA, 0.643; hKyn,Kyn, 0.641; Lys,KynA, 0.637; Ala,Met, 0.632; Asn,AnthA, 0.632; KynA,QA, 0.629; Gly,Trp, 0.627; Pro,QA, 0.627; Met,QA, 0.625; Gly,Ala, 0.624; Pro,KynA, 0.622; Gly,hKyn, 0.622; Gly,Lys, 0.621; Ala,hTrp, 0.621; Met,KynA, 0.619; Gln,Ala, 0.619; His,Ala, 0.617; Gly,QA, 0.617; Met,Kyn, 0.614; Thr,Ala, 0.613; Gly,AnthA, 0.613; Ala,Trp, 0.606; Asn,Ala, 0.603; Ala,Pro, 0.603; Lys,hTrp, 0.592; Ala,Lys, 0.592; Gln,hKyn, 0.587
Arg,Met,NP, 0.825; Thr,Arg,QA, 0.797; Arg,QA,NP, 0.792; Arg,Trp,NP, 0.79; Arg,hTrp,NP, 0.789; Arg,Met,Kyn, 0.787; Arg,KynA,QA, 0.784; Arg,Kyn,NP, 0.784; Arg,Lys,NP, 0.783; Ser,Arg,NP, 0.783; Arg,hKyn,NP, 0.783; Gln,Arg,NP, 0.781; His,Arg,NP, 0.781; Asn,Arg,QA, 0.778; Arg,Pro,NP, 0.778; Ser,Arg,QA, 0.773; His,Arg,QA, 0.771; Arg,AnthA,Kyn, 0.771; Trp,AnthA,KynA, 0.771; Arg,hTrp,QA, 0.77; Gln,Arg,QA, 0.767; Arg,KynA,Kyn, 0.767; His,KynA,NP, 0.767; Arg,Lys,QA, 0.765; Arg,hTrp,Kyn, 0.763; Gly,Arg,QA, 0.763; Arg,hKyn,KynA, 0.763; Arg,hKyn,AnthA, 0.763; Ala,Arg,Kyn, 0.76; Ala,Arg,QA, 0.756; AnthA,KynA,NP, 0.756; Ala,Arg,NP, 0.749; Pro,hKyn,AnthA, 0.749; Arg,hKyn,hTrp, 0.746; Ala,KynA,NP, 0.746; Gly,Arg,hKyn, 0.744; Pro,hKyn,NP, 0.741; hKyn,AnthA,NP, 0.74; Thr,Arg,hKyn, 0.737; Ser,Arg,hKyn, 0.733; Arg,Trp,hKyn, 0.732; Ala,Kyn,NP, 0.73; Arg,Pro,hKyn, 0.729; His,hKyn,AnthA, 0.729; Arg,Lys,hKyn, 0.727; Ala,AnthA,QA, 0.724; Ala,AnthA,Kyn, 0.724; Trp,hKyn,AnthA, 0.724; Ala,Arg,hKyn, 0.722; Ala,hKyn,AnthA, 0.722; hKyn,AnthA,KynA, 0.719; Ala,KynA,Kyn, 0.719; Ala,hTrp,Kyn, 0.717; Lys,hKyn,AnthA, 0.716; Trp,hKyn,KynA, 0.713; Gly,Ala,Kyn, 0.71; Thr,hKyn,AnthA, 0.71; Ala,Kyn,QA, 0.708; Ala,hKyn,Kyn, 0.708; Ala,Trp,Kyn, 0.703; Ala,Lys,Kyn, 0.703; Ala,Met,Kyn, 0.703; Ser,Ala,Kyn, 0.702; Met,hKyn,AnthA, 0.698; Gly,Ala,NP, 0.697; Asn,hKyn,AnthA, 0.697; Ala,hKyn,KynA, 0.697; Ala,hTrp,NP, 0.695; Pro,Lys,hKyn, 0.689; Thr,Ala,KynA, 0.687; Gly,Lys,hKyn, 0.687; Ala,KynA,QA, 0.687; Asn,Ala,KynA, 0.686; Gly,Ala,KynA, 0.686; Lys,hKyn,KynA, 0.686; Lys,hKyn,NP, 0.686; Ala,hKyn,hTrp, 0.684; Ala,Lys,KynA, 0.683; Ala,hKyn,QA, 0.683; Gln,Ala,KynA, 0.683; His,Ala,KynA, 0.683; Ala,Met,KynA, 0.678; Ser,Ala,hKyn, 0.678; Lys,hKyn,hTrp, 0.678; Gly,Trp,hKyn, 0.676; Ala,Trp,hKyn, 0.676; Ala,Pro,hKyn, 0.676; Ala,Pro,KynA, 0.675; Ala,Met,hKyn, 0.675; Ser,Ala,KynA, 0.673; Gly,hKyn,AnthA, 0.673; Thr,Lys,hKyn, 0.671; Ala,Lys,hKyn, 0.671; Lys,hKyn,QA, 0.67; His,Ala,hKyn, 0.668; Gln,Ala,hKyn, 0.667; Gly,Ala,QA, 0.665; Gly,Ala,hKyn, 0.665; Gln,Lys,hKyn, 0.656; Gln,hKyn,AnthA, 0.646
Ser,Arg,KynA,NP, 0.827; Arg,Pro,Met,NP, 0.825; Arg,Met,Trp,NP, 0.824; Arg,AnthA,KynA,NP, 0.822; Gly,Arg,Met,NP, 0.816; His,Arg,Met,NP, 0.814; Arg,Lys,KynA,NP, 0.813; Thr,Arg,KynA,NP, 0.81; Arg,AnthA,KynA,QA, 0.806; Arg,Met,AnthA,QA, 0.805; Arg,Met,Lys,NP, 0.803; Arg,hTrp,KynA,QA, 0.795; Arg,AnthA,KynA,Kyn, 0.79; Arg,hKyn,hTrp,NP, 0.781; Gly,Thr,Arg,QA, 0.779; Ala,AnthA,KynA,NP, 0.779; His,hKyn,AnthA,KynA, 0.775; Ala,Arg,AnthA,KynA, 0.775; Arg,Trp,hKyn,QA, 0.771; Arg,hKyn,hTrp,QA, 0.771; Ala,Arg,Kyn,NP, 0.771; Pro,hKyn,AnthA,KynA, 0.771; Thr,Arg,hKyn,AnthA, 0.768; Thr,Ala,Arg,Kyn, 0.767; Asn,Arg,hKyn,QA, 0.765; Arg,Pro,hKyn,NP, 0.765; Ser,Arg,hKyn,AnthA, 0.765; Ala,Arg,KynA,Kyn, 0.763; Ala,Arg,AnthA,NP, 0.763; Ala,Arg,Kyn,QA, 0.762; Ser,Ala,Arg,Kyn, 0.76; Gly,Ala,KynA,NP, 0.76; Arg,Lys,hKyn,NP, 0.759; Ala,hTrp,AnthA,KynA, 0.759; Ala,Arg,Lys,KynA, 0.757; Ala,Arg,Met,Lys, 0.756; Asn,Ala,Arg,KynA, 0.756; Ala,Arg,Lys,Kyn, 0.754; Ala,Arg,hKyn,AnthA, 0.754; Ser,Ala,AnthA,KynA, 0.754; Ala,Trp,AnthA,KynA, 0.754; Arg,Met,Lys,hKyn, 0.752; Ala,Arg,Met,hKyn, 0.752; Pro,hKyn,KynA,NP, 0.751; His,Ala,AnthA,KynA, 0.751; Gly,Ala,AnthA,KynA, 0.751; Ala,Arg,hKyn,KynA, 0.748; Ala,hTrp,KynA,NP, 0.748; Ala,AnthA,KynA,Kyn, 0.748; Ala,hKyn,AnthA,KynA, 0.748; Ala,Trp,KynA,NP, 0.743; Gln,Ala,KynA,NP, 0.741; Ser,Ala,KynA,NP, 0.741; His,Pro,hKyn,AnthA, 0.74; Ala,Met,AnthA,NP, 0.738; Pro,Trp,hKyn,AnthA, 0.738; Ala,Met,AnthA,KynA, 0.737; Thr,Ala,Arg,hKyn, 0.735; Arg,Lys,hKyn,hTrp, 0.733; Ala,Trp,AnthA,Kyn, 0.732; Gly,Ala,KynA,Kyn, 0.732; Thr,Ala,AnthA,Kyn, 0.73; Ala,hKyn,AnthA,QA, 0.73; Ala,hKyn,hTrp,AnthA, 0.73; Trp,hKyn,hTrp,AnthA, 0.729; Thr,Ala,hKyn,AnthA, 0.725; Gln,Ala,AnthA,Kyn, 0.724; Gly,Ala,AnthA,Kyn, 0.724; Trp,hKyn,AnthA,Kyn, 0.724; Lys,hKyn,AnthA,NP, 0.724; Gln,Ala,Arg,hKyn, 0.722; Ala,Lys,KynA,Kyn, 0.722; Ala,Lys,hKyn,AnthA, 0.722; Ala,hTrp,Kyn,QA, 0.721; His,Ala,AnthA,Kyn, 0.721; Ala,Trp,KynA,Kyn, 0.719; Ala,KynA,Kyn,QA, 0.719; His,Lys,hKyn,AnthA, 0.717; Lys,hKyn,AnthA,QA, 0.717; Gly,Ala,hKyn,AnthA, 0.717; Ala,Lys,hTrp,Kyn, 0.716; Asn,Ala,KynA,Kyn, 0.716; Thr,Lys,hKyn,AnthA, 0.716; Ala,Lys,hKyn,Kyn, 0.714; Ala,Met,KynA,Kyn, 0.714; Asn,Gly,Ala,Kyn, 0.708; Gly,Ala,KynA,QA, 0.708; Ala,hKyn,KynA,QA, 0.708; Gly,Ala,Met,Kyn, 0.702; Asn,Ala,hKyn,KynA, 0.702; Ala,Pro,hKyn,KynA, 0.697; Thr,Ala,hKyn,KynA, 0.697; Thr,Ala,KynA,QA, 0.694; Gly,Ala,hTrp,KynA, 0.694; Ala,Met,hKyn,KynA, 0.694; Thr,Ala,Met,hKyn, 0.687; Gln,Ala,hTrp,KynA, 0.687; Ala,Trp,KynA,QA, 0.687; Ala,Met,KynA,QA, 0.687; Gly,Ala,Lys,hKyn, 0.675
Arg,Pro,hKyn,AnthA,KynA, 0.808; Arg,hKyn,AnthA,KynA,NP, 0.805; Asn,Ala,Arg,Met,NP, 0.805; Ala,Arg,Met,Trp,NP, 0.803; Arg,Pro,Met,hKyn,NP, 0.802; Ala,Arg,Met,AnthA,Kyn, 0.797; Ala,Arg,Met,Trp,Kyn, 0.794; Thr,Ala,Arg,KynA,NP, 0.794; Thr,Ala,Arg,AnthA,KynA, 0.792; His,Ala,Arg,Met,Kyn, 0.789; Gln,Ala,Arg,KynA,NP, 0.789; Gly,Ala,AnthA,KynA,NP, 0.781; Gly,Ala,Arg,Met,Kyn, 0.781; Ala,Arg,Met,Trp,KynA, 0.781; Ala,Arg,AnthA,Kyn,NP, 0.781; Ala,Arg,Met,hKyn,NP, 0.779; Gly,Arg,hKyn,AnthA,NP, 0.779; Arg,hKyn,AnthA,Kyn,QA, 0.779; Thr,Ala,Arg,KynA,QA, 0.778; Ala,Arg,Met,Lys,KynA, 0.778; Asn,Arg,hKyn,AnthA,QA, 0.778; Ala,Arg,Met,hTrp,KynA, 0.776; Asn,Ala,Arg,AnthA,KynA, 0.775; Arg,Met,Lys,hKyn,AnthA, 0.775; Asn,Trp,hKyn,AnthA,KynA, 0.775; Ala,Arg,Pro,KynA,NP, 0.775; Ala,Arg,Trp,Kyn,NP, 0.775; Asn,Ala,Arg,KynA,Kyn, 0.773; Ala,Lys,hTrp,AnthA,KynA, 0.768; Arg,Lys,hKyn,AnthA,Kyn, 0.768; His,hKyn,AnthA,KynA,NP, 0.768; Ala,hKyn,AnthA,KynA,NP, 0.767; Ala,Arg,hKyn,AnthA,KynA, 0.767; Ala,hTrp,AnthA,KynA,QA, 0.763; Ala,Arg,hTrp,KynA,Kyn, 0.763; Ala,hKyn,hTrp,AnthA,KynA, 0.762; Ser,Trp,hKyn,AnthA,KynA, 0.762; Ala,Arg,Met,Trp,hKyn, 0.762; Ala,Met,AnthA,KynA,NP, 0.76; Thr,Ala,hTrp,AnthA,KynA, 0.759; Ala,Arg,hKyn,KynA,QA, 0.759; Ala,Arg,Met,hKyn,hTrp, 0.759; Ala,Arg,hKyn,hTrp,AnthA, 0.757; Ala,hTrp,AnthA,KynA,Kyn, 0.756; Asn,Ala,Arg,hKyn,KynA, 0.756; Gln,Ala,KynA,Kyn,NP, 0.756; Arg,Pro,Lys,hKyn,AnthA, 0.756; Thr,Ala,Arg,hKyn,NP, 0.754; Ala,Trp,AnthA,KynA,QA, 0.752; Ala,hKyn,AnthA,KynA,QA, 0.751; Ser,Gln,Ala,AnthA,KynA, 0.751; Gln,Thr,Ala,KynA,NP, 0.751; Gly,Arg,Lys,hKyn,AnthA, 0.749; Ala,hKyn,AnthA,KynA,Kyn, 0.748; Gly,Ala,AnthA,KynA,Kyn, 0.748; Ser,Pro,Lys,hKyn,AnthA, 0.748; Gly,Pro,hKyn,AnthA,NP, 0.748; Gly,Ala,Arg,Kyn,QA, 0.748; Ala,Pro,AnthA,KynA,Kyn, 0.744; His,Ala,Met,KynA,Kyn, 0.743; Gly,Ala,hTrp,Kyn,NP, 0.743; Gly,Ala,Arg,hKyn,QA, 0.743; Asn,Arg,Met,Lys,hKyn, 0.743; His,Ala,hKyn,AnthA,NP, 0.741; Ala,hKyn,hTrp,AnthA,QA, 0.738; Ala,Met,hTrp,KynA,NP, 0.735; Ser,Ala,AnthA,KynA,Kyn, 0.733; Gly,Ala,hTrp,KynA,Kyn, 0.733; Ala,Met,hKyn,KynA,NP, 0.733; Gln,Ala,hTrp,AnthA,Kyn, 0.733; His,Ala,hTrp,AnthA,Kyn, 0.733; Ser,Ala,Lys,hKyn,AnthA, 0.733; Thr,Ala,hTrp,KynA,Kyn, 0.729; Ser,Gln,Ala,hKyn,AnthA, 0.729; Ala,Met,hKyn,hTrp,AnthA, 0.727; Ala,Lys,Trp,hKyn,AnthA, 0.727; Gly,Ala,Pro,KynA,Kyn, 0.725; Gly,Ala,hKyn,AnthA,QA, 0.725; Gln,Ala,hKyn,AnthA,QA, 0.725; Thr,Ala,Lys,hKyn,AnthA, 0.724; His,Thr,Ala,KynA,Kyn, 0.722; Asn,Thr,Ala,KynA,Kyn, 0.721; Thr,Ala,Pro,KynA,Kyn, 0.721; Gln,Ala,Lys,hKyn,AnthA, 0.721; Gln,Ala,Pro,KynA,Kyn, 0.719; Gln,Ala,Met,KynA,NP, 0.719; Ser,Gly,Ala,hKyn,AnthA, 0.716; Ser,Ala,hTrp,KynA,Kyn, 0.713; Ser,Thr,Ala,hKyn,KynA, 0.71; Ala,Met,Lys,hKyn,AnthA, 0.706; Ala,Pro,hKyn,KynA,QA, 0.705; His,Ala,Met,hKyn,KynA, 0.703; Thr,Ala,hKyn,hTrp,KynA, 0.702; Asn,His,Ala,hKyn,KynA, 0.702; His,Ala,Trp,hKyn,KynA, 0.702; Asn,Ala,hTrp,KynA,QA, 0.702; Ser,Ala,hKyn,KynA,QA, 0.7; Ala,Met,hTrp,KynA,QA, 0.7; Ser,Ala,Trp,hKyn,KynA, 0.698; Gly,Ala,Met,hKyn,KynA, 0.697
Ala,Arg,Met,KynA,QA,NP, 0.814; Asn,Ala,Arg,Lys,KynA,NP, 0.808; Ala,Arg,Pro,Met,Lys,NP, 0.802; Ala,Arg,Met,Lys,KynA,QA, 0.798; Ser,His,Ala,Arg,KynA,NP, 0.798; Gly,Ala,hTrp,AnthA,KynA,NP, 0.797; Ala,Arg,Met,hTrp,Kyn,QA, 0.795; Ala,Arg,Met,Lys,Trp,NP, 0.795; His,Ala,Arg,KynA,Kyn,NP, 0.794; Ala,Arg,Met,Trp,AnthA,QA, 0.794; Thr,Ala,Met,AnthA,KynA,NP, 0.792; Ser,Gly,Ala,Arg,Met,Kyn, 0.784; His,Ala,Arg,Met,hKyn,Kyn, 0.784; Ser,Asn,Ala,Arg,AnthA,Kyn, 0.784; Ala,Arg,Met,hKyn,KynA,QA, 0.783; Pro,Lys,hKyn,AnthA,KynA,Kyn, 0.781; Pro,hKyn,AnthA,KynA,Kyn,NP, 0.781; Arg,Trp,hKyn,hTrp,AnthA,KynA, 0.781; Asn,Gly,Ala,Arg,AnthA,Kyn, 0.781; Asn,Gly,Ala,AnthA,KynA,NP, 0.779; Ser,Arg,Trp,hKyn,AnthA,KynA, 0.779; Asn,Ala,Arg,hTrp,AnthA,KynA, 0.778; His,Ala,Arg,hKyn,AnthA,Kyn, 0.778; Asn,Arg,Trp,hKyn,AnthA,KynA, 0.778; Gly,Ala,Arg,Met,hTrp,KynA, 0.778; Ala,Lys,hKyn,AnthA,KynA,NP, 0.776; Gln,Ala,Lys,AnthA,KynA,NP, 0.776; Ala,Pro,hTrp,AnthA,KynA,QA, 0.776; Asn,Ala,Trp,AnthA,KynA,Kyn, 0.775; Asn,Ala,Trp,hKyn,AnthA,KynA, 0.775; Ala,Arg,Pro,hTrp,AnthA,KynA, 0.775; Ser,Asn,Ala,Arg,AnthA,KynA, 0.775; Thr,Arg,Lys,hKyn,AnthA,KynA, 0.775; Thr,Ala,Arg,Pro,Met,KynA, 0.775; Ala,Arg,Met,Lys,hKyn,NP, 0.771; His,Ala,Pro,AnthA,KynA,QA, 0.771; His,Ala,Arg,Lys,KynA,Kyn, 0.771; Pro,hTrp,AnthA,KynA,QA,NP, 0.771; Gln,Pro,hKyn,AnthA,KynA,QA, 0.77; Asn,Gly,Ala,Trp,AnthA,KynA, 0.765; Asn,Ala,Arg,hKyn,hTrp,AnthA, 0.765; Ala,Arg,Lys,hKyn,AnthA,Kyn, 0.765; Gln,Ala,Arg,hKyn,KynA,Kyn, 0.763; Ser,Asn,Ala,AnthA,KynA,QA, 0.763; Asn,Gly,Ala,hTrp,AnthA,KynA, 0.763; Gly,Arg,Pro,Met,Lys,hKyn, 0.763; Gln,Ala,hTrp,KynA,Kyn,NP, 0.762; Gly,Ala,Lys,AnthA,KynA,QA, 0.762; Gly,Gln,Trp,hKyn,AnthA,KynA, 0.762; Gly,Ala,Arg,hKyn,AnthA,NP, 0.762; Ala,Lys,hKyn,hTrp,AnthA,KynA, 0.76; Ala,Arg,Trp,hKyn,AnthA,NP, 0.76; Ala,hTrp,AnthA,KynA,Kyn,QA, 0.759; Asn,Ala,hKyn,hTrp,AnthA,KynA, 0.759; Pro,Met,Lys,hKyn,hTrp,AnthA, 0.759; Asn,Gly,Thr,Ala,KynA,NP, 0.759; Thr,Ala,Arg,Pro,hKyn,AnthA, 0.759; Ser,Thr,Trp,hKyn,AnthA,KynA, 0.757; Gly,Ala,hTrp,AnthA,KynA,Kyn, 0.756; Asn,Ala,hTrp,AnthA,KynA,Kyn, 0.754; Gly,Thr,Ala,Arg,hKyn,AnthA, 0.754; Ala,Met,Lys,AnthA,KynA,QA, 0.752; Ser,Ala,hKyn,hTrp,AnthA,KynA, 0.749; Asn,Ala,AnthA,KynA,Kyn,QA, 0.749; Gly,Ala,Trp,hKyn,AnthA,KynA, 0.749; Thr,Ala,hTrp,AnthA,KynA,Kyn, 0.748; Thr,Ala,hKyn,AnthA,KynA,Kyn, 0.748; Ala,Pro,AnthA,KynA,Kyn,QA, 0.748; Ala,Pro,Lys,AnthA,KynA,Kyn, 0.746; Gly,Thr,Ala,AnthA,KynA,Kyn, 0.746; Ser,Gln,Ala,hTrp,KynA,NP, 0.746; Asn,Gln,Ala,hTrp,KynA,NP, 0.746; Ala,Trp,hKyn,KynA,Kyn,NP, 0.744; Ser,Gly,Ala,hTrp,KynA,NP, 0.743; Asn,Gln,Ala,KynA,Kyn,NP, 0.743; Ser,Ala,hTrp,AnthA,KynA,Kyn, 0.741; Asn,Ala,hKyn,AnthA,KynA,Kyn, 0.741; Gly,Gln,Ala,hKyn,AnthA,KynA, 0.741; His,Ala,Met,hTrp,KynA,Kyn, 0.741; Gln,His,Ala,Met,KynA,Kyn, 0.741; Gln,His,Ala,AnthA,KynA,Kyn, 0.74; His,Ala,hKyn,hTrp,KynA,Kyn, 0.74; Gln,Ala,Pro,hTrp,KynA,Kyn, 0.74; Ala,Met,hTrp,AnthA,KynA,Kyn, 0.738; Ser,Thr,Ala,AnthA,KynA,Kyn, 0.737; Gly,Ala,hKyn,hTrp,AnthA,Kyn, 0.737; Gly,Ala,Met,KynA,QA,NP, 0.737; Ser,Gly,Ala,Trp,KynA,NP, 0.735; Gly,His,Ala,hTrp,KynA,Kyn, 0.733; Asn,Ala,Lys,hTrp,KynA,Kyn, 0.729; Asn,Thr,Ala,hKyn,KynA,Kyn, 0.727; Thr,Ala,Met,hKyn,AnthA,Kyn, 0.727; Asn,Ala,Trp,hTrp,KynA,Kyn, 0.725; Asn,Gln,Ala,hTrp,KynA,Kyn, 0.724; Ala,Met,hKyn,hTrp,KynA,Kyn, 0.724; Asn,Thr,Ala,KynA,Kyn,QA, 0.724; Gly,Thr,Ala,Met,KynA,Kyn, 0.719; Asn,Gly,Ala,hKyn,AnthA,QA, 0.716; His,Ala,Met,hKyn,hTrp,KynA, 0.711; Gly,Gln,Ala,hKyn,hTrp,KynA, 0.705
Arg,Met, 0.691; Ala,Phe, 0.686; Gly,Arg, 0.681; Ala,Orn, 0.676; Ser,Arg, 0.672; Thr,Arg, 0.671; Gln,Arg, 0.666; Ala,Arg, 0.666; Ala,Met, 0.664; Asn,Ala, 0.66; Arg,Orn, 0.652; Ala,Lys, 0.652; Arg,Ile, 0.65; His,Arg, 0.65; Ala,Cit, 0.65; Gly,Orn, 0.649; Ala,Ile, 0.647; His,Ala, 0.647; Arg,Val, 0.645; Arg,Pro, 0.642; Arg,Tyr, 0.642; Ala,Val, 0.642; Thr,Ala, 0.642; Ala,Pro, 0.64; Arg,Phe, 0.64; Arg,Lys, 0.639; Tyr,Orn, 0.639; Ala,Leu, 0.639; Ala,Tyr, 0.639; Gln,Ala, 0.637; Met,Orn, 0.635; Pro,Orn, 0.633; Cit,Arg, 0.633; Ala,Trp, 0.633; Ser,Ala, 0.633; Ser,Orn, 0.632; Cit,Orn, 0.63; Gln,Orn, 0.628; Asn,Orn, 0.627; Orn,Phe, 0.627; Lys,Phe, 0.625; Orn,Lys, 0.623; Gly,Ala, 0.623; Val,Phe, 0.62; Pro,Phe, 0.62; Orn,Trp, 0.618; Val,Orn, 0.615; Met,Trp, 0.615; Phe,Trp, 0.615; Orn,Leu, 0.611; His,Orn, 0.611; Thr,Orn, 0.611; Cit,Phe, 0.61; Orn,Ile, 0.606; Thr,Phe, 0.606; Cit,Pro, 0.606; Gly,Cit, 0.605; Tyr,Trp, 0.6; Tyr,Phe, 0.596; Thr,Lys, 0.595; Asn,Cit, 0.591; Gly,Trp, 0.588; Cit,Tyr, 0.586; Thr,Cit, 0.586; Cit,Trp, 0.586; Gly,Lys, 0.584; Met,Lys, 0.584; Pro,Trp, 0.584; Ser,Lys, 0.581; Ile,Trp, 0.581; Thr,Pro, 0.579; Leu,Phe, 0.579; Asn,Lys, 0.574; Val,Lys, 0.574; Val,Trp, 0.574; Gln,Trp, 0.573; Cit,Ile, 0.571; Gln,Lys, 0.571; His,Trp, 0.571; Lys,Trp, 0.571; Leu,Trp, 0.571; Tyr,Lys, 0.569; His,Lys, 0.569; Lys,Leu, 0.569; Lys,Ile, 0.569; Thr,Trp, 0.566; Gly,Thr, 0.564
Ala,Orn,Phe, 0.743; Ala,Arg,Met, 0.738; Ser,Arg,Met, 0.715; Gly,Arg,Pro, 0.709; Gly,Arg,Leu, 0.708; Gly,Arg,Ile, 0.708; Asn,Ala,Cit, 0.708; Arg,Val,Met, 0.708; Ala,Cit,Met, 0.708; Ala,Arg,Phe, 0.704; Arg,Pro,Met, 0.703; Asn,Ala,Orn, 0.701; Gly,Thr,Arg, 0.699; Ala,Leu,Phe, 0.696; Pro,Orn,Phe, 0.694; Arg,Met,Orn, 0.693; Ala,Met,Phe, 0.693; Ala,Val,Orn, 0.693; Arg,Tyr,Met, 0.691; Asn,Ala,Arg, 0.689; Gly,His,Arg, 0.688; Gln,Arg,Phe, 0.688; Ser,Ala,Phe, 0.688; Thr,Arg,Trp, 0.686; Gly,Arg,Orn, 0.686; Ala,Lys,Phe, 0.686; Ala,Orn,Ile, 0.686; Thr,Ala,Orn, 0.686; Gly,Gln,Arg, 0.684; Ala,Val,Phe, 0.684; His,Ala,Arg, 0.682; Ala,Phe,Trp, 0.682; Gln,Arg,Pro, 0.681; Ser,Arg,Ile, 0.681; Ala,Arg,Val, 0.681; Thr,Ala,Phe, 0.681; Ala,Tyr,Phe, 0.679; Ser,Ala,Arg, 0.679; Ser,Arg,Pro, 0.677; Ala,Cit,Orn, 0.677; Ala,Ile,Phe, 0.677; Ala,Cit,Lys, 0.674; Ala,Pro,Orn, 0.674; Ala,Pro,Phe, 0.674; Gln,Ala,Phe, 0.674; Ser,Asn,Arg, 0.672; His,Ala,Orn, 0.672; Asn,Ala,Met, 0.671; Ala,Arg,Leu, 0.669; Ser,Cit,Arg, 0.667; Ala,Cit,Arg, 0.667; Val,Orn,Phe, 0.666; Gly,Ala,Arg, 0.666; Ala,Arg,Pro, 0.664; Gln,Ala,Cit, 0.664; Gly,Phe,Trp, 0.662; Ala,Arg,Trp, 0.662; Ala,Tyr,Met, 0.662; Gln,Ala,Met, 0.662; Asn,Gln,Arg, 0.66; Ala,Cit,Ile, 0.66; Ala,Tyr,Trp, 0.659; His,Ala,Cit, 0.659; Asn,Arg,Phe, 0.657; Ser,Ala,Met, 0.657; Arg,Val,Phe, 0.657; Ser,Asn,Ala, 0.655; Tyr,Orn,Phe, 0.654; Asn,Arg,Trp, 0.654; His,Thr,Ala, 0.654; Ala,Cit,Val, 0.654; Asn,Ala,Leu, 0.654; Ala,Cit,Leu, 0.652; Asn,Ala,Trp, 0.65; Pro,Val,Phe, 0.649; Arg,Pro,Tyr, 0.649; Arg,Lys,Phe, 0.649; Arg,Ile,Phe, 0.647; Asn,Gln,Ala, 0.647; Ala,Leu,Trp, 0.642; Ala,Lys,Trp, 0.642; His,Ala,Leu, 0.64; His,Ala,Tyr, 0.64; Gln,Ala,Ile, 0.639; Ser,Ala,Val, 0.639; Cit,Arg,Phe, 0.639; Ser,Ala,Lys, 0.637; Gly,Ala,Leu, 0.633; His,Phe,Trp, 0.632; Val,Phe,Trp, 0.632; Gln,Ala,Lys, 0.632; Ser,His,Ala, 0.63; Ser,Ala,Trp, 0.627; Gln,Ala,Pro, 0.627; Asn,Gly,Ala, 0.627; Gly,Ala,Val, 0.625; His,Ala,Trp, 0.623; Ala,Tyr,Leu, 0.623
Ser,Ala,Orn,Phe, 0.794; Gln,Ala,Orn,Phe, 0.789; Ala,Arg,Met,Leu, 0.765; Gly,Arg,Pro,Met, 0.76; Thr,Ala,Orn,Phe, 0.758; Ala,Orn,Lys,Phe, 0.755; Ala,Pro,Orn,Phe, 0.753; His,Ala,Arg,Met, 0.748; Ala,Arg,Pro,Met, 0.748; Ala,Orn,Ile,Phe, 0.747; Ala,Arg,Met,Ile, 0.745; Ala,Arg,Orn,Phe, 0.743; Ala,Ile,Leu,Phe, 0.738; Thr,Ala,Arg,Met, 0.736; Ala,Arg,Met,Phe, 0.735; Gly,Ala,Arg,Phe, 0.735; Ala,Met,Orn,Leu, 0.733; Ala,Pro,Met,Orn, 0.733; Asn,Ala,Arg,Met, 0.731; Thr,Ala,Met,Orn, 0.73; Ala,Met,Orn,Trp, 0.728; Arg,Met,Leu,Phe, 0.726; Asn,Ala,Arg,Phe, 0.726; Arg,Pro,Met,Leu, 0.726; Ala,Arg,Tyr,Orn, 0.723; Asn,Ala,Cit,Phe, 0.723; Pro,Val,Orn,Phe, 0.718; Thr,Ala,Cit,Met, 0.718; His,Arg,Met,Trp, 0.718; Ser,Arg,Met,Phe, 0.716; Arg,Pro,Val,Met, 0.716; Gln,Ala,Arg,Tyr, 0.715; Gln,Arg,Met,Trp, 0.715; His,Ala,Met,Orn, 0.713; Ala,Tyr,Orn,Ile, 0.711; Arg,Met,Orn,Trp, 0.711; Ala,Cit,Val,Met, 0.711; Asn,Gly,Ala,Arg, 0.711; Asn,Gly,Ala,Orn, 0.711; Ala,Cit,Met,Ile, 0.711; Gly,Arg,Orn,Phe, 0.711; Thr,Arg,Met,Trp, 0.709; Ala,Cit,Met,Leu, 0.709; Ala,Arg,Leu,Phe, 0.708; Gly,Ala,Arg,Lys, 0.708; Ser,Ala,Met,Orn, 0.708; Ala,Arg,Phe,Trp, 0.704; Cit,Arg,Pro,Met, 0.704; Asn,Ala,Val,Phe, 0.704; Ala,Cit,Tyr,Met, 0.703; Ala,Cit,Pro,Met, 0.703; Gln,Ala,Orn,Ile, 0.703; Ala,Val,Lys,Phe, 0.701; Arg,Pro,Tyr,Met, 0.701; Asn,Ala,Orn,Trp, 0.701; His,Ala,Tyr,Orn, 0.701; Gly,Ala,Cit,Met, 0.701; Gln,Ala,Orn,Lys, 0.701; Thr,Arg,Val,Phe, 0.699; Ser,Cit,Arg,Phe, 0.699; Ala,Val,Met,Phe, 0.699; Ala,Tyr,Orn,Lys, 0.699; Asn,Ala,Cit,Orn, 0.699; Asn,Ala,Orn,Leu, 0.699; Gln,Arg,Pro,Met, 0.699; Gln,His,Ala,Orn, 0.699; Asn,Ala,Orn,Ile, 0.698; Gly,Cit,Arg,Phe, 0.698; Gln,Ala,Pro,Orn, 0.696; Ser,Ala,Cit,Phe, 0.696; Ser,His,Ala,Orn, 0.694; Ala,Leu,Phe,Trp, 0.693; Gly,Thr,Arg,Phe, 0.693; Gly,Arg,Ile,Phe, 0.693; Gly,Arg,Leu,Phe, 0.693; Ser,Gln,Arg,Phe, 0.691; Gly,Ala,Leu,Phe, 0.691; Ala,Cit,Lys,Phe, 0.689; Ala,Cit,Tyr,Phe, 0.688; Gln,Arg,Orn,Phe, 0.688; Ser,Ala,Arg,Orn, 0.688; Ser,Ala,Val,Orn, 0.686; Gly,Ala,Tyr,Orn, 0.686; His,Ala,Val,Orn, 0.682; Gly,Thr,Ala,Orn, 0.681; Ala,Cit,Ile,Phe, 0.679; Gly,Ala,Orn,Leu, 0.679; Ser,Ala,Orn,Ile, 0.677; Ser,Ala,Phe,Trp, 0.677; Ala,Met,Leu,Trp, 0.676; Ser,Arg,Pro,Phe, 0.676; Ser,Ala,Tyr,Orn, 0.672; Gln,Ala,Leu,Phe, 0.671; Ala,Met,Lys,Trp, 0.669; Ser,Ala,Orn,Trp, 0.669; Gln,Ala,Met,Trp, 0.667; His,Ala,Met,Trp, 0.667; Arg,Orn,Phe,Trp, 0.662; Ser,Ala,Pro,Orn, 0.657; Thr,Ala,Met,Trp, 0.655
Ala,Met,Orn,Leu,Phe, 0.813; Gly,Ala,Orn,Phe,Trp, 0.802; Gly,Thr,Ala,Orn,Phe, 0.802; Gly,Ala,Orn,Ile,Phe, 0.799; Gly,His,Ala,Orn,Phe, 0.799; Gly,Ala,Cit,Orn,Phe, 0.797; Gly,Ala,Orn,Leu,Phe, 0.797; Gln,Ala,Pro,Orn,Phe, 0.796; Gly,Gln,Ala,Orn,Phe, 0.796; Ser,Ala,Orn,Lys,Phe, 0.794; Gly,Ala,Orn,Lys,Phe, 0.794; Gly,Ala,Arg,Orn,Phe, 0.791; Asn,Ala,Orn,Phe,Trp, 0.784; Ala,Orn,Ile,Leu,Phe, 0.784; His,Ala,Pro,Orn,Phe, 0.78; Gln,Ala,Arg,Orn,Phe, 0.78; His,Ala,Cit,Orn,Phe, 0.779; Ser,Ala,Arg,Orn,Phe, 0.779; His,Ala,Orn,Lys,Phe, 0.774; Asn,Ala,Arg,Met,Leu, 0.77; Asn,Ala,Orn,Lys,Phe, 0.77; His,Ala,Arg,Met,Leu, 0.767; Ala,Cit,Orn,Leu,Phe, 0.764; Ala,Arg,Orn,Leu,Phe, 0.758; Gly,Cit,Arg,Pro,Met, 0.753; Thr,Ala,Arg,Met,Orn, 0.752; Asn,Ala,Cit,Leu,Phe, 0.75; Ala,Pro,Orn,Ile,Phe, 0.747; Ala,Arg,Met,Ile,Phe, 0.747; Gly,His,Ala,Arg,Phe, 0.745; Thr,Ala,Met,Orn,Leu, 0.743; Ala,Arg,Val,Met,Phe, 0.743; Gly,Ala,Arg,Ile,Phe, 0.742; Ala,Met,Ile,Leu,Phe, 0.74; Asn,Ala,Arg,Met,Lys, 0.738; Ala,Cit,Val,Met,Phe, 0.738; Asn,Ala,Arg,Met,Trp, 0.738; Gln,Ala,Arg,Met,Trp, 0.738; Ser,Asn,Ala,Arg,Met, 0.738; Gln,Ala,Ile,Leu,Phe, 0.736; Ala,Met,Orn,Lys,Leu, 0.736; Ala,Pro,Met,Leu,Phe, 0.735; His,Thr,Ala,Met,Orn, 0.733; Gln,Ala,Arg,Met,Phe, 0.733; Ser,Pro,Orn,Lys,Phe, 0.73; Asn,Ala,Met,Orn,Leu, 0.73; Gln,Arg,Met,Leu,Phe, 0.726; Asn,Ala,Arg,Tyr,Phe, 0.726; Asn,Arg,Pro,Met,Leu, 0.726; Gly,Ala,Cit,Met,Phe, 0.726; Gly,Arg,Tyr,Met,Trp, 0.725; Ser,Arg,Pro,Val,Met, 0.723; Gly,Gln,Arg,Met,Phe, 0.72; Ser,Arg,Orn,Lys,Phe, 0.72; Ala,Cit,Lys,Leu,Phe, 0.718; Asn,Ala,Cit,Met,Phe, 0.718; Ala,Cit,Met,Orn,Lys, 0.718; Asn,Gly,Ala,Phe,Trp, 0.718; Ser,Gln,Arg,Orn,Phe, 0.716; Asn,Ala,Met,Orn,Lys, 0.716; Thr,Ala,Arg,Pro,Phe, 0.715; His,Arg,Pro,Val,Met, 0.715; Ala,Cit,Val,Met,Orn, 0.715; Thr,Ala,Cit,Arg,Phe, 0.713; Asn,Gly,Ala,Orn,Ile, 0.713; Gly,Cit,Arg,Pro,Phe, 0.713; Asn,Gln,Ala,Orn,Trp, 0.713; Ser,His,Ala,Arg,Phe, 0.713; Arg,Pro,Tyr,Val,Met, 0.711; Arg,Pro,Tyr,Met,Phe, 0.711; Ser,His,Ala,Arg,Tyr, 0.711; Gly,Gln,Ala,Met,Orn, 0.711; Gly,Thr,Arg,Orn,Phe, 0.709; Gly,Ala,Cit,Met,Leu, 0.709; Asn,Ala,Tyr,Orn,Lys, 0.708; Gly,Gln,Ala,Tyr,Orn, 0.708; Gly,Ala,Cit,Met,Orn, 0.708; Ser,Thr,Arg,Phe,Trp, 0.706; Asn,Ala,Arg,Orn,Lys, 0.706; Ser,Asn,Ala,Leu,Phe, 0.706; Asn,Ala,Tyr,Phe,Trp, 0.706; Asn,Pro,Orn,Phe,Trp, 0.704; Ala,Cit,Tyr,Leu,Phe, 0.704; His,Ala,Val,Met,Phe, 0.704; Ser,Ala,Met,Orn,Lys, 0.704; Ser,Asn,Arg,Phe,Trp, 0.703; Ser,Thr,Arg,Val,Phe, 0.703; Gly,Ala,Leu,Phe,Trp, 0.703; Ala,Cit,Met,Phe,Trp, 0.703; Arg,Val,Met,Phe,Trp, 0.701; Ser,Asn,Thr,Ala,Orn, 0.701; Gly,Ala,Val,Met,Orn, 0.701; Ser,Asn,Ala,Orn,Lys, 0.699; Arg,Pro,Val,Met,Orn, 0.699; Asn,Ala,Tyr,Orn,Leu, 0.699; Gly,Ala,Lys,Phe,Trp, 0.699; Ser,Cit,Arg,Leu,Phe, 0.698; Ser,Arg,Tyr,Val,Phe, 0.698; Gly,Arg,Leu,Phe,Trp, 0.696; Ser,His,Ala,Tyr,Orn, 0.689
Ala,Val,Met,Orn,Leu,Phe, 0.834; Gly,Ala,Met,Orn,Leu,Phe, 0.818; Ala,Arg,Met,Orn,Leu,Phe, 0.816; Ser,Ala,Met,Orn,Leu,Phe, 0.816; Ala,Pro,Met,Orn,Leu,Phe, 0.816; Ala,Met,Orn,Leu,Phe,Trp, 0.816; Ala,Met,Orn,Lys,Leu,Phe, 0.814; Thr,Ala,Met,Orn,Leu,Phe, 0.813; Ser,Gln,Ala,Tyr,Orn,Phe, 0.807; Gly,Ala,Val,Orn,Leu,Phe, 0.806; Ala,Met,Orn,Ile,Leu,Phe, 0.804; Gly,Gln,Ala,Pro,Orn,Phe, 0.804; Gly,His,Ala,Orn,Phe,Trp, 0.801; Gly,His,Ala,Tyr,Orn,Phe, 0.801; Ser,Gly,Ala,Met,Orn,Phe, 0.801; Gly,Gln,Ala,Orn,Lys,Phe, 0.801; Gly,Ala,Val,Met,Orn,Phe, 0.801; Ser,Ala,Cit,Val,Orn,Phe, 0.801; Ser,Ala,Cit,Orn,Ile,Phe, 0.801; Gly,Ala,Val,Orn,Phe,Trp, 0.799; Gly,His,Ala,Met,Orn,Phe, 0.797; Thr,Ala,Val,Orn,Leu,Phe, 0.797; Gln,Ala,Val,Orn,Leu,Phe, 0.797; Gly,His,Ala,Val,Orn,Phe, 0.796; Gln,Ala,Val,Met,Orn,Phe, 0.796; His,Ala,Pro,Met,Orn,Phe, 0.796; Ser,Ala,Arg,Met,Orn,Phe, 0.794; Ala,Arg,Val,Met,Leu,Phe, 0.791; Ala,Cit,Val,Met,Orn,Leu, 0.791; Ser,Thr,Ala,Orn,Phe,Trp, 0.791; His,Ala,Pro,Val,Orn,Phe, 0.789; Asn,Ala,Arg,Pro,Orn,Phe, 0.789; Gln,Ala,Arg,Met,Leu,Phe, 0.787; His,Ala,Val,Orn,Leu,Phe, 0.785; Ala,Arg,Orn,Ile,Leu,Phe, 0.785; His,Ala,Val,Orn,Ile,Phe, 0.784; Asn,Ala,Tyr,Val,Orn,Phe, 0.782; Asn,Ala,Orn,Lys,Phe,Trp, 0.782; Ala,Tyr,Val,Orn,Leu,Phe, 0.782; Gly,Ala,Arg,Val,Met,Leu, 0.779; Gln,Ala,Arg,Orn,Lys,Phe, 0.779; Gly,Ala,Arg,Pro,Met,Orn, 0.779; His,Ala,Cit,Met,Orn,Phe, 0.779; Gly,Ala,Arg,Pro,Met,Phe, 0.779; Thr,Ala,Tyr,Met,Orn,Phe, 0.777; Asn,Ala,Val,Orn,Phe,Trp, 0.775; Ala,Val,Met,Orn,Ile,Leu, 0.774; His,Ala,Arg,Ile,Leu,Phe, 0.772; Ala,Pro,Val,Orn,Leu,Phe, 0.772; Ala,Pro,Orn,Lys,Leu,Phe, 0.772; His,Ala,Val,Met,Orn,Leu, 0.77; Ala,Cit,Orn,Lys,Leu,Phe, 0.77; His,Ala,Orn,Ile,Phe,Trp, 0.77; Gly,Ala,Arg,Met,Lys,Phe, 0.77; Asn,Ala,Cit,Orn,Lys,Phe, 0.77; Ala,Cit,Val,Met,Leu,Phe, 0.77; Ala,Pro,Val,Orn,Lys,Phe, 0.77; Gly,Ala,Arg,Val,Met,Lys, 0.77; Gly,Thr,Ala,Arg,Met,Phe, 0.767; Gly,Ala,Arg,Val,Met,Phe, 0.765; Ala,Arg,Met,Lys,Leu,Trp, 0.764; Ser,Gly,Ala,Arg,Met,Phe, 0.762; Gln,Ala,Arg,Met,Ile,Trp, 0.762; Ser,Ala,Arg,Val,Met,Orn, 0.76; His,Ala,Arg,Tyr,Met,Ile, 0.758; Gly,Ala,Cit,Arg,Pro,Met, 0.758; Gln,Ala,Arg,Tyr,Met,Orn, 0.757; Ser,Thr,Ala,Arg,Met,Orn, 0.755; Asn,Gly,Ala,Arg,Met,Trp, 0.755; His,Ala,Arg,Pro,Met,Phe, 0.755; Gly,Ala,Arg,Met,Ile,Trp, 0.753; Ala,Arg,Tyr,Orn,Lys,Phe, 0.753; Gly,Ala,Cit,Arg,Val,Met, 0.753; Ser,Ala,Cit,Arg,Met,Leu, 0.752; Gln,Ala,Val,Met,Orn,Ile, 0.75; Asn,Ala,Arg,Tyr,Met,Ile, 0.75; Gly,His,Ala,Arg,Val,Met, 0.75; His,Ala,Met,Ile,Leu,Phe, 0.75; Thr,Ala,Cit,Arg,Met,Ile, 0.748; Gly,Gln,His,Ala,Arg,Phe, 0.747; Ser,Thr,Ala,Pro,Met,Orn, 0.747; Ala,Arg,Pro,Val,Orn,Phe, 0.745; Gln,Thr,Ala,Met,Orn,Leu, 0.745; Gly,Ala,Cit,Arg,Val,Phe, 0.745; Ala,Met,Orn,Lys,Leu,Trp, 0.745; Gly,Ala,Cit,Arg,Lys,Phe, 0.743; Gly,His,Ala,Arg,Phe,Trp, 0.742; His,Ala,Cit,Met,Orn,Leu, 0.74; Gln,Ala,Pro,Met,Orn,Leu, 0.738; Gln,His,Ala,Met,Orn,Leu, 0.736; Ser,Thr,Ala,Val,Met,Orn, 0.735; Thr,Ala,Met,Orn,Lys,Ile, 0.733; Ser,His,Ala,Cit,Leu,Phe, 0.733; Ala,Cit,Pro,Met,Orn,Leu, 0.731; Gln,Ala,Cit,Met,Orn,Trp, 0.731; His,Ala,Cit,Met,Orn,Ile, 0.73; His,Ala,Met,Orn,Ile,Leu, 0.73; His,Ala,Met,Orn,Lys,Ile, 0.726; Ser,Ala,Cit,Met,Orn,Trp, 0.72; Ser,His,Ala,Arg,Leu,Phe, 0.709
hTrp,NP, 0.742; AnthA,NP, 0.726; Kyn,NP, 0.725; Pro,NP, 0.725; Ala,hTrp, 0.725; Ala,AnthA, 0.723; QA,NP, 0.72; Ala,Kyn, 0.72; Thr,NP, 0.715; Orn,NP, 0.713; Arg,NP, 0.706; hKyn,NP, 0.704; Lys,NP, 0.703; Arg,hTrp, 0.703; hTrp,AnthA, 0.701; Cit,NP, 0.699; hKyn,AnthA, 0.699; AnthA,Kyn, 0.698; Orn,hTrp, 0.693; Orn,hKyn, 0.693; Ala,NP, 0.691; Trp,NP, 0.689; Arg,hKyn, 0.689; AnthA,QA, 0.686; Arg,QA, 0.684; Pro,hKyn, 0.682; Arg,AnthA, 0.682; Pro,Kyn, 0.681; hTrp,QA, 0.677; Pro,hTrp, 0.677; Arg,Kyn, 0.677; Ala,hKyn, 0.676; Ala,Orn, 0.676; Pro,AnthA, 0.674; Lys,Kyn, 0.672; hKyn,hTrp, 0.671; Thr,Arg, 0.671; Orn,QA, 0.666; Ala,Arg, 0.666; Cit,QA, 0.666; hTrp,Kyn, 0.664; Lys,AnthA, 0.662; Ala,QA, 0.662; Trp,hKyn, 0.66; Cit,hKyn, 0.654; Lys,hKyn, 0.652; Cit,hTrp, 0.652; Arg,Orn, 0.652; Cit,AnthA, 0.652; Trp,Kyn, 0.652; Ala,Lys, 0.652; Trp,AnthA, 0.652; Orn,Kyn, 0.65; Lys,hTrp, 0.65; Ala,Cit, 0.65; Trp,hTrp, 0.649; Orn,AnthA, 0.649; Thr,hTrp, 0.645; Arg,Trp, 0.642; Arg,Pro, 0.642; Thr,Ala, 0.642; Ala,Pro, 0.64; Arg,Lys, 0.639; Thr,hKyn, 0.637; Thr,AnthA, 0.637; Lys,QA, 0.635; hKyn,QA, 0.633; Pro,Orn, 0.633; Cit,Arg, 0.633; Ala,Trp, 0.633; Pro,QA, 0.632; Cit,Orn, 0.63; hKyn,Kyn, 0.63; Thr,Kyn, 0.628; Orn,Lys, 0.623; Cit,Kyn, 0.622; Orn,Trp, 0.618; Kyn,QA, 0.617; Trp,QA, 0.615; Thr,Orn, 0.611; Cit,Pro, 0.606; Thr,QA, 0.605; Thr,Lys, 0.595; Cit,Lys, 0.588; Thr,Cit, 0.586; Cit,Trp, 0.586; Pro,Trp, 0.584; Thr,Pro, 0.579; Lys,Trp, 0.571; Thr,Trp, 0.566
Ala,AnthA,Kyn, 0.772; hTrp,AnthA,NP, 0.764; Ala,hKyn,AnthA, 0.76; Pro,hTrp,NP, 0.755; Ala,hTrp,AnthA, 0.753; Ala,hTrp,Kyn, 0.753; hTrp,Kyn,NP, 0.75; Pro,hTrp,AnthA, 0.75; Ala,hTrp,NP, 0.75; Ala,AnthA,NP, 0.748; Arg,hTrp,NP, 0.747; hTrp,QA,NP, 0.745; Pro,AnthA,NP, 0.745; Pro,hTrp,Kyn, 0.743; Pro,hKyn,hTrp, 0.742; Ala,Orn,Kyn, 0.742; Ala,AnthA,QA, 0.74; Pro,hKyn,AnthA, 0.74; Thr,hTrp,NP, 0.738; Thr,Ala,AnthA, 0.738; hTrp,AnthA,Kyn, 0.736; Cit,hTrp,QA, 0.735; Pro,Kyn,NP, 0.735; Ala,Lys,AnthA, 0.735; Pro,AnthA,Kyn, 0.735; Orn,hKyn,hTrp, 0.733; hKyn,hTrp,NP, 0.733; Ala,Kyn,NP, 0.731; Lys,AnthA,NP, 0.73; hKyn,hTrp,AnthA, 0.73; Ala,Cit,hTrp, 0.73; hTrp,AnthA,QA, 0.728; Ala,hTrp,QA, 0.728; Ala,Arg,hTrp, 0.728; Trp,AnthA,NP, 0.728; Arg,AnthA,NP, 0.728; Ala,Cit,Kyn, 0.728; Pro,hTrp,QA, 0.726; Cit,AnthA,NP, 0.726; Ala,Trp,AnthA, 0.726; AnthA,Kyn,NP, 0.726; Pro,Orn,hKyn, 0.725; Arg,AnthA,Kyn, 0.725; AnthA,QA,NP, 0.725; Ala,Arg,Kyn, 0.725; Pro,QA,NP, 0.723; Ala,Arg,AnthA, 0.723; Ala,Orn,NP, 0.723; Ala,Trp,Kyn, 0.723; hKyn,AnthA,NP, 0.723; Ala,Pro,Kyn, 0.723; Cit,hTrp,AnthA, 0.721; Pro,hKyn,NP, 0.721; Pro,hKyn,Kyn, 0.721; Trp,hTrp,AnthA, 0.72; Ala,Pro,AnthA, 0.72; Orn,hTrp,AnthA, 0.718; Arg,Kyn,NP, 0.718; Ala,Cit,AnthA, 0.718; Ala,Orn,hKyn, 0.718; Ala,Orn,QA, 0.718; Ala,Lys,Kyn, 0.718; Trp,AnthA,Kyn, 0.716; Cit,hKyn,NP, 0.715; Trp,hTrp,NP, 0.713; Orn,hKyn,AnthA, 0.713; Pro,AnthA,QA, 0.713; Cit,Kyn,NP, 0.711; Orn,AnthA,NP, 0.711; Thr,Arg,AnthA, 0.709; Trp,hTrp,Kyn, 0.709; Arg,QA,NP, 0.709; Lys,AnthA,Kyn, 0.709; Lys,hTrp,AnthA, 0.706; Arg,AnthA,QA, 0.706; Ala,Pro,NP, 0.704; Cit,QA,NP, 0.704; Orn,AnthA,QA, 0.703; Trp,hKyn,hTrp, 0.701; Ala,Arg,NP, 0.701; Ala,Lys,NP, 0.701; Cit,hKyn,AnthA, 0.701; Ala,Trp,NP, 0.699; Arg,hKyn,NP, 0.699; Ala,QA,NP, 0.699; hKyn,AnthA,QA, 0.698; Thr,hKyn,AnthA, 0.698; Cit,Arg,AnthA, 0.696; Ala,hKyn,NP, 0.694; Trp,hKyn,NP, 0.693; AnthA,Kyn,QA, 0.693; Lys,AnthA,QA, 0.688; Thr,Pro,AnthA, 0.686; Arg,Pro,AnthA, 0.681; Arg,Trp,AnthA, 0.674; Thr,AnthA,QA, 0.674; Cit,Pro,AnthA, 0.672; Pro,Lys,AnthA, 0.671; Cit,AnthA,QA, 0.671; Pro,Trp,AnthA, 0.669
Ala,hTrp,AnthA,NP, 0.787; Ala,hTrp,AnthA,Kyn, 0.784; Thr,Ala,AnthA,Kyn, 0.784; Pro,hTrp,AnthA,NP, 0.782; Ala,Lys,hTrp,AnthA, 0.78; Ala,Pro,AnthA,Kyn, 0.78; Pro,hKyn,hTrp,AnthA, 0.779; Ala,Trp,AnthA,Kyn, 0.779; Ala,Arg,AnthA,Kyn, 0.775; Ala,Pro,hTrp,Kyn, 0.774; Pro,hKyn,hTrp,Kyn, 0.774; Ala,Lys,hTrp,NP, 0.774; Ala,Orn,hKyn,hTrp, 0.774; Thr,Ala,Pro,AnthA, 0.772; Ala,AnthA,Kyn,NP, 0.772; Ala,Orn,hTrp,AnthA, 0.772; Ala,Lys,AnthA,Kyn, 0.772; Thr,Ala,hTrp,AnthA, 0.77; Ala,hKyn,AnthA,Kyn, 0.77; Cit,hTrp,AnthA,NP, 0.77; Ala,Orn,AnthA,Kyn, 0.767; Ala,AnthA,Kyn,QA, 0.767; Ala,Lys,hTrp,Kyn, 0.767; Ala,Orn,hTrp,NP, 0.767; Ala,Orn,AnthA,NP, 0.765; Arg,hTrp,AnthA,NP, 0.765; Cit,hTrp,Kyn,NP, 0.765; Ala,Cit,hTrp,NP, 0.764; Ala,Orn,hTrp,QA, 0.762; Ala,hKyn,hTrp,NP, 0.762; Ala,hTrp,Kyn,NP, 0.76; Ala,Trp,hKyn,AnthA, 0.76; Pro,hKyn,AnthA,NP, 0.758; Arg,Pro,hTrp,Kyn, 0.758; hKyn,hTrp,AnthA,NP, 0.757; Thr,hTrp,AnthA,NP, 0.757; Thr,Ala,hTrp,NP, 0.757; Ala,Orn,Kyn,NP, 0.757; Pro,hTrp,QA,NP, 0.757; Ala,Cit,hKyn,AnthA, 0.755; Ala,Trp,AnthA,NP, 0.755; Pro,hTrp,AnthA,QA, 0.753; Ala,Pro,hKyn,AnthA, 0.753; Ala,Orn,hKyn,AnthA, 0.753; Ala,Lys,AnthA,QA, 0.753; Ala,hTrp,Kyn,QA, 0.753; Thr,Ala,Arg,AnthA, 0.753; Pro,hKyn,hTrp,NP, 0.753; Thr,Ala,Lys,AnthA, 0.753; Trp,hTrp,AnthA,Kyn, 0.753; Ala,AnthA,QA,NP, 0.752; Arg,Pro,hTrp,AnthA, 0.752; Pro,Trp,AnthA,NP, 0.752; Thr,Ala,Trp,AnthA, 0.752; Pro,Orn,hTrp,NP, 0.752; Cit,Pro,hTrp,NP, 0.752; Pro,hKyn,AnthA,Kyn, 0.75; Ala,Pro,hTrp,NP, 0.75; Arg,AnthA,Kyn,NP, 0.75; Arg,Pro,hKyn,AnthA, 0.747; Thr,Ala,hKyn,AnthA, 0.747; Pro,AnthA,Kyn,NP, 0.747; Ala,Orn,AnthA,QA, 0.747; Pro,AnthA,QA,NP, 0.747; Thr,Pro,hTrp,Kyn, 0.747; Ala,Orn,Trp,AnthA, 0.747; Pro,Trp,hTrp,Kyn, 0.747; Ala,hTrp,QA,NP, 0.747; Ala,Arg,Lys,AnthA, 0.747; Trp,hKyn,hTrp,AnthA, 0.745; Arg,Pro,AnthA,NP, 0.745; Lys,hKyn,hTrp,AnthA, 0.745; Pro,Lys,hTrp,Kyn, 0.745; Ala,Pro,Lys,AnthA, 0.745; Ala,Cit,Lys,AnthA, 0.745; Pro,Trp,hKyn,AnthA, 0.743; Ala,Arg,AnthA,NP, 0.743; Cit,Pro,hKyn,AnthA, 0.742; Ala,Pro,AnthA,NP, 0.742; Ala,Trp,AnthA,QA, 0.742; Cit,hTrp,AnthA,QA, 0.742; Ala,Lys,Trp,AnthA, 0.742; Pro,Lys,hKyn,AnthA, 0.738; Ala,Pro,AnthA,QA, 0.738; Cit,hKyn,AnthA,NP, 0.738; Ala,Arg,AnthA,QA, 0.736; Lys,hKyn,AnthA,NP, 0.736; Ala,Cit,Kyn,NP, 0.736; Pro,Trp,AnthA,Kyn, 0.735; Ala,Cit,Orn,AnthA, 0.735; hKyn,hTrp,AnthA,QA, 0.731; Trp,hKyn,AnthA,NP, 0.725; Thr,Trp,hKyn,AnthA, 0.721; Arg,Trp,hKyn,AnthA, 0.715; Trp,hKyn,AnthA,Kyn, 0.713; Cit,Trp,hKyn,AnthA, 0.711; Trp,hKyn,AnthA,QA, 0.711; Pro,Trp,AnthA,QA, 0.711; Lys,Trp,hKyn,AnthA, 0.706; Pro,Lys,AnthA,QA, 0.706
Thr,Ala,Cit,hTrp,Kyn, 0.801; Thr,Pro,hTrp,AnthA,NP, 0.797; Ala,Trp,hTrp,AnthA,NP, 0.797; Ala,Trp,hTrp,AnthA,Kyn, 0.796; Ala,Orn,Lys,hTrp,AnthA, 0.796; Ala,Cit,hTrp,Kyn,NP, 0.796; Ala,Lys,hTrp,AnthA,Kyn, 0.794; Thr,Pro,hKyn,hTrp,AnthA, 0.794; Ala,Lys,hTrp,AnthA,NP, 0.794; Ala,Pro,hTrp,AnthA,Kyn, 0.791; Thr,Ala,Orn,AnthA,Kyn, 0.791; Thr,Ala,Orn,hTrp,Kyn, 0.791; Thr,Ala,hTrp,AnthA,NP, 0.789; Pro,Trp,hKyn,hTrp,AnthA, 0.789; Ala,hTrp,AnthA,Kyn,QA, 0.789; Ala,hKyn,hTrp,AnthA,NP, 0.789; Ala,Pro,hTrp,AnthA,NP, 0.789; Ala,Arg,Orn,hTrp,Kyn, 0.789; Pro,Lys,hKyn,hTrp,AnthA, 0.787; Ala,Orn,hTrp,AnthA,NP, 0.787; Pro,Lys,hTrp,AnthA,NP, 0.787; Ala,Cit,Orn,hTrp,Kyn, 0.787; Pro,Orn,hKyn,hTrp,AnthA, 0.785; Arg,Pro,hTrp,AnthA,NP, 0.785; Cit,Pro,hTrp,AnthA,NP, 0.785; Ala,hTrp,AnthA,Kyn,NP, 0.784; Thr,Ala,Pro,hTrp,AnthA, 0.784; Ala,hTrp,AnthA,QA,NP, 0.784; Ala,Pro,Orn,hTrp,Kyn, 0.784; Thr,Ala,AnthA,Kyn,QA, 0.784; Ala,Pro,Trp,hTrp,Kyn, 0.784; Thr,Ala,Arg,AnthA,Kyn, 0.782; Ala,Cit,Arg,hTrp,Kyn, 0.782; Thr,Ala,AnthA,Kyn,NP, 0.78; Pro,Orn,hTrp,AnthA,NP, 0.78; Thr,Ala,Lys,hTrp,AnthA, 0.78; Ala,Pro,Lys,AnthA,Kyn, 0.78; Thr,Ala,Trp,AnthA,Kyn, 0.78; Ala,Cit,hKyn,hTrp,Kyn, 0.78; Thr,Pro,hTrp,AnthA,Kyn, 0.779; Pro,hTrp,AnthA,Kyn,QA, 0.779; Ala,Arg,Orn,hTrp,AnthA, 0.779; Ala,Pro,Orn,hTrp,AnthA, 0.779; Ala,Orn,Trp,AnthA,Kyn, 0.779; Ala,Pro,AnthA,Kyn,QA, 0.779; Pro,hKyn,hTrp,AnthA,QA, 0.777; Pro,hKyn,hTrp,AnthA,Kyn, 0.774; Arg,Pro,hKyn,hTrp,AnthA, 0.774; Pro,Trp,hTrp,AnthA,Kyn, 0.774; Thr,Pro,hTrp,AnthA,QA, 0.774; Ala,Trp,hTrp,AnthA,QA, 0.774; Ala,Cit,hTrp,AnthA,QA, 0.774; Ala,Cit,AnthA,Kyn,NP, 0.774; Ala,Lys,AnthA,Kyn,QA, 0.774; Ala,Arg,Lys,AnthA,Kyn, 0.774; Ala,Orn,AnthA,Kyn,QA, 0.772; Ala,Orn,hKyn,hTrp,AnthA, 0.772; Pro,Orn,hTrp,AnthA,Kyn, 0.772; Thr,Arg,Pro,hKyn,AnthA, 0.772; Pro,Lys,hTrp,AnthA,Kyn, 0.769; Cit,Pro,hTrp,AnthA,Kyn, 0.769; Thr,Pro,hKyn,AnthA,NP, 0.769; Thr,Ala,Arg,AnthA,NP, 0.769; Thr,Pro,Trp,hKyn,AnthA, 0.769; Ala,AnthA,Kyn,QA,NP, 0.769; Thr,Pro,hKyn,AnthA,QA, 0.769; Ala,Cit,Orn,hTrp,AnthA, 0.769; Thr,Cit,Pro,hKyn,AnthA, 0.769; Thr,Ala,hKyn,hTrp,AnthA, 0.767; Ala,Arg,hTrp,AnthA,QA, 0.767; Pro,Trp,hTrp,AnthA,QA, 0.767; Ala,Arg,AnthA,Kyn,NP, 0.767; Ala,Orn,hKyn,AnthA,Kyn, 0.767; Thr,Ala,Pro,AnthA,QA, 0.767; Ala,hTrp,Kyn,QA,NP, 0.767; Arg,Pro,Orn,hKyn,AnthA, 0.765; Cit,Pro,hTrp,AnthA,QA, 0.765; Ala,Cit,Orn,AnthA,Kyn, 0.765; Ala,Cit,hKyn,AnthA,Kyn, 0.765; Thr,Pro,hTrp,Kyn,NP, 0.764; Ala,Trp,hKyn,AnthA,NP, 0.764; Ala,Lys,AnthA,QA,NP, 0.764; Thr,Ala,Orn,AnthA,NP, 0.762; Thr,Ala,hTrp,Kyn,NP, 0.762; Ala,Cit,Pro,hTrp,AnthA, 0.762; Pro,Trp,hKyn,AnthA,NP, 0.76; Ala,Lys,hKyn,AnthA,NP, 0.758; Pro,hKyn,AnthA,QA,NP, 0.757; Thr,Ala,Trp,AnthA,NP, 0.757; Cit,Pro,Orn,hKyn,AnthA, 0.757; Pro,Orn,hKyn,AnthA,NP, 0.755; Ala,Pro,Orn,hKyn,AnthA, 0.755; Ala,Orn,Lys,AnthA,NP, 0.755; Ala,Arg,hKyn,AnthA,NP, 0.753; Ala,Arg,Orn,hKyn,AnthA, 0.753; Ala,Cit,Pro,hKyn,AnthA, 0.752; Ala,Arg,Pro,hTrp,AnthA, 0.748; Ala,Pro,hKyn,AnthA,QA, 0.748; Pro,Orn,hKyn,AnthA,QA, 0.748; Pro,Orn,Trp,hKyn,AnthA, 0.745
Thr,Ala,Orn,hTrp,AnthA,Kyn, 0.823; Ala,Arg,Orn,hTrp,AnthA,Kyn, 0.816; Ala,Pro,Trp,hTrp,AnthA,NP, 0.816; Thr,Ala,Cit,hTrp,AnthA,Kyn, 0.813; Thr,Pro,Orn,hKyn,hTrp,AnthA, 0.807; Thr,Ala,Orn,hTrp,AnthA,QA, 0.807; Thr,Ala,Pro,Orn,AnthA,Kyn, 0.807; Thr,Ala,Orn,Lys,hTrp,AnthA, 0.807; Ala,Cit,Trp,hTrp,Kyn,NP, 0.807; Ala,Orn,Trp,hTrp,AnthA,Kyn, 0.806; Ala,Arg,Orn,hTrp,AnthA,NP, 0.806; Ala,Orn,hTrp,AnthA,Kyn,QA, 0.806; Ala,Orn,Lys,hTrp,AnthA,QA, 0.806; Ala,Pro,Lys,hTrp,AnthA,Kyn, 0.802; Thr,Pro,hTrp,AnthA,Kyn,NP, 0.802; Thr,Ala,Pro,hKyn,hTrp,AnthA, 0.802; Thr,Ala,Cit,Orn,hTrp,Kyn, 0.802; Thr,Ala,Orn,hTrp,AnthA,NP, 0.801; Ala,Pro,Orn,hTrp,AnthA,Kyn, 0.801; Thr,Ala,Trp,hTrp,AnthA,Kyn, 0.801; Pro,Orn,Lys,hKyn,hTrp,AnthA, 0.801; Pro,Orn,Trp,hKyn,hTrp,AnthA, 0.801; Arg,Pro,Trp,hTrp,AnthA,NP, 0.801; Thr,Ala,hKyn,hTrp,AnthA,Kyn, 0.799; Thr,Cit,Pro,hKyn,hTrp,AnthA, 0.799; Ala,Cit,hTrp,AnthA,Kyn,NP, 0.797; Thr,Pro,Trp,hKyn,hTrp,AnthA, 0.797; Ala,Orn,Lys,hTrp,Kyn,NP, 0.797; Ala,Cit,hKyn,hTrp,AnthA,Kyn, 0.797; Ala,Trp,hTrp,AnthA,QA,NP, 0.797; Thr,Ala,Arg,Orn,hTrp,AnthA, 0.797; Thr,Ala,Pro,hTrp,AnthA,QA, 0.796; Ala,Lys,hKyn,hTrp,AnthA,NP, 0.796; Ala,Arg,Lys,hTrp,AnthA,NP, 0.796; Ala,Cit,hTrp,AnthA,Kyn,QA, 0.796; Ala,Arg,Trp,hTrp,AnthA,Kyn, 0.796; Ala,Trp,hTrp,AnthA,Kyn,QA, 0.796; Thr,Ala,Arg,Lys,hTrp,AnthA, 0.796; Thr,Ala,Cit,Orn,AnthA,Kyn, 0.796; Ala,Cit,Orn,hTrp,Kyn,NP, 0.796; Thr,Ala,hTrp,AnthA,Kyn,NP, 0.794; Thr,Ala,Cit,hTrp,Kyn,NP, 0.794; Thr,Ala,hTrp,AnthA,Kyn,QA, 0.794; Ala,Lys,hTrp,AnthA,Kyn,QA, 0.794; Thr,Ala,Cit,hTrp,AnthA,QA, 0.794; Thr,Ala,Cit,Lys,hTrp,Kyn, 0.794; Thr,Ala,Lys,hTrp,AnthA,Kyn, 0.792; Pro,Lys,hKyn,hTrp,AnthA,NP, 0.792; Thr,Pro,Lys,hTrp,AnthA,NP, 0.792; Thr,Arg,Pro,hTrp,AnthA,Kyn, 0.792; Ala,Cit,Arg,hTrp,Kyn,NP, 0.792; Ala,Cit,Lys,hTrp,AnthA,QA, 0.792; Thr,Ala,Cit,Lys,hTrp,AnthA, 0.792; Thr,Pro,hKyn,hTrp,AnthA,NP, 0.791; Cit,Pro,Lys,hKyn,hTrp,AnthA, 0.791; Thr,Ala,Pro,Lys,AnthA,Kyn, 0.791; Thr,Ala,Arg,Orn,AnthA,Kyn, 0.791; Ala,Cit,Arg,hTrp,AnthA,Kyn, 0.789; Ala,Pro,Lys,hTrp,AnthA,QA, 0.789; Ala,Orn,Lys,AnthA,Kyn,NP, 0.789; Ala,Pro,Lys,hKyn,hTrp,AnthA, 0.787; Thr,Cit,Pro,hTrp,AnthA,Kyn, 0.787; Thr,Ala,Orn,AnthA,QA,NP, 0.787; Ala,Cit,Orn,Lys,hTrp,Kyn, 0.787; Pro,Trp,hKyn,hTrp,AnthA,NP, 0.785; Ala,Arg,hKyn,hTrp,AnthA,Kyn, 0.785; Ala,Cit,Pro,Lys,hTrp,Kyn, 0.785; Ala,Pro,hTrp,AnthA,QA,NP, 0.785; Thr,Ala,Orn,Lys,AnthA,Kyn, 0.785; Thr,Ala,Lys,AnthA,Kyn,NP, 0.785; Arg,Pro,Orn,hTrp,AnthA,NP, 0.785; Cit,Pro,hTrp,AnthA,QA,NP, 0.785; Ala,Cit,Lys,hKyn,hTrp,Kyn, 0.785; Thr,Ala,Trp,hTrp,AnthA,NP, 0.784; Ala,Arg,hTrp,AnthA,Kyn,QA, 0.784; Thr,Ala,Pro,Lys,hTrp,Kyn, 0.784; Ala,Cit,hTrp,AnthA,QA,NP, 0.784; Thr,Ala,Trp,hTrp,AnthA,QA, 0.782; Thr,Ala,Cit,hKyn,AnthA,Kyn, 0.782; Thr,Ala,Orn,hKyn,AnthA,NP, 0.78; Thr,Ala,Pro,Orn,hKyn,AnthA, 0.779; Ala,Arg,Pro,Lys,hTrp,AnthA, 0.779; Ala,Arg,Pro,Lys,hTrp,Kyn, 0.779; Ala,Arg,Pro,hKyn,hTrp,AnthA, 0.777; Thr,Ala,Pro,hTrp,Kyn,NP, 0.777; Ala,Cit,hKyn,hTrp,AnthA,QA, 0.777; Ala,Pro,Orn,AnthA,Kyn,NP, 0.777; Ala,Arg,Orn,hKyn,hTrp,AnthA, 0.775; Arg,Pro,hTrp,AnthA,Kyn,QA, 0.775; Thr,Ala,Arg,hTrp,Kyn,NP, 0.775; Thr,Pro,Trp,hTrp,AnthA,Kyn, 0.774; Thr,Ala,Pro,Orn,AnthA,NP, 0.774; Ala,Cit,Arg,hTrp,AnthA,QA, 0.774; Arg,Pro,Orn,hKyn,AnthA,NP, 0.774; Ala,Pro,Orn,Lys,AnthA,Kyn, 0.774; Thr,Ala,Cit,hKyn,AnthA,NP, 0.772; Thr,Pro,Trp,hTrp,AnthA,QA, 0.77; Thr,Pro,hKyn,AnthA,QA,NP, 0.769; Thr,Ala,Trp,hKyn,hTrp,AnthA, 0.767; Thr,Ala,Pro,AnthA,QA,NP, 0.767
Claims (17)
- 評価対象の血液中のGlu、Arg、Orn、Cit、His、Val、Phe、Tyr、Met、Pro、Asn、Leu、Lys、Thr、Ile、Gln、Ala、Ser、a-ABA、Trp、Gly、AnthA、hAnthA、hIAA、hKyn、hTrp、IAA、ILA、Kyn、KynA、NFKyn、NP、PA、QA、SerotおよびXAのうちの少なくとも1つの代謝物の濃度値、または、前記濃度値が代入される変数を含む式および前記濃度値を用いて算出された前記式の値を用いて、前記評価対象における免疫チェックポイント阻害剤の薬理作用を評価する評価ステップを含むこと、
を特徴とする評価方法。 - 前記血液は、前記評価対象から、前記免疫チェックポイント阻害剤による治療が開始される前または開始された後に採取されたものであり、
前記評価ステップは、前記評価対象における前記治療の効果を評価するものであること、
を特徴とする請求項1に記載の評価方法。 - 前記血液は、前記評価対象から、前記免疫チェックポイント阻害剤による治療が開始される前に採取されたものであり、
前記評価ステップは、前記評価対象における前記治療による副作用の発生リスクを評価するものであること、
を特徴とする請求項1または2に記載の評価方法。 - 前記評価ステップは、制御部を備えた情報処理装置の前記制御部において実行されること、
を特徴とする請求項1から3のいずれか1つに記載の評価方法。 - 評価対象の血液中のGlu、Arg、Orn、Cit、His、Val、Phe、Tyr、Met、Pro、Asn、Leu、Lys、Thr、Ile、Gln、Ala、Ser、a-ABA、Trp、Gly、AnthA、hAnthA、hIAA、hKyn、hTrp、IAA、ILA、Kyn、KynA、NFKyn、NP、PA、QA、SerotおよびXAのうちの少なくとも1つの代謝物の濃度値ならびに前記濃度値が代入される変数を含む免疫チェックポイント阻害剤の薬理作用を評価するための式を用いて、前記式の値を算出する算出ステップを含むこと、
を特徴とする算出方法。 - 前記血液は、前記評価対象から、前記免疫チェックポイント阻害剤による治療が開始される前または開始された後に採取されたものであり、
前記式は、前記治療の効果を評価するためのものであること、
を特徴とする請求項5に記載の算出方法。 - 前記血液は、前記評価対象から、前記免疫チェックポイント阻害剤による治療が開始される前に採取されたものであり、
前記式は、前記治療による副作用の発生リスクを評価するためのものであること、
を特徴とする請求項5または6に記載の算出方法。 - 前記算出ステップは、制御部を備えた情報処理装置の前記制御部において実行されること、
を特徴とする請求項5から7のいずれか1つに記載の算出方法。 - 制御部を備える評価装置であって、
前記制御部は、
評価対象の血液中のGlu、Arg、Orn、Cit、His、Val、Phe、Tyr、Met、Pro、Asn、Leu、Lys、Thr、Ile、Gln、Ala、Ser、a-ABA、Trp、Gly、AnthA、hAnthA、hIAA、hKyn、hTrp、IAA、ILA、Kyn、KynA、NFKyn、NP、PA、QA、SerotおよびXAのうちの少なくとも1つの代謝物の濃度値、または、前記濃度値が代入される変数を含む式および前記濃度値を用いて算出された前記式の値を用いて、前記評価対象における免疫チェックポイント阻害剤の薬理作用を評価する評価手段
を備えること、
を特徴とする評価装置。 - 前記濃度値に関する濃度データまたは前記式の前記値を提供する端末装置とネットワークを介して通信可能に接続され、
前記制御部は、
前記端末装置から送信された前記濃度データまたは前記式の前記値を受信するデータ受信手段と、
前記評価手段で得られた評価結果を前記端末装置へ送信する結果送信手段と、
をさらに備え、
前記評価手段は、前記データ受信手段で受信した前記濃度データに含まれている前記濃度値または前記式の前記値を用いること、
を特徴とする請求項9に記載の評価装置。 - 制御部を備える算出装置であって、
前記制御部は、
評価対象の血液中のGlu、Arg、Orn、Cit、His、Val、Phe、Tyr、Met、Pro、Asn、Leu、Lys、Thr、Ile、Gln、Ala、Ser、a-ABA、Trp、Gly、AnthA、hAnthA、hIAA、hKyn、hTrp、IAA、ILA、Kyn、KynA、NFKyn、NP、PA、QA、SerotおよびXAのうちの少なくとも1つの代謝物の濃度値ならびに前記濃度値が代入される変数を含む免疫チェックポイント阻害剤の薬理作用を評価するための式を用いて、前記式の値を算出する算出手段
を備えること、
を特徴とする算出装置。 - 制御部を備える情報処理装置において実行させるための評価プログラムであって、
前記制御部において実行させるための、
評価対象の血液中のGlu、Arg、Orn、Cit、His、Val、Phe、Tyr、Met、Pro、Asn、Leu、Lys、Thr、Ile、Gln、Ala、Ser、a-ABA、Trp、Gly、AnthA、hAnthA、hIAA、hKyn、hTrp、IAA、ILA、Kyn、KynA、NFKyn、NP、PA、QA、SerotおよびXAのうちの少なくとも1つの代謝物の濃度値、または、前記濃度値が代入される変数を含む式および前記濃度値を用いて算出された前記式の値を用いて、前記評価対象における免疫チェックポイント阻害剤の薬理作用を評価する評価ステップ
を含むこと、
を特徴とする評価プログラム。 - 制御部を備える情報処理装置において実行させるための算出プログラムであって、
前記制御部において実行させるための、
評価対象の血液中のGlu、Arg、Orn、Cit、His、Val、Phe、Tyr、Met、Pro、Asn、Leu、Lys、Thr、Ile、Gln、Ala、Ser、a-ABA、Trp、Gly、AnthA、hAnthA、hIAA、hKyn、hTrp、IAA、ILA、Kyn、KynA、NFKyn、NP、PA、QA、SerotおよびXAのうちの少なくとも1つの代謝物の濃度値ならびに前記濃度値が代入される変数を含む免疫チェックポイント阻害剤の薬理作用を評価するための式を用いて、前記式の値を算出する算出ステップ
を含むこと、
を特徴とする算出プログラム。 - 請求項12または13に記載のプログラムを記録したコンピュータ読み取り可能な記録媒体。
- 制御部を備える評価装置と制御部を備える端末装置とをネットワークを介して通信可能に接続して構成される評価システムであって、
前記端末装置の前記制御部は、
評価対象の血液中のGlu、Arg、Orn、Cit、His、Val、Phe、Tyr、Met、Pro、Asn、Leu、Lys、Thr、Ile、Gln、Ala、Ser、a-ABA、Trp、Gly、AnthA、hAnthA、hIAA、hKyn、hTrp、IAA、ILA、Kyn、KynA、NFKyn、NP、PA、QA、SerotおよびXAのうちの少なくとも1つの代謝物の濃度値に関する濃度データ、または、前記濃度値が代入される変数を含む式および前記濃度値を用いて算出された前記式の値を前記評価装置へ送信するデータ送信手段と、
前記評価装置から送信された、免疫チェックポイント阻害剤の薬理作用に関する評価結果を受信する結果受信手段と、
を備え、
前記評価装置の前記制御部は、
前記端末装置から送信された前記濃度データまたは前記式の前記値を受信するデータ受信手段と、
前記データ受信手段で受信した前記濃度データに含まれている前記濃度値または前記式の前記値を用いて、前記評価対象における免疫チェックポイント阻害剤の薬理作用を評価する評価手段と、
前記評価手段で得られた前記評価結果を前記端末装置へ送信する結果送信手段と、
を備えること、
を特徴とする評価システム。 - 制御部を備えた端末装置であって、
前記制御部は、
免疫チェックポイント阻害剤の薬理作用に関する評価結果を取得する結果取得手段
を備え、
前記評価結果は、評価対象の血液中のGlu、Arg、Orn、Cit、His、Val、Phe、Tyr、Met、Pro、Asn、Leu、Lys、Thr、Ile、Gln、Ala、Ser、a-ABA、Trp、Gly、AnthA、hAnthA、hIAA、hKyn、hTrp、IAA、ILA、Kyn、KynA、NFKyn、NP、PA、QA、SerotおよびXAのうちの少なくとも1つの代謝物の濃度値、または、前記濃度値が代入される変数を含む式および前記濃度値を用いて算出された前記式の値を用いて、前記評価対象における免疫チェックポイント阻害剤の薬理作用を評価した結果であること、
を特徴とする端末装置。 - 免疫チェックポイント阻害剤の薬理作用を評価する評価装置とネットワークを介して通信可能に接続されており、
前記制御部は、前記濃度値に関する濃度データまたは前記式の前記値を前記評価装置へ送信するデータ送信手段を備え、
前記結果取得手段は、前記評価装置から送信された前記評価結果を受信すること、
を特徴とする請求項16に記載の端末装置。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020227015348A KR20220093122A (ko) | 2019-11-08 | 2020-11-06 | 면역 체크 포인트 저해제의 약리 작용의 평가 방법, 산출 방법, 평가 장치, 산출 장치, 평가 프로그램, 산출 프로그램, 기록 매체, 평가 시스템 및 단말 장치 |
JP2021555140A JPWO2021090941A1 (ja) | 2019-11-08 | 2020-11-06 | |
US17/730,484 US20220268790A1 (en) | 2019-11-08 | 2022-04-27 | Evaluating method for pharmacological actions of immune checkpoint inhibitors, calculating method, evaluating apparatus, calculating apparatus, evaluating program, calculating program, recording medium, evaluating system, and terminal apparatus |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019203363 | 2019-11-08 | ||
JP2019-203363 | 2019-11-08 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/730,484 Continuation US20220268790A1 (en) | 2019-11-08 | 2022-04-27 | Evaluating method for pharmacological actions of immune checkpoint inhibitors, calculating method, evaluating apparatus, calculating apparatus, evaluating program, calculating program, recording medium, evaluating system, and terminal apparatus |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021090941A1 true WO2021090941A1 (ja) | 2021-05-14 |
Family
ID=75848127
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2020/041614 WO2021090941A1 (ja) | 2019-11-08 | 2020-11-06 | 免疫チェックポイント阻害剤の薬理作用の評価方法、算出方法、評価装置、算出装置、評価プログラム、算出プログラム、記録媒体、評価システムおよび端末装置 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20220268790A1 (ja) |
JP (1) | JPWO2021090941A1 (ja) |
KR (1) | KR20220093122A (ja) |
WO (1) | WO2021090941A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023195447A1 (ja) * | 2022-04-08 | 2023-10-12 | 味の素株式会社 | 免疫チェックポイント阻害剤単剤の薬理作用と比較した、免疫チェックポイント阻害剤と併用薬としての抗がん剤との組み合わせの相対的な薬理作用の評価方法、算出方法、評価装置、算出装置、評価プログラム、算出プログラム、記録媒体、評価システム、および端末装置 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016056631A1 (ja) * | 2014-10-08 | 2016-04-14 | 味の素株式会社 | 評価方法、評価装置、評価プログラム、評価システム、及び端末装置 |
WO2018066621A1 (ja) * | 2016-10-04 | 2018-04-12 | 味の素株式会社 | 大腸癌の評価方法、評価装置、評価プログラム、評価システム、及び端末装置 |
WO2019117132A1 (ja) * | 2017-12-12 | 2019-06-20 | 地方独立行政法人神奈川県立病院機構 | がん免疫療法の予後予測のためのバイオマーカー |
WO2019188354A1 (ja) * | 2018-03-27 | 2019-10-03 | 国立大学法人京都大学 | 免疫チェックポイント阻害剤の奏効性の判定を補助する方法、試薬キット、装置及びコンピュータプログラム |
US20190331682A1 (en) * | 2016-02-18 | 2019-10-31 | Institut Gustave Roussy | Methods and kits for predicting the sensitivity of a subject to immunotherapy |
WO2019207942A1 (ja) * | 2018-04-27 | 2019-10-31 | OTA Takayo | 免疫チェックポイント阻害剤によるがん治療の効果を評価するためのバイオマーカー |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6375947B2 (ja) | 2012-05-11 | 2018-08-22 | 味の素株式会社 | 取得方法、評価装置、評価方法、評価プログラム、評価システムおよび端末装置 |
-
2020
- 2020-11-06 KR KR1020227015348A patent/KR20220093122A/ko unknown
- 2020-11-06 WO PCT/JP2020/041614 patent/WO2021090941A1/ja active Application Filing
- 2020-11-06 JP JP2021555140A patent/JPWO2021090941A1/ja active Pending
-
2022
- 2022-04-27 US US17/730,484 patent/US20220268790A1/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016056631A1 (ja) * | 2014-10-08 | 2016-04-14 | 味の素株式会社 | 評価方法、評価装置、評価プログラム、評価システム、及び端末装置 |
US20190331682A1 (en) * | 2016-02-18 | 2019-10-31 | Institut Gustave Roussy | Methods and kits for predicting the sensitivity of a subject to immunotherapy |
WO2018066621A1 (ja) * | 2016-10-04 | 2018-04-12 | 味の素株式会社 | 大腸癌の評価方法、評価装置、評価プログラム、評価システム、及び端末装置 |
WO2019117132A1 (ja) * | 2017-12-12 | 2019-06-20 | 地方独立行政法人神奈川県立病院機構 | がん免疫療法の予後予測のためのバイオマーカー |
WO2019188354A1 (ja) * | 2018-03-27 | 2019-10-03 | 国立大学法人京都大学 | 免疫チェックポイント阻害剤の奏効性の判定を補助する方法、試薬キット、装置及びコンピュータプログラム |
WO2019207942A1 (ja) * | 2018-04-27 | 2019-10-31 | OTA Takayo | 免疫チェックポイント阻害剤によるがん治療の効果を評価するためのバイオマーカー |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023195447A1 (ja) * | 2022-04-08 | 2023-10-12 | 味の素株式会社 | 免疫チェックポイント阻害剤単剤の薬理作用と比較した、免疫チェックポイント阻害剤と併用薬としての抗がん剤との組み合わせの相対的な薬理作用の評価方法、算出方法、評価装置、算出装置、評価プログラム、算出プログラム、記録媒体、評価システム、および端末装置 |
Also Published As
Publication number | Publication date |
---|---|
US20220268790A1 (en) | 2022-08-25 |
JPWO2021090941A1 (ja) | 2021-05-14 |
KR20220093122A (ko) | 2022-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2021177196A (ja) | 大腸癌の評価方法、算出方法、評価装置、算出装置、評価プログラム、算出プログラム、評価システム、及び端末装置 | |
JP7337018B2 (ja) | 取得方法、算出方法、評価装置、算出装置、評価プログラム、算出プログラム、評価システム | |
WO2021090941A1 (ja) | 免疫チェックポイント阻害剤の薬理作用の評価方法、算出方法、評価装置、算出装置、評価プログラム、算出プログラム、記録媒体、評価システムおよび端末装置 | |
JPWO2020067386A1 (ja) | 軽度認知障害の評価方法、算出方法、評価装置、算出装置、評価プログラム、算出プログラム、記録媒体、評価システムおよび端末装置 | |
JP2022046807A (ja) | 取得方法、算出方法、評価装置、算出装置、評価プログラム、算出プログラム、および評価システム | |
WO2020203878A1 (ja) | アミロイドベータの脳内への蓄積の評価方法、算出方法、評価装置、算出装置、評価プログラム、算出プログラム、記録媒体、評価システムおよび端末装置 | |
JP2013178239A (ja) | 早期腎症の評価方法、早期腎症評価装置、早期腎症評価方法、早期腎症評価プログラム、早期腎症評価システムおよび情報通信端末装置 | |
WO2019194144A1 (ja) | 乳癌の評価方法、算出方法、評価装置、算出装置、評価プログラム、算出プログラム、記録媒体、評価システム、及び端末装置 | |
JP7093163B2 (ja) | 取得方法、算出方法、評価装置、算出装置、評価プログラム、算出プログラム、および評価システム | |
WO2023195447A1 (ja) | 免疫チェックポイント阻害剤単剤の薬理作用と比較した、免疫チェックポイント阻害剤と併用薬としての抗がん剤との組み合わせの相対的な薬理作用の評価方法、算出方法、評価装置、算出装置、評価プログラム、算出プログラム、記録媒体、評価システム、および端末装置 | |
KR102475008B1 (ko) | 당뇨병 환자에서의 췌장암의 평가 방법, 산출 방법, 평가 장치, 산출 장치, 평가 프로그램, 산출 프로그램, 평가 시스템 및 단말 장치 | |
JP7093162B2 (ja) | 取得方法、算出方法、評価装置、算出装置、評価プログラム、算出プログラム、および評価システム | |
JP7506646B2 (ja) | 取得方法、算出方法、評価装置、算出装置、評価プログラム、算出プログラム、及び評価システム | |
JP7435856B2 (ja) | 取得方法、算出方法、評価装置、算出装置、評価プログラム、算出プログラム、記録媒体、及び評価システム | |
KR102477319B1 (ko) | 암 모니터링의 방법, 산출 방법, 평가 장치, 산출 장치, 평가 프로그램, 산출 프로그램, 평가 시스템, 및 단말 장치 | |
JP7435855B2 (ja) | 取得方法、算出方法、評価装置、算出装置、評価プログラム、算出プログラム、記録媒体、及び評価システム | |
WO2022009991A1 (ja) | 軽度認知障害の評価方法、算出方法、評価装置、算出装置、評価プログラム、算出プログラム、記録媒体、評価システムおよび端末装置 | |
WO2020184660A1 (ja) | サルコペニアの評価方法、算出方法、評価装置、算出装置、評価プログラム、算出プログラム、記録媒体、評価システム、及び端末装置 | |
WO2020158828A1 (ja) | 脳心血管イベントの将来の発生リスクの評価方法、算出方法、評価装置、算出装置、評価プログラム、算出プログラム、記録媒体、評価システムおよび端末装置 | |
JP2022010154A (ja) | 取得方法、算出方法、評価装置、算出装置、評価プログラム、算出プログラム、及び評価システム |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20884130 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2021555140 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20227015348 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20884130 Country of ref document: EP Kind code of ref document: A1 |